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 Abstract 
VEZF1 is a highly conserved vertebrate transcription factor.  VEZF1 binding sites have 
been reported to function in gene promoter activation, insulator barrier activity and 
protection from de novo DNA methylation.  This study aims to identify VEZF1 binding sites 
across the human genome and to develop a better understanding of the gene regulatory 
processes mediated by VEZF1.  
ChIP-seq was used to map VEZF1 binding sites across the genome of human erythroid 
cells.  A strong association of VEZF1 with regulatory elements was discovered, particularly 
at active promoters and enhancers.  Investigation of the binding specificity of VEZF1 
resulted in the identification of consensus DNA recognition sequences.  VEZF1 has a 
preference for binding to homopolymeric dG motifs in vitro and in vivo.   However, VEZF1 
has a broader specificity for previously undiscovered degenerate motifs in vivo. VEZF1 
interacts with degenerate motifs at erythroid-specific gene regulatory elements, and 
evidence is presented which indicates that VEZF1 co-operates with erythroid-specific 
transcription factors to enable binding to these elements in vivo.  Investigation of 
erythroid-specific regulatory elements in vivo in embryonic chicken erythrocytes, revealed 
a correlation between VEZF1-enrichment of promoter elements, DNA methylation status, 
and expression of the β-globin genes.  These analyses also indicate a role for VEZF1 in 
mediating DNA demethylation. 
The findings presented in this thesis provide an insight into the regulatory functions of 
VEZF1 and indicate a role for VEZF1 in the activation of gene expression. 
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Chapter 1 
Introduction 
1.1  Basic chromatin structure 
Within the eukaryotic cell nucleus DNA exists in the form of chromatin, the basic unit of 
which is the nucleosome.  The nucleosome consists of a stretch of ~147 base pairs (bp) of 
DNA wound around a histone octamer, which is comprised of 2 copies of each of the four 
core histone proteins – H2A, H2B, H3 and H4.  Individual nucleosomes are linked to one 
another via internucleosomal stretches of linker DNA which range from ~10 – 80 bp in 
length.  This basic packaging of DNA is known as the 10 nm ‘beads on a string’ 
configuration and is the primary chromatin structure.  Interactions between individual 
nucleosomes drive further compaction of chromatin to form a secondary chromatin 
structure of ~30 nm diameter which is termed the 30 nm fiber.  Packaging into the 30 nm 
fiber compacts DNA by approximately 50-fold. The stability of the 30 nm chromatin fiber 
is maintained by the interaction of histone H1 with linker DNA and adjacent nucleosomes 
(Felsenfeld and Groudine, 2003).  Despite much effort, the intricacies of nucleosome 
positioning to form the 30 nm chromatin fiber are still unresolved with two models 
having been proposed (Figure 1.1) (Tremethick, 2007, Luger et al., 2012).  In the Solenoid 
model neighbouring nucleosomes remain side by side as the 10 nm fiber bends to form a 
simple one-start helix.  In the Zigzag model the 10 nm fiber adopts a zigzag structure such 
that two nucleosome stacks are formed.  These stacks are joined by the linker DNA 
present between adjacent nucleosomes and as a result of the zigzag pattern this linker 
DNA is seen to cross back and forth between the two nucleosome stacks.  In this model 
alternating nucleosomes interact with each other as they are ultimately positioned side 
by side. 
15 
 
 
Figure 1.1 Two models for chromatin secondary structure.   
The Solenoid model (A and B) consists of a one-start helix where neighbouring 
nucleosomes interact with each other.  The Zigzag model (C and D) consists of a two-start 
helix where alternative nucleosomes interact as two nucleosome stacks are formed.  
Nucleosomes 1-8 are numbered.  In (B) alternate helical gyres are coloured blue and 
purple.  In (D) alternate nucleosome pairs are coloured blue and orange. Figure taken 
from (Luger et al., 2012). 
The 30 nm chromatin fiber is further condensed to form higher order chromatin 
structures of 200 – 300 nm diameter.  During prophase, further condensation of these 
200 – 300 nm fibers is mediated by the condensin complexes I and II, Topoisomerase IIα 
and KIF4A proteins to form compact sister chromatids in preparation for cell division 
during mitosis (Vagnarelli, 2012).  The sister chromatids, or daughter chromosomes that 
are formed during mitosis, are the highest order of condensed chromatin where the DNA 
is compacted 10,000 – 20,000-fold. 
1.2  Structure of the eukaryotic genome 
1.2.1  Coding and non-coding regions 
Eukaryotic genomes contain both coding and non-coding regions.  Coding regions consist 
of sequences which, when transcribed to form RNA or translated into protein products, 
serve a physical function within the cell.  Protein coding sequences are found only in the 
exons of genes and are interspersed with non-coding intron sequences.  During 
transcription exons and introns are linearly transcribed to form pre-messenger RNA (pre-
mRNA), introns are then removed by splicing to produce mRNA, which is translated to 
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generate protein.  Elements which regulate transcription can be found in some introns, 
conferring a role in the regulation of gene transcription to these non-coding sequences. 
The majority of the human genome is composed of non-coding DNA sequence.  In fact, it 
has been shown that protein-coding exons account for only ~2 % of the human genome.  
It has also been shown that increasing organism complexity correlates with increasing 
proportions of non-coding sequences in the genome (Taft et al., 2007).  There is evidence 
that this increase in organism complexity is due to an increase in the number and 
complexity of regulatory pathways as, in addition to introns, non-coding regions are 
known to house numerous regulatory elements including gene promoters, enhancers and 
insulators. 
1.2.2 Regulatory elements 
Expression of each eukaryotic gene is controlled by a number of regulatory elements that 
are associated with that gene in the genome.  Typically genes consist of a promoter from 
where transcription is initiated, the gene body which is comprised of protein-coding 
exons, non-coding introns and a transcription termination site.  Gene expression can also 
be influenced by enhancer or silencer elements.  
1.2.2.1 The core promoter 
The core promoter extends ~40 bp upstream and/or downstream of the TSS and contains 
DNA motifs upon which direct assembly of the pre-initiation complex (PIC) occurs 
(Maston et al., 2006, Baumann et al., 2010) (Figure 1.2).  The PIC is comprised of the 
general transcription factors (GTFs) TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH and RNA pol II 
and functions to mediate transcription initiation.  The first element discovered within 
core promoters was the TATA box which is positioned 30 – 31 bp 5’ of the TSS and 
provides a binding site for the TATA-binding protein (TBP), a subunit of the TFIID.  TFIID is 
responsible for specifying the exact point of transcription initiation by promoting 
assembly of the PIC at a suitable region and TATA boxes can therefore be seen as 
directing PIC assembly to appropriate genomic sites.  Initiator elements span TSSs and 
also function in transcription initiation by promoting assembly of the PIC.  The initiator 
element can work cooperatively with TATA boxes or independently as it is recognised by 
the TAF1 and TAF2 proteins which are subunits of TFIID.  A downstream promoter 
element (DPE) is usually found at TATA-less promoters and requires an initiator element 
to function.  The DPE is also recognised by subunits of TFIID.  TFIIB recognition elements 
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(BREs) have been identified upstream or downstream of TATA boxes and can influence 
the transcriptional activity of the core promoter.  CpG islands (CGIs) have also been 
shown to locate to the core promoters of >70 % of human genes.  CGIs commonly contain 
numerous SP1-like motifs, which are hypothesised to function as sites of PIC formation as 
the transcription factor (TF) SP1 is known to interact with TFIID via its TBP and TAFII110 
subunits (Emili et al., 1994, Gill et al., 1994). 
1.2.2.2 Proximal promoter elements 
Proximal promoter elements are DNA elements located immediately upstream of core 
promoters (Figure 1.2) and can be up to several hundred kilo bases in length.  
Bioinformatic analysis has shown many DNA motifs to be overrepresented at promoter 
proximal sites, some of which have been identified as sequence-specific TF binding sites 
while many have yet to be characterised (Dikstein, 2011).  TF binding at promoter 
proximal elements can enhance transcription by promoting PIC formation or transcription 
initiation, elongation or re-initiation, or by recruiting proteins that contribute to the 
establishment of a more transcriptionally permissive chromatin structure such as histone 
modifying enzymes and chromatin remodelers.   
1.2.2.3 Enhancer elements 
Enhancer elements function to regulate transcription from their target promoters.  They 
are typically 20 – 400 bp in length and comprise of clusters of TF binding sites which 
cumulatively exert affect on the activity of a target promoter (Kulaeva et al., 2012).  
Enhancers are distal regulatory elements that can be found at a distance of hundreds of 
kilo bases up- or downstream of their target promoters (Figure 1.2).  In addition to being 
independent of distance from promoters, enhancer function is also independent of the 
orientation of enhancers relative to promoters.   
3C technologies, which reveal physical interactions between elements throughout the 
genome, have shown that distal enhancers are in close proximity to their target 
promoters upon their activation (Dekker et al., 2002).  A number of transcription factors 
that bind both enhancers and promoters have been shown to be required for 
chromosomal loop formation between these elements (Kadauke and Blobel, 2009).  Some 
gene loci are regulated by multiple distal enhancer elements.  In the case of the β-globin 
gene locus, multiple enhancers that constitute the locus control region (LCR) are found to 
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spatially cluster with one another prior to gene activation.   This so-called active 
chromatin hub then interacts with target promoters to drive high levels of transcription 
(Palstra et al., 2003).   
1.2.2.4 Silencer elements 
Silencer elements have similar properties to enhancers but function to repress 
transcription from their target promoters.  Silencers consist of TF binding sites to which 
repressor TFs bind.  Similar to enhancers, silencer activity is independent of orientation 
and distance from target promoters and as such silencers can be located proximal to 
promoters, within gene introns or at distal sites.  The repressor TFs which bind silencer 
elements can recruit co-repressors that contribute to transcriptional repression by 
physically blocking activator TF binding sites.  Repressor TFs can also recruit histone 
modifying enzymes or chromatin remodelling factors that promote the formation of 
heterochromatin, which inhibits transcription by physically occluding the binding sites of 
activating TFs. 
 
 
Figure 1.2 Schematic of an example gene regulatory region.  
The promoter is composed of core promoter and proximal promoter elements and is 
typically ≤ 1 kb in length.  Distal regulatory elements can include insulators, silencers and 
enhancers which can be found up to hundreds of kilobases away from target gene 
promoters.  Figure adapted from (Maston et al., 2006). 
 
1.3 Chromatin and transcriptional regulation 
1.3.1 Chromatin domains 
In addition to compacting the genome to such an extent that ~2 metres of DNA fits into 
the 6 µm diameter cell nucleus (Peterson and Laniel, 2004), the formation of chromatin 
and regulation of its structure is essential to regulating processes such as gene expression 
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and DNA repair, which require DNA to be accessible for interactions with DNA binding 
proteins.  The genome is known to be divided into transcriptionally permissive and 
repressive chromatin domains which differ in protein accessibility and histone 
modifications (section 1.3.4). 
The terms heterochromatin and euchromatin are used to describe the level of chromatin 
compaction and transcription potential of chromatin domains.  Heterochromatin is highly 
packaged such that DNA sequence elements are inaccessible to DNA binding proteins 
such as transcriptional activators.  Euchromatin domains adopt a more ‘open’ or relaxed 
chromatin conformation which permits DNA binding proteins access to their cognate TF 
binding sites, thus euchromatin can be seen to be more transcriptionally permissive than 
heterochromatin.  
Heterochromatin formation can be dynamic, i.e. regions of heterochromatin can be 
decondensed to adopt a euchromatic state and become more transcriptionally 
competent.  However at specific genomic regions, such as gene poor or repetitive regions, 
heterochromatin structure is constitutive.  Another well-reported feature of 
heterochromatin is its ability to spread throughout the genome (Grewal and Jia, 2007), 
this spreading can be halted by insulator elements (section 1.7). 
1.3.2 Nucleosome density and positioning 
Nucleosome positioning is a key regulator of gene expression, as the packaging of DNA 
into nucleosomes generally inhibits TF binding (Lorch et al., 1987, Polach and Widom, 
1995, Mao et al., 2011).  Profiling nucleosome density across the genomes of yeast and 
higher eukaryotes has revealed that regulatory elements such as promoters or enhancers 
tend to be depleted in nucleosome occupancy (Iyer, 2012, Radman-Livaja and Rando, 
2010). Furthermore it is well established that in the yeast genome the -1 and +1 
nucleosomes flanking promoter elements are highly positioned, and that the extent of 
preferred positioning of subsequent nucleosomes diminishes with increasing distance 
from the promoter (Struhl and Segal, 2013, Radman-Livaja and Rando, 2010).  The 
mechanisms by which nucleosome positioning and nucleosome depleted regions (NDRs) 
are formed have been the subject of extensive study with DNA sequence, DNA binding 
proteins, chromatin remodelling enzymes and the transcription machinery being 
implicated, either independently or cumulatively, as affecting nucleosome positioning 
20 
 
(Radman-Livaja and Rando, 2010, Luger et al., 2012, Struhl and Segal, 2013, Segal et al., 
2006, Bai et al., 2011).   
In 2012, Hughes et al used a functional evolutionary approach to identify the 
determinants of nucleosome positioning using yeast as a model system (Hughes et al., 
2012).  The results of this study suggest a role for each of the afore-mentioned factors in 
determining nucleosome positioning.  Large portions of genomic DNA from the 
evolutionarily distinct yeast species K. lactis, K. waltii and D. hansenii were transformed 
into S. cerevisiae and analysed for the formation and distribution of nucleosomes.  Many 
NDRs which exist in native species were established following sequence transformation 
into S. cerevisiae host cells, indicating that intrinsic DNA sequence is involved in 
generating NDRs.  In concordance with much of the published literature, poly(dA:dT) 
sequence motifs appear to act as the primary DNA sequence determinant directing the 
establishment of NDRs.  This is believed to result from the intrinsic rigidity of poly(dA:dT) 
motifs which inhibits DNA bending around a histone octamer and thus inhibits 
nucleosome formation.   
In the heterologous DNA segments from D. hansenii, NDRs were less conserved following 
transformation into S. cerevisiae because there are fewer poly(dA.dT) motifs in the 
promoters of this species.  Some D. hansenii promoter sequences that lost NDRs in host 
cells contained binding sites for TFs which function as general regulatory factors in D. 
hansenii but not in S. cerevisiae, supporting a role for TF binding in establishing 
nucleosome positioning.  In higher eukaryotes CTCF binding appears to function in the 
regulation of nucleosome positioning (Fu et al., 2008). 
Hughes et al also observed that the distance between adjacent nucleosomes in 
heterologous DNA-associated nucleosome arrays reduced from ~178 bp in native K. lactis 
cells to ~165 bp in S. cerevisiae host cells (Hughes et al., 2012).  This finding shows that 
DNA sequence does not dictate the majority of nucleosome positioning and indicates a 
role for species specific chromatin remodelers.  It was also discovered that the +1 
nucleosome at many TSSs differed between native and host cells, this shift was shown to 
correlate with shifted TSS positions indicating a mechanistic link between transcriptional 
initiation and positioning of the +1 nucleosome.  NDRs flanked by highly positioned -1 and 
+1 nucleosomes were also found to form in coding regions of D. hansenii genes when 
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transferred to S. cerevisiae.  The recruitment of transcription machinery and levels of RNA 
expression were found to correlate with the establishment of these novel NDRs further 
supporting a role for transcription machinery in directing nucleosome positioning.   
1.3.3 Chromatin remodelling complexes 
Chromatin remodelers are multi-protein complexes that function as DNA translocases, 
using the energy generated from ATP hydrolysis to reposition nucleosomes.  Chromatin 
remodelers are divided into four families – SWI/SNF, ISW1, CHD and IN080 – which are 
defined by the various domains present within their ATPase subunits (Figure 1.3) (Clapier 
and Cairns, 2009).  The catalytic ATPase domain of all remodelling enzymes is conserved 
and consists of one DExx and one HELICc domain.  Chromatin remodelling complexes 
affect nucleosome repositioning by mediating sliding, destabilisation, ejection or 
restructuring of nucleosomes. 
 
Figure 1.3 Chromatin remodeler families are defined by their catalytic domains.  
Figure taken from (Manelyte and Langst, 2013). 
Interactions between remodelling complexes and chromatin are mediated by nucleosome 
recognition domains within the subunits of chromatin remodelling complexes.  These 
include bromodomains, which recognise acetylated lysine residues on histone tails, 
chromodomains (CHD) and Plant Homeodomains (PHD), which bind methyl lysine, and 
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Hand-Sant-Slide domains that bind DNA and unmodified histone tails (Clapier and Cairns, 
2009, Erdel et al., 2011) (Figure 1.13). 
Chromatin remodelling is facilitated by the binding of remodelling complexes to 
nucleosomes.  Proposed models suggest that the ATPase/translocase domain binds within 
the nucleosome and remains anchored here.  Meanwhile a DNA binding domain binds 
linker DNA upstream of the nucleosome and draws this linker DNA into the nucleosome 
displacing DNA already associated with the histone octamer and creating a DNA loop 
(Figure 1.4 state 1-2).  The ATPase/translocase domain then pumps DNA towards the 
nucleosome dyad, propagating the DNA loop around the nucleosome surface (Figure 1.4 
state 2-4) (Clapier and Cairns, 2009).  DNA-histone interactions are thus disrupted at the 
leading end of the DNA loop and re-established at the lagging end.  This mechanism of 
feeding DNA around a nucleosome can be seen to facilitate nucleosome repositioning by 
sliding.  Disruption of histone-DNA interactions may also facilitate the ejection of 
nucleosomes or the exchange of histone dimers, for example the exchange of histone 
H2A-H2B dimers for H2A.Z-H2B dimers by the human chromatin remodeler complexes 
SRCAP and p400 (Marques et al., 2010). 
 
 
 
 
23 
 
 
Figure 1.4 Model of a chromatin remodelling event.   
The nucleosome is composed of a histone octamer, which is represented by a grey circle, 
and a 147 bp stretch of DNA.  The first gyre of DNA is depicted by an orange line, after 
crossing the nucleosome dyad the second DNA gyre is represented by a red dotted line.  
The asterix serves as a point of reference to aid visualisation of DNA translocation.  The 
remodelling complex interacts with the nucleosome via an ATPase/translocase (Tr) 
domain, which binds within the nucleosome where it remains anchored, and a DBD which 
binds linker DNA upstream of the nucleosome.  The combined action of the DBD and the 
Tr creates a DNA loop which is pumped around the histone core resulting in the 
repositioning of nucleosomes.  Figure taken from (Clapier and Cairns, 2009). 
1.3.4 Histone modifications 
Histone proteins have N-terminal tails which protrude from the nucleosome core.  These 
protein tails are highly basic and can make contacts with neighbouring nucleosomes, they 
also serve as substrates for post-translational modification.  Post-translational 
modification of histone tails functions to regulate chromatin structure by three 
mechanisms; firstly the physical presence of histone modifications can alter the contacts 
between neighbouring nucleosomes, secondly the post-translational modifications 
(PTMs) can recruit ATP-dependent chromatin remodelling enzymes and other binding 
proteins which can disrupt or reposition nucleosomes (section 1.3.3) and thirdly PTMs can 
inhibit specific TFs from interacting with DNA.  At least 13 types of histone PTM have 
been reported to date in the published literature including acetylation, methylation, 
phosphorylation and ubiquitination (Tan et al., 2011).  Following their deposition, PTMs 
can induce chromatin to adopt a more condensed heterochromatin conformation or a 
more open euchromatin conformation depending on the modification and which residues 
within the histone tail are affected (Bannister and Kouzarides, 2011).  In regulating 
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chromatin structure, PTMs have been shown to regulate the accessibility of DNA to TFs 
with the outcome of exerting either positive or negative effects on transcription.  In the 
following sections I will discuss the histone PTMs that are directly relevant to this thesis.  
1.3.4.1 Histone Acetylation 
Lysine acetylation was the first histone PTM to be reported in 1964 and has since been 
found to occur in the tails of all four core histones (Tan et al., 2011).  Lysine acetylation is 
a dynamic modification deposited by histone acetyl transferases (HATs).  HATs transfer 
the acetyl group from acetyl-coenzyme A to the ε-amino group of lysine side chains.  
Lysine acetylation is removed by histone deacetylases (HDACs).    Acetylation of lysine 
neutralises its positive charge, likely weakening interactions between DNA and histone 
proteins.  The resulting reduction in nucleosome stability can lead to the adoption of a 
more open chromatin structure, and in accordance with this, lysine acetylation is known 
to positively correlate with transcriptional activity (Bannister and Kouzarides, 2011, 
Zentner and Henikoff, 2013).   
Histone acetylation is targeted by the recruitment of HATs to specific genomic regions by 
transcriptional co-activators.  For example the TFs BRCA1 and c-Myc interact with the 
TRRAP protein which is a subunit of macromolecular HAT-containing complexes.  This 
TRRAP interaction mediates the association of BRCA1 with the GCN5 HAT, and 
recruitment of BRCA1/TRRAP/GCN5 complexes to BRCA1 target sites has been shown to 
correlate with acetylation of histone H3 (Oishi et al., 2006).  In similar systems, 
association of TRRAP with C-Myc has been reported to recruit both the GCN5 and TIP60 
HATs to C-Myc binding sites (McMahon et al., 2000, Frank et al., 2003). 
Following their deposition, acetyl lysine marks recruit proteins containing bromodomains 
via an interaction between the acetyl group and the bromodomain.  Bromodomains are 
generally found in proteins that act as regulators of chromatin structure and gene 
expression such as the BRG1 protein, one of the protein subunits of the ATP-dependent 
SWI/SNF chromatin remodelling complex.  The BRG1 bromodomain is required for full 
binding of SWI/SNF to H3- and H4-acetylated nucleosomes (Hassan et al., 2006, Awad and 
Hassan, 2008).  Subsequent chromatin remodelling by means of nucleosome sliding and 
eviction results in genomic DNA regions that were previously inaccessible due to 
nucleosome positioning becoming accessible to DNA binding factors (Wilson and Roberts, 
2011). 
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1.3.4.2 Histone methylation 
Methylation of specific lysine and arginine residues has been reported to occur in the tails 
of all four core histones (Tan et al., 2011).  Lysine residues can be mono-, di-, or tri-
methylated, while arginine residues can be mono-methylated and symmetrically or 
asymmetrically di-methylated (Bannister and Kouzarides, 2011).  Histone methyl 
transferase enzymes catalyse the transfer of a methyl group from S-adenosylmethionine 
(SAM) to target residues within histones.  Lysine methylation is catalysed by either SET-
domain-containing proteins or DOT1-like proteins, which transfer a methyl group to the ε-
amino group of lysine.  Arginine methylation, meanwhile, is catalysed by members of the 
PRMT protein family, which transfer a methyl group to the ω-guanidino group of arginine.  
Histone methyl transferases tend to show high specificity towards the lysine or arginine 
residues that they target and the level of methylation they impart, for example the 
histone lysine methyl transferase (HKMT) complex SET7/9 specifically targets H3K4 for 
monomethylation (Xiao et al., 2003).  
Methylation of amino acid residues within histone tails does not alter histone charge as 
acetylation does, however this PTM exerts effects on chromatin structure by recruiting 
various chromodomain-containing proteins such as chromatin remodelling complexes.  
Histone methylation can therefore result in either positive or negative effects on 
transcription depending on which lysine or arginine residues are affected and the extent 
of methylation (e.g. mono-, di-, or tri-methylation). 
It has been proposed that DNA sequence, long non-coding RNAs (lncRNA) and DNA 
methylation can direct histone methylation throughout the genome (reviewed in (Greer 
and Shi, 2012).  In Drosophila, the H3K4 methyltransferase TRX is known to be recruited 
to trithorax group response elements (TREs), while the Polycomb repressive complex 2 
(PRC2), which catalyses trimethylation of H3K27, is recruited to Polycomb group response 
elements (PREs).  Recruitment of methyltransferases to these specific genomic sites in 
Drosophila is likely mediated by sequence-specific DNA binding proteins such as the PHO 
protein (Brown et al., 1998, Fritsch et al., 1999).  PHO is a polycomb group protein (PcG) 
that binds specific DNA motifs frequently found at PREs and functions in the recruitment 
of PcG complexes.  The mechanism of PcG complex targeting in mammals is not well 
understood, however the protein YY1 has been identified as the mammalian functional 
homologue of drosophila PHO (Atchison et al., 2003).  siRNA-mediated knock down of YY1 
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results in reduced recruitment of the EZH2 PcG methyltransferase and a subsequent loss 
of H3K27me3 at YY1 binding sites (Caretti et al., 2004).  Some aspects of PcG complex 
recruitment therefore appear to be conserved between drosophila and mammals.  To 
date only a small number of putative PREs have been identified in mammals (Sing et al., 
2009, Woo et al., 2010, Bengani et al., 2013).  
Reported interactions between lncRNAs, histone methyltransferases and demethylases 
have led to the hypothesis that lncRNAs may function in directing these enzymes to their 
genomic target sites.  For example, the human lncRNA HOTAIR interacts with both the 
HKMT complex PRC2 and the lysine demethylase LSD1, directing these enzymes to 
distinct  regions of the genome (Tsai et al., 2010).  DNA methylation has also been 
implicated in directing histone methylation, as the methyl-CpG binding domain (MBD) of 
the Arabidopsis thaliana H3K9 histone methyltransferase SUVH4 interacts with 
methylated DNA, and mutation of the SUVH4 MBD results in diminished levels of 
H3K9me2 (Johnson et al., 2007). 
Although for some time histone methylation was believed to be irreversible, it is now well 
established that this is in fact a dynamic modification but with a slower turnover than 
other histone PTMs (Shi et al., 2004, Bannister and Kouzarides, 2011).  Histone 
demethylation is catalysed by histone demethylase enzymes and distinct demethylases 
act on methylated lysine or arginine substrates.  Two families of lysine demethylases have 
been identified; amine oxidase and jumonji C (JmjC)-domain-containing, iron-dependent 
deoxygenases (Greer and Shi, 2012).  Similarly to HKMTs, lysine demethylases show a 
high level of substrate specificity.  The enzymes that mediate arginine demethylation 
have largely evaded characterisation to date, however in 2007 JMJD6 was discovered to 
have arginine demethylase activity (Chang et al., 2007). 
1.3.5 Histone variants 
In addition to the five core histone proteins are histone variants.  Variants of the core 
histones H1, H2A, H2B and H3 have been discovered and characterised (reviewed in 
(Sarma and Reinberg, 2005, Kamakaka and Biggins, 2005, Talbert and Henikoff, 2010).  
The incorporation of non-canonical histones into nucleosomes has been shown to alter 
nucleosome properties by inducing changes in histone-DNA interactions.  It is known that 
certain histone variants localise to specific genomic regions, indicating that they may 
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perform specific functions at these elements.  In support of this hypothesis, histone 
variants have been found to function in a number of cellular processes including 
transcription initiation and repression, DNA repair and X-chromosome inactivation. 
The most studied histone variant is H2A.Z, which is deposited into nucleosomes by the 
exchange of H2A-H2B dimers for H2A.Z-H2B dimers.  This histone dimer exchange is 
catalysed by both the SRCAP (Wong et al., 2007, Yang et al., 2012) and p400 (Gévry et al., 
2007, Lee et al., 2012) ATP-dependent chromatin remodelling complexes in human cells.  
However it is unclear how H2A.Z deposition throughout the genome is targeted (Marques 
et al., 2010).   H2A.Z is a key regulatory protein involved in mediating both positive and 
negative effects on gene expression (Marques et al., 2010).  A positive role for H2A.Z in 
gene regulation is supported by the finding that this variant is frequently incorporated 
into the nucleosomes that flank nucleosome depleted regions at transcription start sites 
(TSS) where it functions in recruiting RNA pol II (Adam et al., 2001, Hardy et al., 2009, 
Gévry et al., 2009, Barski et al., 2007).  A mutually antagonistic relationship has also been 
reported between H2A.Z and DNA methylation (an epigenetic modification associated 
with transcriptional repression, see section 1.4) in the genomes of numerous organisms 
including Arabidopsis thaliana, mouse and human (Zilberman et al., 2008, Zemach et al., 
2010, Edwards et al., 2010, Conerly et al., 2010, Yang et al., 2012).  However H2A.Z has 
also been reported as accumulating throughout transcriptionally silent gene bodies 
located within heterochromatic regions, suggesting a potential role for H2A.Z in the 
establishment or maintenance of the heterochromatic state (Hardy et al., 2009).   
Contradictory findings regarding the stability of H2A.Z-containing nucleosomes have been 
reported in the published literature.  Some groups have reported H2A.Z incorporation to 
increase nucleosome stability (Park et al., 2004, Thambirajah et al., 2006) while others 
report H2A.Z-containing nucleosomes to be more unstable than those containing  major 
H2A (Suto et al., 2000, Abbott et al., 2001, Zhang et al., 2005).  However it appears that 
these disparities may in part reflect the histone partners of H2A.Z within the nucleosome.  
Jin and Felsenfeld have shown nucleosomes containing the histone variant H2A.Z only, to 
be at least as stable as nucleosomes composed solely of major histone proteins (Jin and 
Felsenfeld, 2007).  Meanwhile nucleosomes containing both the histone variants H2A.Z 
and H3.3 were found to be more laible than H2A/H3 or H2A.Z/H3 nucleosomes.  
H2A.Z/H3.3 nucleosomes are found at the promoters, enhancers and coding regions of 
highly expressed genes (Jin and Felsenfeld, 2007) where the instability of these 
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nucleosomes presumably allows them to be easily displaced by the transcriptional 
machinery. 
1.3.6 Histone cross-talk 
Diverse combinations of histone modifications can work in concert to achieve fine-tuning 
of chromatin structure by both directly altering chromatin structure and regulating the 
recruitment of specific chromatin remodelling complexes.  The deposition of some PTMs 
is dependent upon the presence of others, for example ubiquitination of H2B has been 
shown to be required for H3K4 and H3K79 methylation by specific HKMTs in yeast (Lee et 
al., 2007a).  H2B ubiquitination is also required for the Setd1-mediated di- and tri-
methylation of H3K4 in humans (Kim et al., 2009).  Other histone modifications can be 
mutually exclusive such as acetylation and methylation of the same lysine residue.  The 
presence of one PTM may inhibit protein binding to a neighbouring modification, for 
example the binding of Chp1 to H3K9me2/3 in yeast is inhibited by H3K4ac (Xhemalce 
and Kouzarides, 2010).  Bivalent chromatin domains have also been reported such as 
those enriched by both the active H3K4me3 modification and the repressive H3K27me3 
mark.  Such bivalent domains have been found to be largely transcriptionally inactive but 
are believed to represent chromatin domains which are poised for active transcription 
(Greer and Shi, 2012). 
1.3.7 Histone modifications at regulatory elements 
NDRs found at regulatory elements such as promoters and enhancers are flanked by 
highly positioned nucleosomes, which contain specific histone modifications.  The 
formation of NDRs allows TF binding to specific regulatory elements, contributing to the 
formation of the PIC and initiation of transcription.  H3K4me3 is a characteristic mark of 
active promoter elements.  One mechanism by which H3K4me3 can be targeted to active 
promoters is via initiating RNA pol II.  Initiating RNA pol II is post-translationally 
phosphorylated at serine 5, the HKMT Set1 is recruited to sites of transcriptional initiation 
via interaction with this modification.  Set1 tri-methylates H3K4 leading to H3K4me3 
enrichment being a characteristic mark of active promoters (Ng et al., 2003, Hampsey and 
Reinberg, 2003).  H3K4me2 and H3K4me1 marks are also deposited by Set1-containing 
complexes, H3K4me2 locates to promoter and enhancer elements while H3K4me1 
preferentially associates with enhancers.  The H3K27ac PTM also associates with active 
regulatory regions, this modification is found at promoters and has been shown to 
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distinguish active enhancers from inactive or poised enhancers (Creyghton et al., 2010).  
The histone H3K36me3 mark maps to transcribed regions of the genome.  H3K36me3 is 
deposited by the Set2 HKMT which is recruited to transcribed regions by the elongating 
RNA pol II isoform which is phosphorylated at serine 2 (Krogan et al., 2003, Hampsey and 
Reinberg, 2003).  In addition to active histone modifications, the histone variant H2A.Z is 
also known to be enriched at the highly positioned nucleosomes flanking NDRs at active 
regulatory elements (Talbert and Henikoff, 2010). 
Chromatin signatures associated with repressed genomic regions include H3K9me3, 
which is deposited by the SUV39H1 HKMT in humans, and the H3K27me3 mark, which is 
deposited by the PRC2 complex.  As mentioned previously, bivalent chromatin domains 
have been identified that are enriched by both the active PTM H3K4me3 and the 
repressive modification H3K27me3.   Such bivalent domains are generally 
transcriptionally inactive but are believed to mark promoter elements that are poised for 
active transcription (Greer and Shi, 2012). 
1.3.8 General transcription factors 
In eukaryotic systems, RNA polymerase II requires the presence of transcription factor 
proteins to initiate transcription of mRNA from a DNA template.  The six general 
transcription factors - TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH - are components of the 
basic transcription machinery and function in all RNA pol II-mediated transcription events 
by interacting with RNA pol II to form the PIC.  TFIID binds specific DNA sequence 
elements (described in section 1.2.2.1) at promoters via its TBP or TAF subunits, TFIIA and 
TFIIB are then recruited via interactions with the TBP subunit.  RNA pol II and TFIIF are 
then recruited via their interactions with the TFIID-TFIIB complex.  TFIIE subsequently 
binds the complex and recruits TFIIH (Cooper, 2000).  TFIIH contains ATPases and 
helicases that unwind double stranded DNA (Schaeffer et al., 1993, Schaeffer et al., 1994).  
TFIIH also contains a protein kinase that phosphorylates the C-terminal domain of the 
large RNA pol II subunit, this phosphorylation event releases RNA pol II from its 
association with the PIC allowing active transcription to proceed (Akoulitchev et al., 
1995).  This is the minimal system required for in vitro transcription however additional 
transcription factors are frequently required for the recruitment of the PIC at individual 
regulatory elements.  There is also evidence that RNA pol II can form complexes with the 
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general transcription factors TFIIB, TFIIE, TFIIF and TFIIH prior to the formation of the PIC 
on DNA (Greenblatt, 1997, Davis et al., 2002).  These complexes are termed RNA pol II 
holoenzymes and are recruited to promoter elements via direct interactions with TFIID to 
facilitate transcription.   
1.3.9 Transcription factors and co-operativity 
Transcription factor binding sites are known to cluster at regulatory genomic elements.  
Combinatorial binding of transcription factors to clustered binding sites enables the 
precise regulation of transcriptional activity (Spitz and Furlong, 2012).  Co-operativity 
between transcription factors can increase the DNA binding affinity of these proteins 
(Spitz and Furlong, 2012).  Direct co-operativity between transcription factors may result 
from direct protein-protein interactions between factors with neighbouring binding sites, 
these interactions can facilitate or stabilise interactions between transcription factors and 
their binding sites.  Indirect transcription factor co-operativity may result when binding of 
a transcription factor to its recognition site induces local DNA bending which in turn may 
assist binding of another transcription factor to a neighbouring binding site.  Another 
form of indirect transcription factor co-operativity, termed collaborative competition, has 
been observed when two or more proteins that compete for a single binding site are 
expressed simultaneously. Co-expression can increase transcription factor occupancy as 
multiple proteins compete more efficiently than a single protein with nucleosomes for 
DNA binding, thus inhibiting nucleosome repositioning over the binding site and 
increasing net transcription factor binding (Polach and Widom, 1996). 
1.4 DNA methylation 
1.4.1 Cytosine methylation 
DNA methylation in vertebrates is the process by which a methyl group is covalently 
linked to the 5th carbon of a deoxycytosine residue.  DNA methylation is largely restricted 
to cytosine residues that exist within CpG dinucleotides and is catalysed by DNA methyl 
transferase enzymes (DNMTs) (Robertson and Wolffe, 2000, Robertson, 2005).  This 
epigenetic modification is widely reported as being associated with transcriptional 
inhibition which can be a result of; i) the methyl group impeding transcription factor 
binding or ii) methyl-binding domain proteins (MBDs) associating with methylated CpG 
sites and recruiting transcriptional co-repressors and/or chromatin remodelers.   
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DNA methylation is of great importance in healthy tissues as it is involved in the 
regulation of a number of critical cellular processes including differentiation, X-
chromosome inactivation and silencing of retrotransposons (Robertson and Wolffe, 2000, 
Strathdee et al., 2004).  Aberrant cytosine methylation has also been linked to several 
human diseases such as Rett, fragile X and ICF syndromes (Robertson and Wolffe, 2000, 
Robertson, 2005).    Compelling correlations have been reported between aberrant DNA 
methylation and cancer, where hypermethylation of tumor suppressor gene promoters is 
a characteristic epigenetic change observed in malignancies which can lead to the loss of 
tumor suppressor activity (Esteller, 2007).  Loss of transcriptional activity has been widely 
reported as correlating with an accumulation of DNA methylation, highlighting the 
importance of maintaining correct DNA methylation patterns (Deaton and Bird, 2011).  
Aberrant DNA methylation in disease establishment and progression is of major interest 
as, unlike genetic alterations, DNA methylation has the potential be effectively reversed 
due to its dynamic nature.  Indeed it has already been shown that treatment with 5-
azacytidine inhibits DNA methylation and, over time, leads to a pronounced 
demethylation which correlates with re-expression of associated genes (Christman, 2002). 
1.4.2 CpG-containing DNA elements 
Approximately 70 – 80 % of CpG dinucleotides within the human genome are methylated.  
However regions with elevated CpG frequencies, termed CpG islands (CGIs), have been 
shown to remain largely unmethylated (Deaton and Bird, 2011).  CGIs have been 
classically defined as being 0.5 – 5 kb in length, containing >50% GC content, and 
exhibiting an observed-to-expected CpG ratio >0.6 (Gardiner-Garden and Frommer, 
1987).  This ratio is elevated in comparison to non-CGI regions of the genome due to the 
propensity of methylated cytosine to undergo deamination, resulting in its conversion to 
thymine (Robertson and Wolffe, 2000).  CGIs have a tendency to be located at regulatory 
regions of the genome, such as promoters, and it is hypermethylation of these elements 
that strongly correlates with promoter silencing and gene repression (Esteller, 2007).  As 
>70% of annotated gene promoters contain a CGI (Saxonov et al., 2006), maintenance of 
appropriate CGI methylation is of great importance. 
1.4.3 Directing DNA methylation 
CpG methylation is established and maintained by DNMT enzymes.  De novo DNA 
methylation is mediated by DNMT3A and DNMT3B, while the maintenance 
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methyltransferase DNMT1 acts upon hemi-methylated DNA to preserve established 
methylation patterns following DNA replication.  DNMTs show little or no DNA sequence 
specificity and appear to rely on protein-protein interactions to target them to DNA 
elements.  For example the DNMT3L protein, which lacks a catalytic domain, can interact 
with the amino terminus of histone H3 and recruit the de novo methyltransferases 
DNMT3A and DNMT3B thereby directing de novo DNA methylation (Robertson, 2002).  
DNMTs may also be recruited to specific genomic regions by histone methyltransferases 
such as EZH2.  EZH2 is a polycomb group protein that functions as a histone 
methyltransferase mediating deposition of the repressive H3K27me modification.  EZH2 
can interact with DNMTs 1, 3A and 3B recruiting them to EZH2 target sites where DNA 
methylation marks can be deposited (Viré et al., 2006).  DNMTs have also been also been 
shown to be recruited to specific genomic regions via protein-protein interactions with 
HDACs.  In addition to these targeting mechanisms, interactions between DNMTs and TFs 
have been reported to direct DNA methylation.  For example DNMT3A interacts with the 
MIZ1-MYC repressive protein complex and is recruited to MIZ1 target sites where de novo 
DNA methylation is established accompanied by transcriptional repression (Brenner et al., 
2005).   
1.4.4 Protection from DNA methylation 
Several mechanisms have been described in the published literature as mediating 
protection from DNA methylation.  The first protein-DNA interaction shown to protect 
DNA from de novo methylation was between the E. coli lac repressor (LacI) and lac 
operator (lacO) (Han et al., 2001).  These studies showed that when lacO sites were 
introduced into mammalian cells, as episomes or via stable integration into genomic DNA, 
they were protected from DNA methylation via binding of LacI.  IPTG treatment of the cell 
culture, which inhibits LacI binding to lacO sites, abolished this protective action 
demonstrating its function in prevention of de novo DNA methylation.  A similar 
experimental design has also shown LacI binding to lacO sites to direct demethylation of 
pre-methylated lacO sites (Lin et al., 2000, Lin and Hsieh, 2001).  Subsequent to this 
finding, evidence in the published literature has both suggested and demonstrated roles 
for numerous proteins in protecting the unmethylated state of DNA elements via 
interactions with associated binding sites.  For example, the interaction of CTCF with 
specific binding sites has been shown to protect the H19 differentially methylated region 
(DMR) and the retinoblastoma (Rb) promoter from DNA methylation (Lewis and Murrell, 
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2004, Schoenherr et al., 2003, Pant et al., 2003, Dávalos-Salas et al., 2011, Fedoriw et al., 
2004).  Further to this, CTCF sites have been shown to mediate demethylation of a pre-
methylated H19 DMR following its integration into mouse ES cells (Rand et al., 2004).   
The unmethylated CpG binding protein Cfp1 has also been shown to function in the 
protection of DNA from de novo methylation.  Cfp1 interacts with the HKMT Setd1, 
recruiting it to unmethylated regions of the genome whereupon Setd1 deposits the active 
H3K4me3 PTM (Thomson et al., 2010).  As described previously, DNMT3L binding to the 
amino terminus of histone H3 can direct DNA methylation by recruiting the de novo 
DNMTs.  Tri-methylation of histone H3K4 inhibits DNMT3L binding (Ooi et al., 2007), as a 
result of this DNMT3A and DNMT3B are not recruited and DNA is therefore protected 
from de novo methylation. 
 The histone variant H2A.Z has also been implicated as having a role in protecting DNA 
from methylation as H2A.Z occupancy of genomic elements has been shown to inversely 
correlate with DNA methylation in the Arabidopsis thaliana, puffer fish and human 
genomes (Zilberman et al., 2008, Zemach et al., 2010, Conerly et al., 2010).  In 
Arabidopsis DNA methylation has been shown to exclude H2A.Z from associated 
nucleosomes, but H2A.Z nucleosomal incorporation has also been shown to prevent 
associated DNA from becoming methylated.  Thus the histone variant H2A.Z appears to 
mediate another mechanism of protection from DNA methylation. 
Computational studies have shown a number of DNA motifs to be over-represented 
within unmethylated CGIs and in their boundaries indicating a potential functional role in 
protection from DNA methylation.   These motifs likely function as binding sites for 
specific TFs or other proteins whose binding may prevent the establishment of DNA 
methylation (Fan et al., 2007).  To date a small number of these sites have been validated 
as functioning to protect DNA from the establishment of de novo methylation.  The 
mouse and hamster aprt gene promoter-associated CGI contains three DNA motifs which 
match the consensus binding site of the TF SP1.  Deletion and mutation of these sites 
have been shown to result in hypermethylation of the CGI (Macleod et al., 1994, Brandeis 
et al., 1994).  Furthermore, the presence of these intact SP1-like binding motifs directs 
active demethylation of a pre-methylated aprt CGI following integration into the genomes 
of mouse ES cells, with this activity being lost in the absence or mutation of these protein 
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binding sites (Brandeis et al., 1994).  These findings demonstrate that SP1-like motifs in 
the aprt promoter function in maintaining the unmethylated state of the associated CGI.  
Subsequently Marin et al (Marin et al., 1997) knocked out the Sp1 gene in mouse 
embryo’s however, no effect on the methylation status of the mouse aprt CGI was 
observed, i.e. the CGI remained unmethylated.  It can therefore be concluded that 
binding of Sp1 to the crucial Sp1-like binding sites does not maintain the unmethylated 
status of this CGI.  In a later publication by Dickson et al, VEZF1 was found to bind one of 
the SP1-like sites in the aprt CGI (Dickson et al., 2010).  All three SP1-like elements were 
then replaced with VEZF1-specific binding motifs and the modified aprt CGI was found to 
remain protected from DNA methylation and to direct demethylation when pre-
methylated upon integration into the genome of mouse ES cells (Dickson et al., 2010).  In 
other published literature, OCT and SOX protein binding sites have been shown to be 
required to prevent de novo DNA methylation (Hori et al., 2002, Kaufman et al., 2009). 
1.4.5 DNA demethylation 
It has been apparent for some time that DNA methylation at numerous genomic locations 
is dynamic.  However a passive demethylation mechanism, whereby downregulation of 
DNMTs results in demethylation over the course of numerous cell divisions, does not 
explain rapid DNA demethylation events (Bhutani et al., 2011).  An example of this is the 
demethylation of the paternal chromosome complement, which has been observed to 
occur in post-fertilisation zygotes (Oswald et al., 2000).  The mechanism of active DNA 
demethylation remained unresolved until Tahiliani et al showed methyl cytosine (5mC) 
can be converted, by oxidation and hydroxylation, to hydroxymethylcytosine (5hmC) by 
members of the ten-eleven translocation (TET) protein family (Figure 1.5) (Tahiliani et al., 
2009).  Further studies have shown 5hmC to be deaminated by activation-induced 
cytidine deaminase (AID), a member of the APOBEC protein family, generating the base 
hydroxymethyl uracil (5hmU) (Cortellino et al., 2011, Guo et al., 2011).  5hmU is in turn 
recognised by members of the uracil DNA glycosylase (UDG) protein family, TDG and 
SMUG1, which mediate a 5hmU to cytosine conversion via the base excision repair 
pathway (BER), completing the conversion from methylated cytosine to unmethylated 
cytosine (Figure 1.5) (Cortellino et al., 2011, Guo et al., 2011). 
 More recently, reports have been published showing that TET1 proteins can further 
oxidise 5hmC, generating the newly identified 5-formylcytosine (5fC) and 5-
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carboxylcytosine (5caC) (He et al., 2011, Ito et al., 2011).  These bases also appear to 
function in DNA demethylation as 5caC can be excised and replaced by cytosine via the 
action of TDG in the BER pathway (Figure 1.5) (He et al., 2011).  Ito et al also showed that 
5caC could be directly converted to cytosine, without BER, in a reaction mediated by a 
putative decarboxylase (Ito et al., 2011).  
 
 
Figure 1.5 Active DNA demethylation.   
5mC can be directly deaminated by AID to form thymine.  Such cytosine to thymine 
conversions can be recognised and repaired by the BER pathway or can persist unrepaired 
resulting in a permanent base conversion to thymine.  5mC can also be converted to 
5hmC by the TET family enzymes.  5hmC can be deaminated to form 5hmU or further 
oxidised by TET proteins to form 5fC and 5caC.  5hmU and 5caC are removed by the BER 
pathway and replaced by cytosine residues. 
Genome-wide studies of 5hmC distribution have revealed a general enrichment at active 
enhancer elements and gene bodies (Stroud et al., 2011) as well as a positive correlation 
between 5hmC enrichment and active gene expression (Song et al., 2011).  These findings 
indicate a potential role for 5hmC in the regulation of gene expression.  It is currently 
unknown how transient 5hmC is, but it is possible that this base has a role in protecting 
DNA from methylation.  It has been reported that DNA binding of the MBD protein Mecp2 
is impaired when 5mC in the target sequence is replaced by 5hmC (Valinluck et al., 2004).  
As MBD protein binding to methylated DNA recruits histone modifying complexes which 
in turn mediate the establishment of a repressive chromatin state (Nan et al., 1998, Jones 
et al., 1998, Fuks, 2005), the inhibition of MBD-DNA interaction is likely to impair 
heterochromatin formation.   It has also been reported that the DNA binding activity of 
DNMT1 is impaired by 5hmC (Valinluck and Sowers, 2007, Tahiliani et al., 2009), further 
supporting a putative role for 5hmC in protection of DNA from methylation.  In this case, 
impaired DNA binding of DNMT1 would function to prevent maintenance DNA 
methylation and passive demethylation over cell divisions would be promoted.   
TET
TET
TET
AID
AID
BER
BER
BER
36 
 
1.4.6 Bisulphite sequencing 
The bisulphite sequencing method for profiling DNA methylation was developed and first 
described by Clark et al (Clark et al., 1994).  This technique allows the methylation status 
of individual cytosine residues to be elucidated.  The process uses sodium bisulphite to 
convert unmethylated cytosine nucleosides to uracil in conditions where methylated 
cytosine is unchanged.  The first step in this process is the sulfonation of unmethylated 
cystosine residues to produce cytosine sulfonate.  These modified residues then undergo 
hydrolytic deamination which converts cytosine sulfonate to uracil sulfonate following 
which alkali desulphonation removes the sulfonate group yielding uracil (Figure 1.6).   
 
Figure 1.6 Schematic representation of the bisulphite conversion reaction.  
 Adapted from (Clark et al., 1994). 
A number of kits are now commercially available with which to achieve bisulphite 
conversion of target DNA.  For the DNA methylation studies presented in this thesis the 
EZ DNA Methylation Direct Kit from Zymo Research was used.  The manufacturers of this 
kit claim that >99.5 % of non-methylated cytosine residues are converted to uracil, and 
that >99.5 % of methylated cytosines are protected from bisulphite conversion when 
using this kit. 
Bisulphite conversion of DNA is followed by PCR amplification of a specific genomic region 
of interest.  Numerous online tools are available to aid with the design of primers to 
amplify bisulphite modified DNA as several factors require consideration.  Primers should 
be designed to amplify bisulphite modified DNA templates presuming that 100 % 
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conversion of unmethylated cytosine residues will be achieved.  Thus cytosine residues 
that are not part of a CpG dinucleotide will be presumed to have been converted to uracil 
in the template DNA and must be paired with adenine residues in the primer.  The 
presence of CpG dinucleotides within primer binding sites should be avoided as whether 
these cytosine residues will remain cytosine following bisulphite modification or be 
converted to uracil is dependent on their DNA methylation state and likely unknown at 
the point of primer design.  The incorporation of CpG sites in primers can bias the PCR 
amplification of methylated or unmethylated DNA and will not allow the DNA 
methylation state of the associated cytosine residue to be determined by sequencing.  
The process of bisulphite modification is known to cause degradation of DNA (Grunau et 
al., 2001) and the presence of uracil residues slows DNA polymerase-mediated 
amplification of target sequences.  The combination of these factors creates a correlation 
between shorter target amplicon size and increased PCR yield however amplicons of up 
to ~ 1 Kb are generally quite achievable.   
1.5 Genome-wide mapping of epigenetic modifications 
The identification and characterisation of epigenetic modifications across the genome 
allows the detection of regulatory elements and provides an insight into the regulatory 
mechanisms that function at these elements.  Many experimental techniques have been 
developed to aid the genome-wide mapping of epigenetic modifications, some of which 
are described below. 
1.5.1 Chromatin Immunoprecipitation  
Chromatin immunoprecipitation (ChIP) was first described in 1988 (Solomon et al., 1988) 
and is now a standard technique employed to investigate protein-DNA interactions.  
Conventional ChIP uses formaldehyde to cross-link proteins to associated DNA after 
which chromatin is fragmented by sonication.  Immunoprecipitation, using an antibody 
specific for a protein of interest, enriches for complexes containing that protein.  Enriched 
DNA sequence elements are then purified away from associated proteins.  Analysis of 
these enriched sequences provides information regarding the DNA elements with which a 
protein of interest interacts.  This analysis can be achieved by qPCR to assay the 
enrichment of specific sequence elements, or by the high throughput methods of 
hybridising ChIP-enriched DNA onto microarrays (ChIP-chip) or using massively parallel 
sequencing technology to directly sequence enriched DNA elements (ChIP-seq).   
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1.5.1.1 ChIP-chip 
High throughput quantitation of immunoprecipitated DNA can be achieved by 
hybridisation to tiled genomic DNA microarrays (ChIP-chip) which allows the 
simultaneous analysis of thousands of DNA sequence elements to determine their 
enrichment following ChIP.  Microarrays are typically glass surfaces to which thousands of 
single stranded oligonucleotide probes are attached.  A variety of high density DNA 
microarrays are commercially available that are generated by in situ synthesis of 
oligonucleotides, of typically 50-80 bases in length, directly on the chip surface.  
Affymetrix arrays are generated using photolithography where each DNA residue contains 
a photolabile protection group.  A series of masks are used to direct specific patterns of 
UV light onto the chip in order to cleave UV-labile protection groups from targeted 
oligonucleotide chains allowing addition of the next nucleotide.  Nimblegen arrays are 
synthesised using the same chemistry however a system of digital mirrors is used in place 
of masks to direct UV light to specific oligonucleotide chains.  Agilent arrays are 
generated using an in situ synthesis printing process that utilises SurePrint Inkjet 
technology to deposit oligonucleotide monomers on to chips.  Microarrays can also be 
generated by attaching double stranded PCR products of 200-400 bp in length to solid 
chips via 5’-(C6) amino-link modifications that are present on one strand of the PCR 
products (Dhami et al., 2005).  Unmodified strands are separated from their partner 
strands by denaturing and are removed from the chip by washing to generate a complete 
microarray.  The choice of DNA microarray platform is a balance between the high 
resolution and high genome coverage of commercial printed tiling arrays and the 
increased sensitivity offered by PCR product arrays (Dhami et al., 2005). 
In ChIP-chip, fluorescently labelled ChIP DNA and input or control DNA are labelled with 
different fluorophores and co-hybridised to the genomic DNA microarray.  Fluorescent 
spots can then be detected across the microarray corresponding to genomic sequence 
elements that are bound by labelled ChIP or input DNA due to their complementary 
sequences.  The ratio of ChIP to input DNA fluorescence intensities at each element 
represented on the microarray is calculated to provide a measure of the extent of protein 
binding to the corresponding genomic locus (Iyer et al., 2001). Thus by identifying the 
DNA probe sequence that each fluorescent spot maps to we can identify genomic regions 
that are bound by the protein of interest for which ChIP was performed. 
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1.5.1.2 ChIP-seq 
Conventional ChIP followed by massively parallel sequencing (ChIP-seq) is a technology 
that emerged in 2007 (Robertson et al., 2007) following the establishment of ChIP-chip 
platforms.  Comparisons of these two technologies have shown the enrichment profiles of 
protein factors to be highly conserved between them.  However these comparisons have 
also shown ChIP-seq to generate enrichment profiles with higher sensitivity and 
specificity than ChIP-chip due to the higher spatial resolution achievable with ChIP-seq 
profiling (Robertson et al., 2007, Ho et al., 2011).  The ability of ChIP-seq to profile binding 
sites of a protein of interest across the whole genome simultaneously is another 
advantage to the ChIP-seq technology, in addition to this ChIP-seq has been reported to 
be the more cost-effective method of analysing mammalian genomes.  This technique is 
now routinely used to profile the interactions of a protein of interest with DNA elements 
on a genome-wide scale. 
There are several next generation sequencing (NGS) platforms available including Applied 
Biosystems’ SOLiD platform, Applied Science’s 454 Sequencing platform, Ion Torrent PGM 
and Illumina sequencing platforms.  These platforms differ in many aspects including 
sequencing biochemistry, instrument cost, sequence yield per run, sequencing cost, run 
time, read length and accuracy.  Illumina NGS platforms have dominated the field in 
recent years and as Illumina sequencing was used in this project I shall explain this 
method in more detail below. 
In order to undergo next generation sequencing (NGS), genomic ChIP DNA must first be 
used to create ChIP-seq libraries.  This involves the ligation of adaptor oligos to either end 
of ChIP-enriched genomic DNA fragments, followed by PCR amplification and size 
selection.   ChIP-seq library samples are denatured and loaded into separate channels of a 
flow cell.  The flow cell surface is covered by a lawn of primer pairs complementary in 
sequence to the adapters that are ligated to ChIP DNA during library preparation.  DNA 
fragments from ChIP-seq libraries are bound by the flow cell primers which are extended 
by PCR to generate copies of ChIP-enriched DNA sequences that are covalently bound to 
the flow cell surface (Figure 1.7).  Denaturing and washing removes the original template 
DNA strands leaving single stranded molecules bound to the flow cell in random patterns.  
The free end of each single stranded DNA molecule then binds to an adjacent primer on 
the flow cell to form a bridge (Figure 1.7).  PCR extends the newly bound primer to create 
a double stranded bridge.  Denaturing results in the generation of two single stranded 
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DNA molecules originating from one ChIP-seq library fragment.  Repetition of bridge 
amplification generates many bridges from one original library fragment (Figure 1.7).  This 
process of clonal bridge amplification proceeds to generate millions of unique DNA 
sequence clusters over the whole flow cell channel surface and is termed Cluster 
Generation.   
Upon completion of bridge amplification, double stranded bridges are denatured.  
Reverse DNA strands are then cleaved and removed from the flow cell by washing, 
leaving whole clusters that consist only of forward DNA strands (Figure 1.7). 
During the sequencing stage the millions of clusters present in each flow cell channel are 
sequenced simultaneously (Figure 1.7).  DNA strands are bound by sequencing primers 
and the synthesis of complementary strands commences.  The dNTPs used in these 
sequencing reactions are fluorescently labelled, with a different coloured fluorophore 
corresponding to each of the four DNA bases.  Following the addition of each new 
nucleotide, clusters are excited by a laser which stimulates the emission of a detectable 
colour from the newly added nucleotide allowing its identification and the generation of 
DNA sequence information.  The dNTPs used in sequencing also contain a terminator 
group which prevents more than one base being added per cycle.  Once the fluorescence 
signal of the latest base addition has been detected, the fluorescent label and blocking 
group are removed from the newly added nucleotide and the next base may be added to 
the sequencing DNA strand.  
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Figure 1.7 Schematic of NGS cluster generation and sequencing using an Illumina 
platform.   
ChIP-seq library fragments bind to a lawn of primers on the flow cell surface via their 
complementary adapter sequences.  Primer extension generates a copy of the ChIP-seq 
library sequence which is covalently bound to the flow cell and the original sequence is 
removed.  Clonal bridge amplification generates millions of unique DNA sequence clusters 
across the flow cell channel, which are then sequenced simultaneously using 
fluorescently labelled dNTPs.  Adapted from 
http://mi.caspur.it/workshop_NGS09/docs/Cappelletti_NGS09.pdf 
Upon completion of NGS runs, the sequence reads generated must be aligned to a 
reference genome in order to map enrichment of the protein of interest across the 
genome.  From each sequencing reaction tens of millions of reads can be expected to be 
generated, NGS can therefore be seen to generate a huge volume of data at relatively low 
cost.  A major issue associated with NGS is the processing of the large amount of 
sequence data produced per run, to extract and interpret biologically meaningful 
information.  This has presented bioinformatics challenges for the quality scoring of data, 
processing data and storing of data (Shendure and Ji, 2008). 
1.5.2 MeDIP 
Methylated DNA immunoprecipitation (MeDIP) is technique developed for the detection 
of DNA methylation (Weber et al., 2005).  Genomic DNA is fragmented by sonication and 
a monoclonal antibody, which specifically recognises 5mC, is used to enrich for 
methylated DNA fragments.  MeDIP-enriched DNA sequences can then be analysed by 
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QPCR, to determine the relative enrichment of individual regions, or by the high-
throughput microarray or NGS methods, to profile DNA methylation on a genome-wide 
scale. 
1.5.3 ENCODE 
The Encyclopaedia of DNA Elements (ENCODE) project was launched in 2003 by the 
National Human Genome Research Institute (NHGRI) with the aim of generating a 
catalogue of functional genomic elements and mapping their precise locations.  This 
project was a multi-national collaborative effort.  During the initial pilot and technology 
development stage functional elements were characterised across 44 genomic regions, 
equating to ~30Mb or ~1% of the human genome.  14 of these regions, which covered 
~15Mb, were specifically selected as well-studied loci, the remaining 30 regions were 
selected randomly using a stratified random sampling method (Birney et al., 2007, 
Consortium, 2004).  The volume and quality of the data generated by the pilot study was 
unprecedented as the project mapped transcriptional activity, histone modifications, 
novel TSSs, chromatin structure and TF binding sites across the ~1% of the human 
genome corresponding to the ENCODE regions (Birney et al., 2007). 
Upon completion of the pilot stage in 2007, the second phase of the ENCODE project was 
entered which aimed to catalogue functional genomic elements on a genome-wide scale.  
During this phase great use was made of recently developed, powerful NGS technologies 
and techniques including ChIP-seq, DNase-seq, FAIRE-seq etc were used to map 
transcribed regions, protein-coding regions, TF binding sites, histone modifications and 
variants, chromatin structure, DNA methylation sites and chromosome-interacting sites 
across the human genome.  A collection of 30 papers were published in Nature, Genome 
Research and Genome Biology in 2012 detailing the extensive findings of this stage of the 
ENCODE project which ultimately assigned biochemical function to 80% of the human 
genome by analysis of 1,640 data sets (Dunham et al., 2012). 
In order to allow maximal comparisons and integration of data sets, laboratories involved 
in the ENCODE consortium mainly focussed on a small group of selected cell types classed 
as ‘tier 1’ or ‘tier 2’ based on their priority.  Tier 1 cell types were the erythroleukemia cell 
line K562, the B-lymphoblast cell line GM12878 and the H1 embryonic stem cell line H1 
hESC.  Tier 2 included HeLa-S3 cervical carcinoma cells, HEPG2 hepatoblastoma cells and 
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primary human umbilical vein endothelial cells (HUVECs).  Despite this focus on tier 1 and 
tier 2 cell types, data generated from a total of 147 cell types was collected in this phase 
of the ENCODE project.  
In 2010 a chromatin state annotation algorithm was generated by an ENCODE consortium 
lab which discovers chromatin states and assigns them to regions throughout the genome 
(Ernst and Kellis, 2010).  ChromHMM is a multivariate Hidden Markov Model which uses 
combinations of chromatin marks (determined by ChIP-seq, DNase-seq etc) and the 
spatial context of chromatin states relative to each other to assign chromatin state 
annotations throughout the genome at a 200 bp resolution.  ChromHMM provides a 
means of combining a multitude of individual data sets to identify combinations of 
chromatin marks that are biologically meaningful and can be used to annotate functional 
genomic elements and indicate what the functions of these elements are.   
ChromHMM has been used to generate chromatin state maps across the genomes of nine 
common cell types including ENCODE tier 1 and tier 2 cell types (Ernst et al., 2011).  
Chromatin states were defined and assigned based on the presence or absence of nine 
chromatin marks - H3K27ac, H3K27me3, H3K36me3, H3K4me1, H3K4me2, H3K4me3, 
H3K9ac, H3K20me1 and CTCF - as determined by ChIP-seq.  Once ChromHMM had 
assigned chromatin state annotations to each of the nine cell types analysed a file was 
produced containing genome-wide tracks mapping these states, these files are publicly 
accessible and can be viewed in the UCSC genome browser. 
1.6 The chicken β-globin locus 
The chicken β-globin locus has been extensively studied as a paradigm for long-range 
gene regulation.  This locus contains the ρ, βH, βA and ε genes and is located within a 
developmentally regulated genomic region under the control of the β-globin locus control 
region (LCR) (Figure 1.8).  The 5’ and 3’ boundaries of the β-globin locus are marked by 
the constitutive 5’ HS4 and 3’ hypersensitive (HS) sites respectively.  
Approximately 16 kb 5’ of the chicken HS4 site is the folate receptor 1 (FOLR1) gene, 
which is expressed in primitive erythrocytes but repressed in definitive erythrocytes 
(Prioleau et al., 1999).  The 16 kb that separates the FOLR1 gene from the β-globin locus is 
packaged into condensed chromatin (Prioleau et al., 1999).   3’ of the chicken β-globin 
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gene locus, at approximately 3 kb downstream of the 3’ HS site, is the olfactory 51M1 
(OR51M1) gene (Bulger et al., 2000), which is expressed in cells of the olfactory 
epithelium. 
The chicken β-globin genes are expressed in a developmentally regulated manner in 
erythroid cells.  During the early stages of chick embryogenesis primitive erythrocytes are 
produced from blood islands in the yolk sac from where they enter the circulation (Sheng, 
2010).  These primitive erythrocytes have a specific haemoglobin gene expression profile 
as they express the ρ and ε genes (Bruns and Ingram, 1973).  As chick embryogenesis 
progresses definitive erythrocytes are produced from definitive erythropoietic clusters in 
the yolk sac (Sheng, 2010).  These cells enter the circulation at embryonic day 5 and by 
embryonic day 7 most circulating erythrocytes in the chick embryo are definitive.   Later 
in embryogenesis, at approximately embryonic day 12 (E12), definitive erythrocytes begin 
to be produced intra-embryonically by the bone marrow and by E13-15 most circulating 
erythrocytes are definitive and bone marrow-derived.  As with primitive erythrocytes, 
definitive erythrocytes exhibit a specific haemoglobin gene expression profile.  These cells 
strongly express the βA gene and βH is also expressed at very low levels in definitive chick 
erythrocytes (Bruns and Ingram, 1973).  As a result of these changes in the proportion of 
primitive versus definitive erythrocytes, the ρ and ε genes appear to be highly expressed 
in circulating erythrocytes early in embryogenesis but this expression is seen to fall as 
embryogenesis progresses.  In parallel with this, the βA gene is seen to transition from 
non-expressed to highly expressed in the circulating erythrocyte population between E5-
10. 
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Figure 1.8 The β-globin gene locus and HS4 insulator element.   
Boxes depict genes - (L-R) Folate Receptor, ρ, βH, βA, ε and Chicken Olfactory Receptor. 
Arrows show DNase I hypersensitive site, constitutive DNase I hypersensitive sites are 
shown in blue.  Those DNase I hypersensitive sites comprising the chicken globin LCR are 
indicated.  The 250 bp core of the HS4 element is enlarged to show the distribution of the 
five DNase I footprinted regions.   
As the constitutive 5’ HS4 site was known to mark a boundary between 3’ erythroid-
specific regulatory elements and a 5’ region of condensed chromatin, its ability to 
function as an insulator was investigated and it became the first insulator element to be 
identified in a vertebrate species (Chung et al., 1993).  
1.7 Insulators 
Insulators function to prevent genes from being inappropriately influenced by the 
transcriptional activity of their surrounding environment.  These elements are generally 
~0.5 – 3 kb in length and their activity is both position- and orientation-dependent.  
Insulators are defined as possessing one or both of two activities – enhancer blocking and 
barrier activity (Maston et al., 2006, West et al., 2002).  Enhancer blocking activity 
functions to prevent promiscuous enhancers from interacting with promoter elements in 
a non-regulated manner, but only occurs when the insulator is positioned between the 
enhancer and promoter elements (Figure 1.9 A).  Barrier activity describes the activity by 
which insulators can halt the spread of repressive heterochromatin, thereby preventing 
the inappropriate silencing of a gene or gene locus (Figure 1.9 B).  
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Figure 1.9 Mechanisms of insulator activity.   
Insulator elements function to protect genes from inappropriate transcriptional 
influences in their surrounding environment.  (A) Insulators can function as enhancer 
blockers when positioned between enhancer and promoter elements.  (B) Insulators can 
function as barrier elements to halt the spread of repressive heterochromatin. 
Transcriptionally repressive nucleosomes are coloured blue, transcriptionally permissive 
nucleosomes are coloured green.   
 
The chicken HS4 element functions as an insulator and is the best characterised 
vertebrate insulator element to date.  The HS4 insulator has both enhancer blocking 
(Chung et al., 1993) and barrier activity (Pikaart et al., 1998), both of which are mediated 
by a 250 bp DNA element that can be divided into five DNase I footprinted regions (FI – V) 
(Figure 1.8) (Chung et al., 1997).  Dissection of HS4 has shown its enhancer blocking and 
barrier activities to be regulated by separable mechanisms, which involve protein binding 
to specific DNA motifs within the HS4 footprinted regions.   Binding of CTCF to HS4 FII 
mediates the enhancer blocking activity of the insulator (Bell et al., 1999).  Meanwhile 
binding of USF1/2 heterodimers to FIV is necessary for barrier activity (West et al., 2004).  
USF1/2-mediated barrier activity prevents the spread of silencing histone modifications 
across the insulator and into downstream chromatin by co-ordinating the deposition of 
active histone marks on surrounding nucleosomes (West et al., 2004, Ma et al., 2011).  It 
is believed that this collection of active histone modifications functions to prevent the 
deposition of repressive histone marks, thereby terminating heterochromatin assembly 
(West et al., 2004, Huang et al., 2007, Ma et al., 2011).  However, binding of USF1/2 to 
FIV is not sufficient to mediate barrier activity of the HS4 insulator and DNA motifs within 
HS4 footprints I, III and V, which function as binding sites for the TF VEZF1, have been 
found to be essential for preventing transgene silencing in barrier assays (Dickson et al., 
2010).  Deletion of any of the three VEZF1 binding sites results in de novo DNA 
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methylation of the transgene and HS4 insulator, and silencing of the transgene (Dickson 
et al., 2010), suggesting a role for VEZF1 binding sites in protecting DNA elements from 
the spread of de novo DNA methylation. 
1.8 VEZF1 
In 1988 a chicken factor, named BGP1, was identified as binding to a (dG)16 sequence in 
the chicken βA promoter in erythrocytes (Lewis et al., 1988).  Subsequently, human DB1 
(Koyano-Nakagawa et al., 1994) and the highly homologous mouse Vezf1 (Xiong et al., 
1999) proteins were identified.  Sequencing later showed BGP1 to be the chicken 
homologue of VEZF1 (Dickson et al., 2010).  VEZF1 proteins are highly conserved across 
species with 89% homology between full length chicken, mouse and human VEZF1 
proteins and 99% homology within their ZF domains, indicating a common and important 
biological function.  
It was initially hypothesised that VEZF1 would function as a TF due to its glutamine 
stretch and proline-rich C-terminal region, which are characteristic of transcriptional 
activators (Gerber et al., 1994) (Figure 1.10).  Luciferase reporter assays showed that a 
VEZF1 binding site activates the human endothelin 1 (EDN1) promoter in endothelial cells 
(Aitsebaomo et al., 2001) while studies by Miyashita et al (Miyashita et al., 2004, 
Miyashita and Sato, 2005) indicated a role for VEZF1 in regulating expression of the OP18 
and Metallothionein 1 (MT1) genes, although direct interaction between VEZF1 and these 
gene elements has not been investigated.  The (dG)16 VEZF1 binding motif in the chicken 
βA promoter does not affect transcriptional activity of this promoter (Jackson et al., 1989, 
Barton et al., 1993) but has been implicated in assisting nucleosome positioning at this 
element (Buckle et al., 1991).    
 
Figure 1.10 Domain organisation of VEZF1.   
Red boxes represent the six C2H2 zinc fingers; blue box represents the polyglutamine 
chain; yellow box represents the C-terminal proline-rich domain. 
The EDN1, OP18 and MT1 genes have roles in angiogenesis.  In keeping with these 
findings, VEZF1 has been shown to be vital for the development of the vascular and 
lymphatic systems.   The vasculature in the head, neck and back of VEZF1 null mouse 
6 C2H2 Zinc fingers Glu Pro-rich
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embryos is underdeveloped and poorly organised and these embryos have an embryonic 
lethal phenotype due to severe haemorrhaging, which is caused by a lack of vascular 
integrity resulting from the abnormal expression of cell junction and extra cellular matrix 
(ECM) proteins (Kuhnert et al., 2005, Zou et al., 2010). 
There have been some contradictory findings reported regarding the expression patterns 
of VEZF1.  Lewis et al (Lewis et al., 1988) reported that BGP1 was expressed in circulating 
chicken erythrocytes but not in the human HeLa cell line.  This was determined by the 
formation of a specific complex in EMSA reactions, between the nuclear extract of 
embryonic or adult chicken erythrocytes and the (dG)16 VEZF1 binding motif.  No specific 
band appeared to form between nuclear extract from the human HeLa cell line and the 
(dG)16 sequence motif, however the unpublished observations of Dr Adam West found 
the human VEZF1/G-string complex to have slightly higher mobility than the chicken 
VEZF1/G-string complex.  This increased mobility leads to the specific human VEZF1/G-
string complex being masked by a non-specific band of the same mobility in the EMSAs 
presented by Lewis et al (Lewis et al., 1988) and to the mistaken conclusion that VEZF1 
was not expressed in HeLa cells.  In support of this, VEZF1 mRNA and protein expression 
have since been profiled in the HeLa cell line by RT-QPCR and western blotting 
respectively (Strogantsev, 2009), these analyses show VEZF1 to be expressed in HeLa 
cells.  VEZF1 protein expression in HeLa cells was also demonstrated by western blotting 
by Gowher et al (Gowher et al., 2012).  Human VEZF1 has in fact been shown to be 
expressed across a broad range of human somatic cells by northern blotting, RT-PCR, RT-
QPCR, western blotting and cDNA microarray analyses (Koyano-Nakagawa et al., 1994, 
Strogantsev, 2009) (Figure 1.11).  Consistent with these findings in human, mouse VEZF1 
has been shown to be broadly expressed across a range of adult mouse tissues and cell 
lines by northern blotting.  VEZF1 expression has also been shown to be up-regulated in 
vascular cells during vasculogenesis in mouse, consistent with the essential function of 
VEZF1 in vasculogenesis (Kuhnert et al., 2005, Zou et al., 2010).   
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Figure 1.11 VEZF1 is broadly expressed across human somatic tissues.   
Microarray analysis of VEZF1 cDNA levels in various human somatic tissues.  Figure taken 
from GeneCards (www.genecards.org; GeneCards ID:GC17M056048). 
 
To date a small number of VEZF1 binding sites have been identified in the human, mouse 
and chicken genomes.  VEZF1 binding to the chicken βA promoter and the human IL3 and 
EDN1 promoters has been shown to occur in cell types where these genes are expressed 
(Lewis et al., 1988, Koyano-Nakagawa et al., 1994, Aitsebaomo et al., 2001).  These 
findings indicate a role for VEZF1 in positively regulating gene expression which is 
supported by the fact that VEZF1 binding to the EDN1 promoter in endothelial cells 
activates the promoter causing expression of an associated transgene (Aitsebaomo et al., 
2001).  VEZF1 does not function as a direct transactivator of βA globin gene expression 
however it has been hypothesised that its interaction with the gene promoter may aid 
transcriptional activation via nucleosome repositioning (Lewis et al., 1988, Clark et al., 
1990).   
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Three VEZF1 binding sites in the chicken HS4 insulator element have been characterised.  
These sites have been shown to be essential for the barrier activity of HS4 and function to 
prevent the accumulation of de novo DNA methylation (Dickson et al., 2010) (Section 1.7).  
VEZF1 binding sites have also been shown to mediate protection of the hamster Aprt CGI 
from de novo DNA methylation and to direct demethylation of a pre-methylated CGI 
(Dickson et al., 2010) (section 1.4.4).  Analysis of DNA methylation profiles in VEZF1 knock 
out or knock down cell lines is required in order to categorically define the role of this 
protein in protection of DNA from hypermethylation.  However this is complicated by the 
fact that DNA methylation is deficient in Vezf1 null mouse ES cells as Vezf1 itself is 
required for optimal expression of DNMT3B (Gowher et al., 2008). 
It has been reported that VEZF1 affects alternative splicing by causing the elongating 
serine 2-phosphorylated RNA polymerase II isoform (Pol II-Ser2ph) to pause during 
transcription (Gowher et al., 2012).  Pol II-Ser2ph pausing can alter the inclusion of 
alternative exons in mRNA transcripts, thus altering expression of different protein splice 
forms.  One gene reported to be affected by this process is Dnmt3b.  Data published by 
Gowher et al suggest that expression of the catalytically active Dnmt3b1 isoform is 
mediated by VEZF1 binding to an intronic DNA sequence element located towards the 3’ 
end of the Dnmt3b gene (Gowher et al., 2008).  It was reported that VEZF1 binding to 
Dnmt3b induces pausing and accumulation of Pol II-Ser2ph at the VEZF1 binding site 
promoting expression of the active Dnmt3b1 isoform.  In a Vezf1 knock out ES cell line, 
accumulation of Pol II-Ser2ph did not occur at the VEZF1 binding site and a decrease in 
levels of the Dnmt3b1 isoform was observed which in turn lead to a global loss of DNA 
methylation (Gowher et al., 2012). 
1.9  VEZF1 ChIP-chip  
In a previous project in my supervisors’ lab, in collaboration with the lab of Dr David 
Vetrie, ChIP-chip was used to map VEZF1 binding sites in the K562 cell line across the 
ENCODE region (see section 1.5.3), which covers ~1% of the human genome (Strogantsev, 
2009, Consortium, 2004).  Immunoprecipitated DNA from VEZF1 ChIP in K562 cells was 
fluorescently labelled with Cy3 CTP nucleotides and hybridised to microarray chips which 
were scanned using a confocal laser-based scanner.  The intensities of fluorescent spots 
were quantified using ScanArray express software (Perkin Elmer) and z-scored to 
generate a standardised signal intensity ratio.  Signal intensities across the genomic 
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regions represented on microarrays were visualised in the UCSC genome browser, 
allowing identification of genomic regions bound by VEZF1.  The same experimental 
pipeline was followed using immunoprecipitated DNA from an anti-FLAG ChIP in the D3/6 
K562 cell line (created by Dr Dan Li) which expresses a recombinant FLAG-tagged VEZF1 
fusion protein at ~50 % of the level of endogenous VEZF1.  An example window from the 
UCSC genome browser showing VEZF1 and FLAG-VEZF1 enrichment profiles across ~250 
kilo bases of chromosome 1 is shown in Figure 1.12. 
 
Figure 1.12 VEZF1 binding at specific elements revealed by ChIP-chip.   
VEZF1 ChIP in K562 (top track) and FLAG-ChIP in D3/6 K562 (second track from top) z-
scored enrichment profiles across chr 1: 47,268,059-47,520,104.  Peaks identified using 
the ChIPOTle algorithm at p-value of significance = 0.0001 are shown as black boxes.  CpG 
islands are shown as green boxes.  UCSC annotated genes are shown in blue and direction 
of transcription is indicated by arrows (bottom track). 
VEZF1 ChIP-chip fluorescence peaks were identified using the ChIPOTle peak-finding 
algorithm.  This approach identified 125 VEZF1 peaks across the 1 % of the human 
genome profiled. 
A comparison of the locations of VEFZ1 binding sites and the locations of known protein-
coding genes using the Galaxy on-line interface showed that the majority of DNA 
elements bound by VEZF1 are gene-associated.  A bias for VEZF1 binding towards the 5’ 
end of genes was also identified, with 64% of VEZF1 binding sites mapping to promoters - 
defined as being within 1 kb of an annotated TSS - and a further 32 % of VEZF1 peaks 
mapping to distal regulatory elements such as enhancers and insulators - defined as being 
>1kb from a TSS and associated with DNaseI hypersensitivity and H3K4 mono-, di-, or tri-
methylation (Figure 1.13).  This striking association of VEZF1 with gene regulatory 
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elements indicates a potential role for VEZF1 in regulating gene expression, a hypothesis 
supported by the results of RNA-microarray analysis which showed approximately 80 % of 
genes that were associated with VEZF1 in K562 cells to be expressed in this cell line 
(Strogantsev, 2009).  
 
Figure 1.13 VEZF1 ChIP-chip enrichment peaks map to regulatory regions.  
Location of VEZF1 ChIP-chip peaks with respect to gene regulatory elements.  Promoters 
are defined as being within 1 Kb of a TSS; distal regulatory regions are defined as being > 
1 kb from a TSS and associated with DHSs and H3K4 methylation peaks; remaining peaks 
as classed as ‘other’. 
Although very informative, the 125 VEZF1 enrichment peaks identified across the ENCODE 
region were not sufficient in number to allow further analyses, for example by grouping 
peaks based on their enrichment rank or type of associated regulatory element.  The 
enrichment peaks generated by ChIP-chip were also very broad and often contained 
multiple potential VEZF1 binding sites.  It was therefore difficult to predict which motifs 
function as VEZF1 binding sites at enriched elements.  As described previously, ChIP-seq 
generates higher resolution enrichment profiles in which maximal points of enrichment 
generally correlate well with DNA motifs bound by the protein of interest.  It was 
therefore considered that performing ChIP-seq for VEZF1 would generate higher 
resolution VEZF1 enrichment profiles which would enable the sequence motifs most likely 
to function as VEZF1 binding elements in vivo to be identified.  
1.10 Methods for identifying TF binding sites and generating 
consensus binding sequences 
As regulatory elements are composed of TF binding sites, identification of motifs to which 
TFs bind is essential to the discovery and characterisation of regulatory networks.  Many 
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techniques have been developed to aid the identification and characterisation of TF 
binding sites, a selection of which are discussed below. 
1.10.1 DNase I footprinting 
DNase I footprinting is an in vitro protection assay used to identify protein-bound DNA 
elements.  In this assay a double stranded DNA substrate is radiolabelled at its 3’ 
phosphate and incubated in a binding reaction with nuclear extract or purified or 
recombinant proteins of interest.  Binding reactions are then treated with a range of 
endonuclease DNase I concentrations.  DNase I cleaves DNA substrates in a largely 
sequence independent manner creating a ladder of DNA fragments, however DNA 
elements which are bound by protein are protected from digestion as the protein 
prevents DNase I accessing the bound DNA.  Cleavage reactions are electrophoresed 
through denaturing polyacrylamide gels and visualised by autoradiography or 
phosphorimaging.  Digest reactions lacking protein appear as a ladder of DNA fragments 
while sequence-specific protein-DNA interactions will be revealed as ‘footprints’ that are 
protected from nuclease action.  In order to identify the exact sequence of DNaseI 
footprints, Maxam-Gilbert sequencing marker lanes are run alongside cleavage reactions.  
DNaseI footprinting can be extremely helpful for the initial characterisation of novel 
regulatory elements and can provide a reference point from where the characterisation 
of specific protein binding motifs can proceed.  However, the in vitro nature of this 
technique means that the binding events detected may not necessarily correspond to 
genuine in vivo binding events. 
1.10.2 EMSA 
Electrophoretic mobility shift analysis (EMSA) is a technique which allows the visualisation 
of protein-DNA interactions in vitro.  During EMSA double stranded radiolabelled 
oligonucleotide (probe DNA) of a specific sequence is incubated with either a 
recombinant protein of interest or the nuclear lysate of a specific cell type to allow 
protein-DNA binding to occur.  Binding reactions are then electrophoresed through a 
native polyacrylamide gel, following which gels are dried and the distribution of 
radiolabelled probe throughout the gel is visualised by phosphorimaging.  During 
electrophoresis, free unbound probe resolves as a single band at the base of the gel, 
meanwhile probe that has interacted with protein to form protein-DNA complexes 
electrophorese at a much slower rate due to the increased mass of the complex.  Protein-
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probe complexes therefore appear as discrete bands which locate higher up the gel than 
free probe.  The specificity of complexes detected by EMSA can be tested by the addition 
of an antibody specific for a protein of interest to the binding reaction.  Association of the 
antibody with the protein-DNA complex will further increase the mass of this specific 
complex causing even slower migration and resulting in the corresponding band 
appearing ‘super-shifted’.  Interaction between protein and antibody may also interfere 
with protein-DNA complex formation.  Unlabelled double stranded competitor 
oligonucleotides can be added to EMSA binding reactions in order to either demonstrate 
the sequence specificity of complex formation or to test for the ability of specific DNA 
sequences to compete with the probe sequence for binding to the protein of interest.  
This technique allows the validation of putative protein binding motifs in isolation, in 
vitro.  Individual nucleotides or groups of nucleotide bases can be mutated from the wild 
type sequence to comprehensively determine which specific nucleic acid residues are 
important for protein binding.  However, if the binding of a protein of interest to a 
specific binding site in vivo requires cooperativity with another transcription factor, it may 
not be detected by EMSA, for example if the co-binding protein is not present in the 
binding reaction or the binding site of the co-binding protein is not present on the DNA 
oligonucleotide.  As EMSA detects protein-DNA interactions in vitro, however, it cannot 
be presumed that binding events detected by this method will correspond to those that 
occur in vivo. 
1.10.3 Microwell-based protein DNA-binding specificity assay 
A high throughput method for determining the DNA binding specificity of transcription 
factors was developed by Hallikas and Taipale (Hallikas and Taipale, 2006) (Figure 1.14).  
The premise of this technique is similar to that of EMSA in that it allows the validation and 
characterisation of putative protein binding motifs in vitro.  A transcription factor of 
interest is expressed as a fusion product with the Renilla luciferase reporter enzyme.  This 
fusion protein is incubated in a binding reaction with biotinylated double stranded DNA 
oligonucleotides, which correspond in sequence to a known consensus binding sequence 
for the protein.  Non-biotinylated competitor oligos may also be included in the binding 
reaction, these oligos can correspond to putative binding sequences or contain base 
substitutions in the consensus binding site.  The binding reactions are then transferred to 
individual wells of a streptavidin-coated 96-well plate, where biotinylated oligos are 
captured by their interactions with streptavidin.  After washing to remove unbound 
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material, a luminometer is used to measure the amount of fusion protein captured in 
each well along with biotinylated sequences.  This assay can be used to rapidly screen 
vast numbers of competitor sequence motifs, allowing the binding specificity of a specific 
transcription factor to be determined quickly.  However, the assay can only be performed 
with recombinant luciferase-fusion proteins, meaning that cell nuclear extracts cannot be 
used to demonstrate the presence of specific proteins in specific cell types, as can be 
achieved by EMSA.  As with EMSA, if co-binding of another protein is required for binding 
of the protein of interest to a putative binding site, this interaction will not be detected.  
Also, as this assay detects in vitro protein-DNA binding events, these interactions may not 
be conserved in vivo. 
 
Figure 1.14 The microwell-based protein-DNA binding specificity assay.   
Adapted from (Hallikas and Taipale, 2006). 
1.10.4 SELEX-seq 
The systematic evolution of ligands by exponential enrichment (SELEX) is a well 
established method for the characterisation of protein binding sites.  In this method, 
double stranded (ds) DNA libraries are generated which contain all possible oligo 
sequences of a given length.  A protein of interest is incubated with the dsDNA library in a 
binding reaction following which protein-bound DNA sequences are purified and enriched 
by PCR amplification.  The process of protein binding, complex purification and 
amplification of bound sequences is repeated several times to enrich for DNA sequences 
that act as binding sites for the protein of interest (Wang et al., 2011).  Enriched DNA 
56 
 
motifs isolated by the SELEX method can now be sequenced by NGS.  Bioinformatic 
analyses of sequencing data can then be performed to generate consensus binding motifs 
or position weight matrix models.  The SELEX-seq technique can produce large quantities 
of data regarding the in vitro DNA binding specificity of specific transcription factors.  
However, this technique does not identify specific genomic locations that may function as 
transcription factor binding sites in vivo. 
1.10.5 ChIP-seq 
As described previously, ChIP-seq is a powerful tool that allows genomic sites at which a 
protein of interest is enriched in vivo to be mapped on a genome-wide scale.  For DNA-
binding transcription factors, the peak of ChIP-seq enrichment generally correlates quite 
well with transcription factor binding sites (Zhang et al., 2008), however further 
experimentation (such as EMSA) is required to define and characterise specific protein 
binding motifs.  For DNA-binding transcription factors, analysis of ChIP-seq enrichment 
data using motif discovery bioinformatic tools should allow the generation of a consensus 
binding motif for the protein of interest.  As ChIP-seq profiles sites of protein enrichment 
in vivo, if binding of a protein of interest is mediated by the co-binding of another factor, 
these sites will be detected by ChIP-seq.  However, ChIP-seq cannot reveal whether a 
protein interacts with DNA directly or if it is part of a multi-protein complex in which 
another protein factor mediates binding to DNA.  
1.11 The K562 cell line 
The K562 cell line was chosen as a model system for use in investigating the genomic 
interactions of VEZF1 for a number of reasons (section 3.1). Among these were the fact 
that our lab had already mapped VEZF1 binding across 1 % of the human genome by ChIP-
chip in this cell line (Strogantsev, 2009).  The classification of K562 as a tier 1 cell line by 
the ENCODE consortium has also resulted in an abundance of NGS data from this cell line 
being generated and made publicly available.  This makes K562 an attractive system to 
use as ChIP-seq data generated in this project could be compared to the wealth of 
publicly available data.  As part of the ENCODE analyses, a ChromHMM chromatin state 
map had also been generated for the K562 cell line which was also very useful in my 
project (Ernst et al., 2011). 
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K562 is an immortalised leukemic cell line which was established in 1970 from cells 
isolated from the pleural effusion of a female patient with chronic myeloid leukaemia 
(CML) during blast crisis (Lozzio and Lozzio, 1975).  Karyotyping has revealed K562 cells to 
have a hypotriploid chromosome complement with a modal chromosome number of 67 
and 21 marker chromosomes which are the product of translocations, duplications and 
inversions (Naumann et al., 2001).  Analysis of copy number variation shows the majority 
of the K562 genome to have a normal copy number while specific regions are amplified or 
heterozygously deleted and a very small proportion of chromosome 9 is homozygously 
deleted (Figure 1.15).  From this analysis it is apparent that despite the hypotriploid 
karyotype of this cell line the majority of the genome is present in normal copy number 
complement. 
 
Figure 1.15 The majority of the K562 genome is present in normal copy number 
complement.   
Chromosome numbers are shown to the right or left of each chromosome.   Genomic 
regions present in normal copy number are indicated by a green block, amplified regions 
are marked by red blocks, heterozygous and homozygous deletions are marked by purple 
and blue blocks respectively. 
K562 is a multipotent hematopoietic precursor cell line with erythroid properties that 
include expression of the red blood cell membrane-spanning protein glycophorin 
(Andersson et al., 1979).  K562 cells have the potential to differentiate along the 
megakaryocyte or erythroid lineages.  Erythroid differentiation can be promoted by 
1
2
3
4
5
6
7
8
9
10
11
X
22
21
20
19
18
17
16
15
14
13
12
Normal
Amplified
Homozygous deletion
Heterozygous deletion
58 
 
treatment of K562 cells with a number of inducing agents and induces the expression of 
the embryonic globin genes in approximately the same proportions as are evident during 
early human embryogenesis.  Analysis of the K562 genome has found no deletions or 
rearrangements of the globin genes (Rutherford et al., 1981), therefore their expression 
in this cell line is considered to represent a good system for investigating the regulation of 
globin gene expression.    
While the K562 cell line cannot be considered as a ‘normal’ system, evidence in the 
published literature suggests that gene regulatory events are very similar between K562 
cells and primary erythroid cells.  ChIP-chip, ChIP-seq and DNase I HS profiles show 
histone modifications, TFBSs and DNase I HSs to be highly conserved between K562 and 
primary erythroid cells (Anguita et al., 2001, Follows et al., 2006, De Gobbi et al., 2007, 
Fujiwara et al., 2009).  For example following ChIP-seq of the TF GATA-1 in K562 cells 36 
GATA-1 binding sites were analysed for enrichment in mouse primary erythroblasts by 
GATA-1 ChIP-QPCR (Fujiwara et al., 2009).  32 of the 36 sites investigated were found to 
be enriched relative to a negative control element.  These findings demonstrate the 
conservation of GATA-1 enriched sites between the K562 cell line and primary 
mammalian erythroblasts.  GATA-1 factors are key regulators of hematopoiesis therefore 
the conservation of enriched sites between K562 cells and primary erythroblasts indicate 
the usefulness of this cell line as a model system.  The treatment of K562 and primary 
erythroid cells with various inducing agents has also been shown to cause highly 
comparable effects on globin gene expression indicating that regulation of these genes is 
mediated by the same mechanisms in these two cell types (Lampronti et al., 2003, Pace et 
al., 2003, Zhou et al., 2000).  The K562 cell line is therefore considered to be useful 
platform with which to investigate erythroid-specific regulatory events. 
1.12 Aims and objectives of this thesis 
This project was established with the aim of identifying and characterising VEZF1 binding 
sites in the human genome.  ChIP-chip across 1 % of the human genome and EMSA 
analyses of specific putative VEZF1 binding sites have been performed previously 
(Strogantsev, 2009, Koyano-Nakagawa et al., 1994, Aitsebaomo et al., 2001).  I aimed to 
further these findings by mapping VEZF1 binding sites on a genome-wide scale and 
validating a proportion of novel putative VEZF1 binding sites by EMSA analyses.  We also 
wanted to characterise VEZF1-enriched sites – for example as promoter, enhancer, or 
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insulator elements, etc. – with a view to creating a better understanding of the functions 
that VEZF1 binding to genomic elements may mediate.  Based on findings that VEZF1 
binding sites within the chicken HS4 insulator element are essential for barrier activity 
(Dickson et al., 2010), we anticipated that profiling VEZF1 binding sites across the human 
genome would identify putative novel insulator elements within the human genome.  The 
general aims of this work were to: 
1. Identify VEZF1 binding sites across the human genome in K562 cells using the 
ChIP-seq method. 
2. Characterise VEZF1 binding sites by comparison to chromatin states defined by 
the ENCODE consortium. 
3. Investigate the DNA binding specificity of VEZF1 using motif discovery tools and 
EMSA. 
4. Utilise the in vivo chick embryogenesis model system to investigate the 
relationship between VEZF1 binding, promoter DNA methylation and transcription 
of the chicken β-globin genes during development. 
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Chapter 2 
Materials and Methods 
Materials 
2.1 Cell lines 
Cell line Reference                   Source 
K562 (Lozzio and Lozzio, 1997) Prof Tony Green, School of Clinical  
  Medicine, University of Cambridge, via 
  Dr David Vetrie, Institute of Cancer  
  Sciences Epigenetics Unit, University of 
  Glasgow 
2.2 Reagents 
2.2.1 Cell culture reagents 
Product  Manufacturer Product Code 
RPMI Medium 1640 (1X) + GlutaMAX™ -l Gibco 61870 
Fetal Bovine Serum Sigma F9665 
Penicillin/Streptomycin Sigma P0781 
 
2.2.2 Antibodies 
Anti-VEZF1 antibodies were raised against a C-terminal portion of the chicken VEZF1 
protein (amino acids 377-548) (Dickson et al., 2010).   
Antibody Manufacturer Product Number 
FLAG (M2) Sigma A2220 
Non-immune rabbit IgG Sigma I5006 
Non-immune mouse IgG Sigma I5381 
 
2.2.3 Enzymes 
Enzyme Manufacturer Product Number 
T4 PNK NEB M0201 
Proteinase K Sigma P5568 
RNase A Fermentas EN0531 
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RNase OUT Invitrogen 160000840 
RNase H NEB M0297 
Bgl II NEB R0144 
 
2.2.4 Oligonucleotides 
Oligonucleotides were ordered from Biomers or MWG Eurofins.  Sequences are given in 
appendix. 
2.2.5 Plasmids 
pCITE4b-VEZF1 (Dickson et al., 2010) In vitro transcription vector  
  containing full length cDNA  
  encoding chicken VEZF1 
pGEM®-T easy Vector System I Promega Product number: A1360 
2.2.6 Chemicals 
Reagent  Manufacturer Product Number 
Ammonium Persulfate Fisher Scientific A/6160/53 
TEMED Sigma T9281 
Acrylamide:Bisacrylamide (37.5:1) Amresco 0254 
Acrylamide:Bisacrylamide (19:1) Sigma A2917 
Acrylamide:Bisacrylamide (29:1) Sigma A2792 
Phenol-Chloroform Sigma P3803 
Chloroform Fisher Scientific C/4960/17 
Trizol Life Technologies 15596026 
BCP Sigma B9673 
Ethidium Bromide Sigma E1510 
Safeview NBS Biologicals Ltd NBS-SV1 
 
2.2.7 Other molecular biology reagents  
Reagent  Manufacturer Product Number 
100 bp DNA ladder NEB N32315 
1 Kb DNA ladder Invitrogen 10787-018 
PageRuler Prestained Protein Ladder Thermo Scientific 26616 
γ32 P ATP Perkin Elmer BLU502H250UC 
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DTT Melford Laboratories Ltd MB1015 
Triton X-100 Sigma T8787 
BSA NEB B9001S 
RNasin Ribonuclease Inhibitor Promega N211A30683007 
100 mM dNTP set Invitrogen 10297018 
Taq DNA Polymerase NEB M0267S 
Platinum Taq DNA Polymerase Invitrogen 10966-018 
Subcloning Efficiency™ DH5α™  
Competent Cells 
Invitrogen 18265-017 
X-gal Fisher Scientific 7240-90-6 
Glycogen Roche 10901393007 
Protein A Agarose Millipore 16-157 
Protein G Agarose Millipore 16-266 
Illumina Genomic Adaptor Oligo Mix Illumina 1000521 
Illumina Genomic PCR Primers 1.1 Illumina 1000537 
Illumina Genomic PCR Primers 2.1  Illumina 1000538 
FastStart Universal SYBR Green 
Master (Rox) 
Roche 04913914001 
TaqMan® Universal Master Mix II AB 4427788 
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2.3 Buffer Recipes  
All buffers are prepared using sterile deionised water. 
2.3.1 General buffers 
TBE Buffer (5X) 
1.1 M Tris 
900 mM Boric Acid 
25 mM EDTA 
 
TAE Buffer 
2 M Tris 
1 M Glacial Acetic Acid 
50 mM EDTA 
 
Glycerol Loading Buffer 
30 % Glycerol 
0.02 % Bromophenol Blue 
0.02 % Xylene Cyanol 
 
2.3.2 Buffers used in oligonucleotide purification 
Formamide Loading Buffer 
80 % formamide  
0.5X TBE 
10 mM NaOH 
 
Oligo Elution Buffer 
0.5 M NH4OAc 
1 mM EDTA 
 
2.3.3 Buffers used in EMSA probe preparation 
Probe Annealing and Storage Buffer (10X) 
100 mM NaCl 
10 mM Tris pH 7.5 
1 mM EDTA 
 
2.3.4 Buffers used in SDS-PAGE 
LSB Buffer (2X) (Sample Loading Buffer) 
124 mM Tris pH 6.8 
4 % SDS 
20 % Glycerol 
20 mM DTT 
0.02 % Bromophenol Blue 
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Resolving Buffer (4X) 
1.5 M Tris pH 8.8 
0.4 % SDS 
 
Stacking Buffer (4X) 
0.5 M Tris pH 6.8 
0.4 % SDS 
 
SDS-PAGE Running Buffer 
25 mM Tris 
250 mM Glycine 
0.1 % SDS 
 
2.3.5 Buffers used in Electrophoretic Mobility Shift Analysis (EMSA) 
Binding Buffer (2X) 
40 mM HEPES pH 7.9 
100 mM KCl 
10 % Glycerol 
 
2.3.6 Solutions used in bacterial cell transformation and culture 
SOB medium 
20 g Bacto-tryptone 
5 g Yeast extract 
0.584 g NaCl 
0.186 g KCl 
Dissolve in 950 ml dH20 
Adjust to pH 7.0 with NaOH 
Bring to 1000 ml with dH20 and autoclave 
For SOC medium add 1 ml of 2 M glucose to 98 ml of SOB medium 
 
LB medium 
20 g LB broth powder 
Bring to 800 ml with dH20 and autoclave 
 
2.3.7 Solutions used in ChIP 
7 % Formaldehyde Stock Solution 
7 % Formaldehyde 
0.1 M NaCl 
0.5 mM EGTA 
50 mM HEPES pH 8 
1 mM EDTA 
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ChIP Lysis Buffer 
0.25 % Triton X-100 
10 mM EDTA 
0.5 mM EGTA 
10 mM Tris pH 8 
 
Nuclei Rinse Buffer 
0.2 M NaCl 
1 mM EDTA 
0.5 mM EGTA 
10 mM Tris pH 8 
 
Nuclei Lysis Buffer 
50 mM Tris pH 8 
10 mM EDTA 
0.5 % SDS 
 
X-ChIP Buffer 
1.1 % Triton X-100 
1.2 mM EDTA 
16.7 mM Tris pH 8.1 
167 mM NaCl 
 
ChIP Wash Buffer 1 
0.1 % SDS 
1 % Triton X-100 
2 mM EDTA 
20 mM Tris pH 8.1 
150 mM NaCl 
 
ChIP Wash Buffer 2 
0.1 % SDS 
1 % Triton X-100 
2 mM EDTA 
20 mM Tris pH 8.1 
500 mM NaCl 
 
ChIP Wash Buffer 3 
0.25 M LiCl 
1 % NP-40 
1 % Sodium Deoxycholate 
1 mM EDTA 
10 mM Tris pH 8.1 
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Tris-EDTA Buffer (TE) 
10 mM Tris pH 8.1 
1 mM EDTA 
 
ChIP Elution Buffer 
1 % SDS 
0.1 M NaHCO3 
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2.4 Cell Culture 
K562 Cell Line 
Wild type K562 cells and the K562 D3/6 cell line (which contains a stably integrated FLAG 
epitope-tagged, VEZF1 transgene that is expressed at approximately 50 % of endogenous 
VEZF1 levels.  This cell line was made by Dr Dan Li) were cultured in RPMI 1640 growth 
medium supplemented with 10 % FBS, 1 % penicillin/streptomycin. Immediately following 
thawing, 1 ml cell stocks were diluted in 10 ml culture medium and centrifuged at 1100 x 
g for 5 minutes.  Supernatant was discarded to remove DMSO and cell pellets were 
resuspended in 10 ml growth medium and cultured in a T25 flask at 37 ᵒC with 5 % CO2.   
Cultures were typically split three times a week at a 1 in 5 ratio when cells reached ~80 % 
density.  Frozen cell line stocks were prepared by aliquoting 1 x 106 cells in 1 ml freezing 
media (90 % FBS, 10 % DMSO) into cryotubes.  Tubes were placed in CoolCell® LX  or 
CoolCell® FTS30 boxes and stored at -80 ᵒC overnight before transfer to a liquid nitrogen 
storage facility. 
2.5 Chromatin Immunoprecipitation (ChIP) 
Formaldehyde Fixation of Cells 
1. Cells were transferred from culture vessels to 50 ml falcon tubes and centrifuged 
at 500 x g for 5 minutes at room temperature to pellet cells. 
2. Supernatant was removed and cell pellets were resuspended in fresh warmed 
media.  An aliquot of cell suspension was used to perform a viable cell count. 
3. The cell suspension was adjusted so as to contain 1 x 108 cells in 30 ml media. 
4. 3.4 ml of a 7 % formaldehyde stock solution was added to each 30 ml cell 
suspension (0.8 % final concentration) and reactions were incubated on a roller at 
room temperature for 5 minutes. 
5. The cross-linking reaction was stopped by adding 3.5 ml of 1.5 M glycine to each 
sample (0.175 M final concentration) and incubating on a roller for 5 minutes at 
room temperature.  Following this incubation, samples were always kept on ice. 
6. Fixed cells were centrifuged at 300 x g for 5 minutes at 4 ᵒC. 
7. Supernatant was removed and cell pellets were resuspended in 30 ml ice-cold 
PBS. 
8. Centrifugation at 300 x g for 5 minutes at 4 ᵒC was repeated. 
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Preparation of Chromatin 
9. Supernatant was removed and cells were lysed by resuspending pellets in 15 ml of 
ice-cold ChIP Lysis Buffer. 
10. Samples were incubated on ice for 10 minutes and were then centrifuged at 700 x 
g for 5 minutes at 4 ᵒC. 
11. Pellets were washed with 15 ml ice-cold Nuclei Rinse Buffer. 
12. Samples were centrifuged at 700 x g for 5 minutes at 4 ᵒC. 
13. Supernatant was removed and nuclei were resuspended in 1.5 ml Nuclei Lysis 
Buffer. 
14. Samples were incubated on ice for 10 minutes. 
Sonication 
15. Chromatin samples were transferred to 5 ml round-bottomed FACS tubes and 
volumes were brought to 2ml with X-ChIP buffer. 
16. Sonication was performed using a Misonix automatic sonicator.  The microtip was 
positioned to reach the bottom 3rd of the chromatin sample and the tube was 
secured in place on ice. 
17. Sonication was performed using the following programme: 
Amplitude/Output: 4.5 
ON: 10 seconds 
OFF: 20 seconds 
Total sonication time: 5 minutes 
18. Sonicated chromatin samples were transferred to 1.5 ml microcentrifuge tubes 
and centrifuged at 15000 x g for 10 minutes at 4 ᵒC to pellet debris. 
19. Supernatants were transferred to 50 ml falcons and brought to 20 ml with X-ChIP 
buffer (final concentration 5 x 106 cells worth of chromatin/ml). 
20. Samples were snap frozen in 1 ml aliquots either on dry ice/ethanol or using a 
Cool Box™ 30 (Biocision) and stored at -80 ᵒC. 
Immunopurification of Cross-linked Chromatin 
21. 1 ml of chromatin was thawed for each immunopurification reaction.  Chromatin 
was pooled for preclearing. 
22. 1 ml of chromatin was precleared with 5 µg non-immune IgG and 100 µl of protein 
A/G agarose beads.  Preclearing reactions were incubated at 4 ᵒC on a rotating 
wheel for 3 hours. 
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23. Samples were centrifuged at 800 x g for 1 minute at 4 ᵒC to pellet agarose beads.  
200 µl of supernatant was taken to be used as input template for qPCR.  The 
remaining supernatant was aliquoted into 1.7 ml eppendorf tubes at a volume of 1 
ml per IP.  
24. Specific antibodies were added to each precleared chromatin sample and binding 
reactions were incubated on a rotating wheel at 4 ᵒC overnight. 
25. 50 µl of 50 % washed protein A/G agarose beads were added to each chromatin 
sample and incubated at 4 ᵒC on a rotating wheel for 3 hours.  
26. Samples were centrifuged at 800 x g for 1 minute at 4 ᵒC to pellet agarose beads.  
Supernatants were discarded. 
27. 700 µl of ice-cold X-ChIP buffer was used to transfer beads to a new eppendorf 
tube. 
28. Samples were centrifuged at 800 x g for 1 minute at 4 ᵒC to pellet agarose beads.  
Supernatants were discarded. 
29. Beads were washed with a series of buffers as indicated below.  Each wash was 
incubated for 3 minutes with gentle rotation at room temperature before being 
centrifuged at 800 x g for 1 minute at 4 ᵒC. 
Washed once using 1 ml of ice-cold Wash Buffer 1. 
Washed once using 1 ml of ice-cold Wash Buffer 2. 
Washed once using 1 ml of ice-cold Wash Buffer 3. 
Washed twice using 1 ml of ice-cold TE buffer. 
 
Elution and Reverse Cross-linking 
30. Beads were resuspended in 200 µl ChIP Elution Buffer and transferred to a new 
eppendorf.  Samples were then incubated in ChIP Elution Buffer at room 
temperature for 15 minutes with occasional agitation. 
31. Samples were centrifuged at 800 x g for 1 minute at room temperature and 
eluates were transferred to new eppendorfs. 
32. Steps 30 and 31 were repeated so that both eluates from each IP were combined. 
33. Cross-links were reversed by adding 18 µl of 5 M NaCl to each 400 µl sample and 
incubating overnight at 65 ᵒC. 
34. 1 µl of RNase A was added to each sample and incubated at 37 ᵒC for 1 hour. 
35. 1 µl of Proteinase K was added to each sample and incubated at 45 ᵒC for 2 – 4 
hours. 
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DNA purification 
36. 500 µl of phenol-chloroform was added to each IP and samples were mixed by 
vortexing briefly before centrifuging at max speed (16000 x g?)for 5 minutes at 4 
ᵒC. 
37. The aqueous phase of each sample was transferred to a new eppendorf tube and 
500 µl of chloroform was added to each.  Samples were vortexed briefly and 
centrifuged at 16000 x g for 5 minutes at 4 ᵒC. 
38. The aqueous phase of each sample was transferred to a new eppendorf tube and 
DNA was precipitated by adding 1 µl of glycogen and 750 µl of 100 % ethanol.   
39. Samples were vortexed to mix and incubated at room temperature for 30 
minutes. 
40. Precipitated DNA was pelleted by centrifuging samples at max speed for 45 
minutes at room temperature.  Supernatants were discarded. 
41. DNA pellets were washed with750 µl of 80 % ethanol and centrifuged at max 
speed for 15 minutes at room temperature.  Supernatant was discarded. 
42. DNA pellets were air dried and resuspended in 50 µl of 10 mM tris pH8. 
43. ChIP DNA samples were stored at -20 ᵒC. 
2.6 Preparation of ChIP-seq DNA libraries 
In order for ChIP DNA to be analysed using the Illumina deep sequencing platform, ChIP-
seq DNA libraries were constructed.  Library preparation consisted of end repair, dA-
tailing, adapter ligation, PCR amplification and size selection of DNA fragments as 
outlined below. 
End Repair 
The end repair reaction was assembled as follows: 
ChIP DNA 30 µl 
10X Phosphorylation Reaction Buffer 5 µl 
dNTPs (10 mM) 2 µl 
T4 DNA Polymerase 1 µl 
Klenow DNA Polymerase(diluted 1:5) 1 µl 
T4 PNK 1 µl 
H20 10 µl 
Total volume 50 µl 
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Reactions were incubated at 20 ᵒC for 30 minutes in a thermocycler. 
The QIAquick PCR Purification Kit (Qiagen) was used to purify blunt-ended fragments 
according to the manufacturers’ instructions.  DNA was eluted in 34 µl of elution buffer. 
dA-tailing 
The dA-tailing reaction was assembled as follows: 
End-repaired DNA 34 µl 
dATP (1 mM) 10 µl 
Klenow Fragment Buffer 5 µl 
Klenow Fragment (3’→5’ exo-) 1 µl 
Total volume  50 µl 
Reactions were incubated at 37 ᵒC for 30 minutes in a thermocycler. 
The MinElute PCR Purification Kit (Qiagen) was used to purify dA-tailed fragments 
according to the manufacturers’ instructions.  DNA was eluted in 10µl of elution buffer. 
Adapter Ligation 
The adapter ligation reaction was assembled as follows: 
Illumina Adapter Oligo Mix (diluted 1:10) 1 µl 
2X Quick Ligation Reaction Buffer 15 µl 
Quick T4 DNA ligase 4 µl 
Total volume 20 µl 
Reactions were incubated at room temperature for 15 minutes. 
Unligated adapters were removed using the QIAquick PCR Purification Kit according to 
the manufacturer’s instructions.  Adapter-ligated DNA fragments were eluted in 36 µl of 
elution buffer. 
PCR amplification of adapter-ligated ChIP DNA  
The PCR reaction was assembled as follows: 
5X Phusion High-Fidelity Buffer 10 µl 
dNTPs (10 mM) 1.5 µl 
Illumina PCR Primer 1.1 1 µl 
Illumina PCR Primer 2.1 1 µ 
Phusion DNA Polymerase 0.5 µl 
Total volume 14 µl 
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PCR was performed using a thermocycler programmed to perform the following 
temperature cycles: 
Segment Cycles Temperature Time 
1 1 98 ᵒC 30 seconds 
2 18 98 ᵒC 10 seconds 
65 ᵒC 1 minute 
72 ᵒC 30 seconds 
3 1 72 ᵒC 5 minutes 
 
The MinElute PCR Purification Kit (Qiagen) was used to purify PCR products according to 
the manufacturers’ instructions.  DNA was eluted in 10µl of elution buffer. 
Agarose gel size selection of amplified libraries 
PCR amplified ChIP-seq libraries were electrophoresed on a 2 % agarose 1X TAE gel.  One 
well was left blank in between samples so as to avoid contamination between libraries.  A 
1 Kb DNA ladder (NEB) was also run on the gel to provide a marker for size selection.  Gels 
were electrophoresed at 60 – 70 volts for 2 hours and were then stained by adding 50 µl 
ethidium bromide to 1X TAE running buffer and incubating on an orbital shaker for 30 
minutes.  DNA was visualised using a transilluminator and fragments of 200 – 300 bp 
were excised from the gel using a sterile scalpel.  DNA was purified from agarose gel slices 
using the QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s instructions.  
ChIP-seq library DNA fragments were eluted in 30 µl elution buffer.  
2.7 High throughput sequencing analysis 
ChIP-seq libraries were single end sequenced to 76 bp on an Illumina Genome Analyzer IIx 
at the Glasgow Polyomics Facility by Julie Galbraith. Sequences were converted into fastq 
format using CASAVA v1.8.2 software (Illumina) by Dr. Pawel Herzyk, Polyomics Facility. 
The performance of all sequencing runs was checked using the FastQC software 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc) as described in section 3.2.4.  
Sequence reads from VEZF1 and non-immune IgG ChIP-seq from K562 cells were aligned 
to the hg19 reference genome using Bowtie v0.12.3 software (Langmead et al., 2009) by 
Dr. Andrew Crossan, Vetrie group, ICS, University of Glasgow using the settings --
solexa1.3-quals -p 6 -M 3 -3 40 –t. Alignments were formatted for the UCSC genome 
browser, as described in section 3.2.4, by Andy Crossan. Sequence reads from VEZF1 
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ChIP-seq from 5 and 10 day chicken embryonic erythrocytes were aligned to the gg4 
reference genome using Bowtie v0.12.7 software by Dr. Tony McBryan, Adams group, ICS, 
University of Glasgow using the settings -m 3 --phred33-quals --chunkmbs 512 -p 16 --
best –t. These alignments were formatted for the UCSC genome browser as described in 
section 3.2.4 and shown in chapter 6, by Tony McBryan. 
2.8 ChIP-seq peak finding 
VEZF1 ChIP-seq peaks were identified using MACS v1.4 software (Zhang et al., 2008) using 
the settings -t VEZF1.bed -c IgG.bed -n RS_macs_s25 -f BED -g hs -s 25 --bw=300 --
mfold=10,30 --shiftsize=150 --keep-dup=1 by Dr Ruslan Strogantsev, University of 
Cambridge. Clustered ChIP-seq peaks were resolved into discrete signal peaks using 
PeakSplitter (http://www.ebi.ac.uk/bertone/software.html). Peak summits from MACS 
and PeakSplitter were merged. For summits closer than 100bp apart, the one with highest 
read count was retained. If there was an identical read count in these cases, the midpoint 
coordinate was taken to deal with slightly shifted summits.  
VEZF1 ChIP-seq peaks were ranked by read enrichment levels relative to IgG control ChIP-
seq. The number of VEZF1 and IgG ChIP-seq reads overlapping 50 bp either side of each 
summit was determined using Seqmonk software 
(http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/). These values were 
normalised for total sequence count (expressed as reads per million). The IgG rpm scores 
were subtracted from the VEZF1 rpm scores to allow ranking of peaks by enrichment over 
control.  
2.9 Annotation of chromatin features at VEZF1 peaks 
The gene and chromatin state annotation of VEZF1 peaks in K562 cells is described in 
chapter 4. The enrichment of ChIP-seq reads at VEZF1 peaks or TSS was profiled using 
seqMINER software (Ye et al., 2011). The locations of hg19 TSS were taken from the 
annotation included with seqMINER. The ENCODE project (Dunham et al., 2012) datasets 
analysed in this study are listed in Table 2.1. 
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Dataset ENCODE reference number 
K562 ChromHMM chromatin state track wgEncodeEH000790 
H3K4me1 wgEncodeEH000046 
H3K4me3 wgEncodeEH000048 
H3K27ac wgEncodeEH000043 
H3K27me3 wgEncodeEH000044 
H3K9me3 wgEncodeEH001040 
H3K36me3 wgEncodeEH000045 
H2A.Z wgEncodeEH001038 
DNase-seq wgEncodeEH000484 
FAIRE-seq wgEncodeEH000531 
RNA-seq wgEncodeEH000484 
RNA Polymerase II (unphosphorylated CTD) wgEncodeEH000727 
SP1 wgEncodeEH001578 
YY1 wgEncodeEH001623 
ELF1 wgEncodeEH001619 
EGR1 wgEncodeEH001646 
HMGN3 wgEncodeEH001863 
TAF1 wgEncodeEH001582 
TBP wgEncodeEH001825 
CMYC wgEncodeEH002800 
TAL1 wgEncodeEH001824 
GATA1 wgEncodeEH000638 
BRG1 wgEncodeEH000724 
P300 wgEncodeEH002834 
NFE2 wgEncodeEH000624 
CEBPβ wgEncodeEH002346 
BACH1 wgEncodeEH002846 
Table 2.1 The ENCODE project datasets analysed in this study. 
2.10 Binding site motif discovery 
The preferred DNA binding specificity of VEZF1 was firstly derived from a probabilistic 
model (http://compbio.cs.huji.ac.il/Zinc/, (Kaplan et al., 2005)). DNA sequence motifs of 
up to 30 bp in length enriched within the 100 bp surrounding VEZF1 ChIP-seq peak 
summits were determined using the MEME web portal (http://meme.nbcr.net/meme/, 
(Machanick and Bailey, 2011) as described in section 5.3.1. DNA sequence motifs of 8 or 9 
bp in length enriched within the 200 bp surrounding VEZF1 ChIP-seq peak summits were 
determined using the POSMO web portal (http://cb.utdallas.edu/Posmo/index.html, (Ma 
et al., 2012). 
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2.11  Incubation of fertilised eggs and isolation of erythrocytes 
 from chicken embryos 
Fertilised chicken eggs were a kind gift from Aviagen, Midlothian, UK.  Eggs were stored at 
13 ᵒC, 80 % humidity overnight.  Eggs were incubated at 37.6 ᵒC in an Octagon 400X 
incubator (Brinsea UK) for 5 – 10 days.  Eggs were inverted once per day. 
Circulating erythrocytes were isolated from chicken embryos as follows: 
1. An egg was placed apical end down in an egg tray. 
2. The egg shell above the air pocket was cracked by tapping with the blunt end of a 
scalpel and a disc of shell was removed using fine forceps. 
3. The membrane was cut with scissors and peeled back using forceps. 
4. Some of the liquid was discarded by tilting the egg and allowing it to run out into a 
petri dish. 
5. A peripheral artery was nicked using scissors and blood was collected using a 
P200.  If the yolk sac broke the egg was discarded. 
6. Blood was transferred into a 50 ml falcon tube containing 3 ml cold PBS and 
stored on ice. 
7. Once bleeding was complete, the embryo was tipped into a petri dish and 
decapitated. 
2.12 Bisulphite Sequencing  
2.12.1 Bisulphite Conversion of DNA 
Bisulphite conversion of DNA was performed using the EZ DNA Methylation-Direct Kit 
(Zymo Research, Cat. No. D5020).  Manufacturers’ instructions were followed when 
performing this technique. 
1. 1 x 105 cells were isolated and resuspended in 12 l PBS. 
2. DNA was isolated by assembling the following reaction: 
2X M-Digestion buffer 13 l 
Sample (1 x 105 cells) 12 l 
Proteinase K 1 l 
3. Reactions were incubated at 50 ᵒC for 20 minutes. 
4. Samples were mixed thoroughly and centrifuged at 10 000 x g for 5 minutes.  20 l 
of supernatant was added to 130 l of CT conversion reagent  
5. Reactions were placed in a thermocycler and the following programme run. 
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Temperature Time 
98 ᵒC 8 minutes  
64 ᵒC 3.5 hours 
4 ᵒC Up to 20 hours 
 
6. DNA was purified by spin column.  DNA bound to the column filter underwent 
several washes and a desulphonation step before elution in 10 l elution buffer. 
2.12.2 PCR Amplification from Bisulphite Converted DNA 
PCR primers for amplification of genomic regions of interest from bisulphite modified 
DNA were designed using the MethPrimer online tool (Li LC and Dahiya R. MethPrimer: 
designing primers for methylation PCRs. Bioinformatics. 2002 Nov;18(11):1427-
31. PMID: 12424112).  PCR reactions for amplification from bisulfite modified DNA were 
set up as follows: 
Reaction Buffer  2.5 l 
50 mM MgCl2  1.5 l 
Forward Primer (10 mM) 0.5 l 
Reverse Primer (10 mM) 0.5 l 
dNTPs (10 mM)     1 l 
Platinum Taq DNA Polymerase 0.2 l 
dH20  15.8 l 
Bisulphite Modified DNA     3 l 
TOTAL    25 l  
PCR was performed using a thermocycler programmed to perform the following 
temperature cycles: 
Segment Cycles Temperature Time 
1 1 95 ᵒC 5 minutes 
2 34 95 ᵒC 1 minute 
55 ᵒC 1 minute 
72 ᵒC 2 minutes 
3 1 72 ᵒC 10 minutes 
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Once complete, the PCR reactions were loaded onto a 1 % agarose gel stained with 
Safeview (Company) and electrophoresed at 120 volts for 35 minutes.   
DNA bands of the desired size were excised from the gel using a scalpel and DNA was 
purified from agarose fragments using the QIAquick Gel Extraction Kit (Qiagen, cat. no. 
28704) according to manufacturers’ instructions. 
2.12.3 Ligating Bisulphite Converted DNA into pGEMT Easy Vector 
Bisulphite converted PCR products were ligated into the pGEMT Easy vector by TA-cloning 
using the pGEMT Easy Vector System I (Promega, cat. no. A1360). 
2X Rapid Ligation Buffer  5 l 
pGEMT Easy Vector (50 ng)  1 l 
PCR product   3 l 
T4 DNA Ligase   1 l   
TOTAL  10 l 
Reactions were mixed and incubated at 4 ᵒC overnight. 
2.12.4 Transformation of competent E. Coli 
Subcloning efficiency DH5-α E. coli were transformed with ligations as follows: 
1. Competent DH5- α cells were thawed on ice and mixed by gently flicking  the 
tube. 
2. 50 l of competent cells were aliquoted into individual eppendorf tubes per 
transformation and kept on ice. 
3. 2 l of ligation reaction was added per tube and mixed by gently flicking the tube. 
4. A positive control transformation using 2.5 l (250 pg) pUC19 plasmid was 
performed alongside every transformation. 
5. Reactions were incubated on ice for 30 minutes. 
6. Cells were heat-shocked in a water bath at 42 ᵒC for 20 seconds. 
7. Reactions were incubated on ice for 2 minutes. 
8. 950 l of room temperature SOC was added to each reaction and tubes were 
transferred to a 37 ᵒC bacterial shaker set to 225 rpm for 1 hour. 
9. 50 l and 200 l of transformation reactions were spread on agar plates 
containing 50 g/ml ampicillin for selection of transformed bacteria.  These plates 
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had been coated with 40 l of 20 mg/ml X-Gal to allow blue/white colony 
screening, and pre-warmed by incubating at 37 ᵒC for 1 hour. 
10. Plates were incubated at 37 ᵒC overnight to allow colony formation and were 
subsequently stored at 4 ᵒC. 
2.12.5 Screening colonies for presence of insert 
The multiple cloning region of the pGEMT Easy Vector lies within the α-peptide coding 
region of the β-galactosidase enzyme.  β-galactosidase cleaves X-Gal producing a blue 
colour that can be easily detected by eye, thus if the pGEMT Easy Vector self-ligates and 
the β-galactosidase coding region is intact, active enzyme will be produced by 
transformed DH5-α cells and bacterial colonies will appear blue.  If PCR product is 
successfully ligated into the pGEMT Easy Vector, the β-galactosidase coding region is 
interrupted such that the enzyme cannot be expressed by transformed bacterial cells and 
colonies will appear white.  Therefore, blue/white screening of bacterial colonies was 
performed in order to differentiate between bacterial colonies containing DNA inserts of 
interest and those containing self-ligated plasmid. 
 
Colony PCR 
To ensure that the white bacterial colonies selected did contain DNA inserts of interest, 
colony PCR was performed. 
1. A pipette tip was used to pick white bacterial colonies from X-Gal-coated agar 
plates. 
2. The bacterial colony on the pipette tip was submerged in 50 l dH20 in an 
eppendorf tube and mixed. 
3. The tip was then streaked over the surface of a pre-warmed agar plate containing 
50 g/ml ampicillin, this streak plate was incubated at 37 ᵒC overnight to allow 
colony formation. 
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4. Colony PCR reactions were set up as follows: 
 10X reaction buffer 2.5 l 
 Forward primer (10 mM) 0.5 l 
 Reverse primer (10 mM) 0.5 l 
 dNTPs (10 mM) 1 l 
 Taq DNA polymerase 0.2 l 
 dH20  15.3 l 
 Template (bacterial colony in H20) 5 l 
 TOTAL  25 l 
5. PCR was performed using a thermocycler programmed to perform the following 
temperature cycles: 
Segment Cycles Temperature Time 
1 1 94 ᵒC 2 minutes 
2 34 94 ᵒC 30 seconds 
55 ᵒC 30 seconds 
72 ᵒC 1 minute 
3 1 72 ᵒC 10 minutes 
 
6. Once complete, the PCR products were analysed on a 1 % agarose gel stained with 
Safeview.   
2.12.6 Purification of plasmid DNA 
1. A small sample of bacterial cells from the streak plate was transferred to 2 ml of 
LB + 50 g/ml ampicillin in a round bottomed falcon tube using a sterile pipette 
tip.  This culture was incubated in a 37 ᵒC bacterial shaker set to 225 rpm for 16 
hours. 
2. ~1.4 ml of overnight bacterial culture was transferred to a 1.5 ml eppendorf and 
centrifuged at 13000 rpm for 5 minutes to pellet bacterial cells. 
3. The supernatant was removed and plasmid DNA purified from the bacterial cell 
pellet using the QIAprep Miniprep kit (Qiagen, cat. no. 27106) according to 
manufacturers’ instructions.  
4. The concentration of eluted DNA was measured by nanodrop. 
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2.12.7 Sequencing of bisulphite modified DNA 
Purified plasmid DNA was sent to Source Bioscience for Sanger Sequencing of bisulphite 
modified DNA inserts.   
- 20 l of 100 ng/l plasmid DNA was sent for sequencing. 
- Sequencing was performed using the M13 reverse primer for all samples. 
- Upon receipt of complete sequencing files, DNA sequences were reverse 
complemented using an online tool and aligned to the original DNA target 
sequence in a Microsoft Word document. 
- Sequences were checked for complete conversion of non-CpG-associated 
cytosines to thymine. 
- The methylation state of individual CpG-associated cytosine residues was then 
analysed. 
2.13 RNA Preparation 
2.13.1 RNA extraction from cell pellets 
1. Cell pellets containing 5 – 10 x 106 cells were resuspended in 1 ml trizol 
(Invitrogen) by pipetting.  A ‘reagents only’ extraction control was also set up, i.e. 
1 ml trizol without cells. 
2. Samples resuspended in trizol were incubated at room temperature for 5 minutes. 
3. 100 µl of 1-Bromo-3-chloropropane (BCP) (Sigma) per 1 ml of trizol was added to 
each sample. 
4. Tubes were shaken vigorously for 30 seconds, then incubated at room 
temperature for 15 minutes. 
5. Samples were centrifuged at 12000 x g for 15 minutes at 4 ᵒC. 
6. 500 µl of isopropanol was added to a set of fresh eppendorfs. 
7. The aqueous phase of each sample was transferred to a fresh eppendorf 
containing isopropanol, tubes were then vortexed and incubated at room 
temperature for 10 minutes. 
8. Samples were incubated at -20 ᵒC for a minimum 20 minutes. 
9. Samples were centrifuged at 12000 x g for 15 minutes at 4 ᵒC. 
10. Supernatent was poured off as waste and tubes were touched to a clean paper 
towel. 
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11. RNA pellets were washed with 1 ml of 75 % EtOH and centrifuged at 7500 x g for 5 
minutes at 4 ᵒC. 
12. Supernatent was poured off. 
13. Steps 11 and 12 were repeated. 
14. Samples were pulse centrifuged at 12000 x g and as much of the remaining liquid 
as possible was removed without disturbing the RNA pellet. 
15. Tubes were left open and covered with a clean paper towel to allow RNA pellets 
to air dry. 
16. RNA pellets were resuspended in 50 µl sterile water. 
17. RNA yield was quantified using a NanoDrop. 
18. Samples were stored at -80 ᵒC. 
2.13.2 RNA quality checks by agarose gel electrophoresis 
1. RNA sample quality was analysed by loading 1 or 2 µg of RNA preparation per well 
of a 1 % agarose-TBE gel.  These gels contained no nucleic acid stains. 
2. Gels were run at 120 volts. 
3. Ethidium bromide (Sigma) was then added to 1 x TBE running buffer at a 1 in 
10000 dilution and the gel was incubated in this buffer for 30 minutes on an 
orbital shaker. 
4. Gels were transferred to ethidium bromide-free running buffer and incubated for 
10 minutes on an orbital shaker to de-stain. 
5. Gels were then imaged using a Fujifilm FLA-5000 scanner.  
2.14 cDNA synthesis 
cDNA synthesis was performed using the Invitrogen Superscript III kit (cat #) 
1. The following were combined in PCR tubes: 
RNA (100 ng/µ)     4 µl 
dNTPs (10 mM) 0.5 µl 
Random primers (50 ng/µl)    1 µl 
dH20    1 µl 
TOTAL 6.5 µl 
2. Reactions were incubated at 65 ᵒC for 5 minutes, then transferred to ice for at 
least 2 minutes. 
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3. A master mix was prepared (as shown below per reaction) of which 3.5 µl was 
added to each cDNA synthesis reaction. 
5 x First Strand Synthesis (FS) Buffer 2 µl 
RNase OUT 0.5 µl 
DTT 0.5 µl  
Superscript III Reverse Transcriptase 0.5 µl 
TOTAL 3.5 µl 
Final Volume 10 µl 
 
4. cDNA synthesis was performed using a thermocycler programmed to perform the 
following temperature cycles:  
Temperature Time 
25 ᵒC 10 minutes 
50 ᵒC 50 minutes 
85 ᵒC 5 minutes 
 
5. Template RNA was digested by adding 1 µl of RNase H (NEB) to each reaction and 
incubating at 37 ᵒC for 20 minutes. 
6. cDNA samples were then diluted with RNase- and DNase-free H20 and either used 
immediately for qPCR or stored at -20 ᵒC. 
2.15 Real-time PCR 
Two real-time PCR methods were used to generate the work presented and are described 
below. 
2.15.1 SYBR® Green real-time PCR 
SYBR® green is a nucleic acid stain which binds preferentially to double stranded DNA and 
emits a fluorescence signal.  Thus as PCR products accumulate with each amplification 
cycle, increased SYBR Green® fluorescence signal is detected.  SYBR® Green real-time PCR 
was used in the analysis of gene expression from diluted cDNA templates. 
SYBR® Green PCR reactions were set up as follows: 
 
 
83 
 
2X SYBR® Green Master Mix 10 µl 
Forward and Reverse Primer Mix (4 or 4.5 µM per primer)   4 µl 
cDNA template   4 µl 
dH20   2 µl 
TOTAL 20 µl 
SYBR® Green real-time quantitative PCR reactions were run on a Stratagene Mx3000P 
thermocycler programmed to perform the following temperature cycles: 
Segment Cycles Temperature Time 
1 1 95 ᵒC 10 minutes 
2 40 95 ᵒC 15 seconds 
60 ᵒC 30 seconds 
 
A dissociation curve was performed upon completion of each real-time PCR in order to 
measure the dissociation temperature of PCR products between 60 ᵒC – 95 ᵒC. 
Ct values were generated using the MxPro version 4.0 software. 
2.15.2 Taqman® real-time PCR 
Taqman® real-time PCR is designed to have a higher specificity for the target amplicon 
than the SYBR® Green method.  In addition to forward and reverse primers, Taqman® PCR 
also utilises a probe oligonucleotide which is designed to bind a target DNA sequence 
between the forward and reverse primer binding sites.  This probe is conjugated to a FAM 
fluorophore at its 5’ end and a TAMRA quencher at its 3’ end.  The close proximity of 
these two molecules results in the quencher absorbing the emission energy of the 
fluorophore, thus preventing the detection of any fluorescence signal.   Extension of the 
forward primer across the Taqman probe binding site during PCR results in degradation of 
the bound probe due to the 5’ -> 3’ exonuclease activity of the Taq polymerase enzyme 
used in Taqman® PCR.  Degradation of the Taqman probe separates the associated 
fluorphore and quencher molecules.  The result of this is that the emission energy of the 
fluorophore is no longer masked by the quencher therefore a fluorescence signal which is 
proportional to the amount of specific amplicon product can be detected.  Taqman® real-
time PCR was used in the analysis of gene expression from diluted cDNA templates and in 
analyses following ChIP and hMeDIP assays. 
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Taqman® PCR reactions were set up as follows: 
2X Taqman® Master Mix 10 µl 
Forward and Reverse Primer Mix (1.5 or 4.5 µM per primer)   4 µl 
Taqman Probe (1.5 – 2 µM)   2 µl 
DNA template   4 µl 
TOTAL 20 µl 
Taqman® real-time quantitative PCR reactions were run on a Roche LC480 thermocycler 
programmed to perform the following temperature cycles: 
Segment Cycles Temperature Time 
1 1 95 ᵒC 10 minutes 
2 45 95 ᵒC 30 seconds 
60 ᵒC 1 minute 
3 1 40 ᵒC 10 seconds 
 
Ct values were generated using the Light Cycler® 480 software. 
2.15.3 Real-time PCR primer design 
The following guidelines were utilised in the design of primer sets for real-time PCR: 
 Primer Tm’s should be 60 ᵒC +/- 2 ᵒC 
 The G/C content of primers should be 40 – 60 % 
 Primers are 18 – 28 bp in length (optimal length 20 bp) 
 Target amplicon size is 50 – 150 bp 
 Either the forward or reverse primer of a primer pair should span an exon-exon 
junction.  This should prevent amplification of contaminating genomic DNA that 
may be present in cDNA samples. 
 Taqman probes were designed such that their annealing temperatures were 10 ᵒC 
higher than those of the forward and reverse primers. 
 
The BLAST similarity search tool was used to check if designed primer sequences aligned 
to multiple sites in the genome. 
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2.15.4 Validation and optimisation of real-time PCR primers 
Several of the primer sets used had previously been validated and are widely used in the 
lab.  qPCR using newly designed primer sets was optimised using various ratios of final 
primer concentration per reaction (shown below): 
Reverse Forward 
 50 nM 300 nM 900 nM 
50 nM 50/50 300/50 900/50 
300 nM 50/300 300/300 900/300 
900 nM 50/900 300/900 900/900 
 
Following amplification, PCR products were analysed by agarose gel electrophoresis to 
ensure only one PCR product was generated. 
Optimal primer concentrations were chosen based on Ct values, amplification plots, 
dissociation plots and agarose gel images. 
Standard curves were then generated for each primer set at their chosen concentration.   
 
2.15.5 Real-time PCR analysis 
1. Gene expression in protein knock down experiments was analysed as follows: 
 Expression of the gene of interest was normalised to expression of a housekeeping 
gene to generate a  Ct value: 
  Ct = Ct (gene of interest) – Ct (housekeeping gene) 
 A   Ct value was then calculated by subtracting the  Ct of the gene of interest in 
wild type cells from the  Ct of the gene of interest in KD cells: 
  Ct =  Ct (treated) -  Ct (wild type) 
   Ct values were then used to calculate fold change in gene expression using the 
following formula: 
Fold change = N^(-  Ct); where ‘N’ = PCR amplification efficiency (typically = 2). 
2. Gene expression of endogenous proteins in chicken circulating erythrocytes was 
analysed as follows: 
 A  Ct value was generated by normalising expression of a gene of interest to that 
of a housekeeping gene: 
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 Ct = Ct (gene of interest) – Ct (housekeeping gene) 
 Fold expression of a gene of interest relative to housekeeping gene expression 
was calculated using the following formula: 
Fold expression = N^(- Ct); where ‘N’ = PCR amplification efficiency. 
2.16 Electrophoretic Mobility Shift Analysis (EMSA) 
2.16.1 Oligonucleotide Purification 
Gel Preparation 
1. Glass plates were separated using 1.5 mm spacers and held in place with bulldog 
clips, the base of the glass plates was sealed using masking tape.  50 ml gel casting 
solution was prepared per gel using the SequaGel UreaGel system (National 
Diagnostics), as indicated below, with APS being added last.  This solution was 
carefully pipetted into the gel casting construction and a 10 well plastic comb was 
inserted.  The final acrylamide concentration of this preparation is 8 % and was 
routinely used for all oligonucleotide purifications.  
Sequagel Concentrate  16 ml 
Sequagel Diluent 29 ml 
Sequagel Buffer 5 ml 
TEMED 20 µl 
10 % APS (adenosine phosphosulfate) 400 µl 
2. Once gel polymerisation was complete, the comb and tape at the base of the gel 
were removed and the cassette was fastened into sandwich clamps and fixed into 
the central cooling unit of the Protean II xi XL Vertical Electrophoresis cell (Bio-
Rad). 
3. 5 litres of 0.5X TBE was heated to 55 – 600C and ~3 litres were poured into the 
electrophoresis tank, the cooling unit containing the acrylamide gel was then 
placed inside the tank and the upper buffer reservoir was filled with 0.5X TBE to 
completely submerge the electrode. 
4. A syringe was used to wash out the wells with 0.5X TBE. 
5. The gel was pre-run at 400 volts for 15 – 30 minutes. 
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Oligonucleotide Preparation  
6. 100 µl of formamide loading buffer was added to each tube of lypholised 
oligonucleotide.  Tubes were centrifuged briefly, sat at room temperature while 
the gel pre-ran, and mixed by pipetting prior to loading gel. 
Electrophoresis of Oligonucleotides  
7. The gel pre-run was stopped and 50 µl of resuspended oligonucleotide was loaded 
per well 
8. 30 µl of 30 % glycerol loading buffer containing bromophenol blue and xylene 
cyanol dyes was loaded in the far left hand lane to orient gels and monitor 
electrophoresis. 
9. Gels were run at 400 volts for ~ 50 minutes, until the bromophenol blue dye 
reached the base of the gel. 
Purification of Oligonucleotides 
10. Following electrophoresis, the gel was transferred from the glass plates to a sheet 
of clingfilm which was placed on top of a phosphorimaging screen. 
11. In a dark room, oligonucleotide bands were visualised by UV shadowing, i.e. a UV 
lamp was shone over the gel and phosporimaging screen allowing the visualisation 
of DNA as dark purple bands. 
12. Visible bands were excised from gels using a clean scalpel.  Roughly the bottom 
quarter of each DNA band was not removed from the gel in order to ensure the 
exclusion of prematurely terminated oligonucleotides. 
13. Excised gel bands were transferred to a 1.5 ml eppendorf (whose tip had been 
removed) which sat inside a second intact 1.5 ml eppendorf. 
14. Double eppendorfs were placed in the inner ring of a Sigma 1-14 microfuge and 
pulse centrifuged for ~7 seconds.  Gel fragments appeared crushed in the bottom 
eppendorf. 
15. 400 µl of elution buffer was added to each crushed gel fragment and mixed by 
vortexing briefly 
16. Samples were incubated at 37 ᵒC overnight to elute oligonucleotides from the gel. 
17. Filter columns (Millipore cat. no. 30HV00) were prepared by adding 400 µl of 1X 
TE buffer to the column, pulse centrifuging for ~10 seconds and removing the flow 
through from the collection tube. 
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18. Eluted oligonucleotide/crushed acrylamide gel mix was transferred to the filter 
column and centrifuged at 2000 x g for 1 minute. 
19. The volume of eluted DNA was measured and transferred to a fresh eppendorf. 
20. 3 x volumes of ethanol and the volume of 3 M NaAc required for a 0.3 M final 
concentration were calculated.  3 M NaAc was added to samples first, followed by 
100 % ethanol. 
21. Tube contents were mixed by inverting and sat on ice for 1 hour. 
22. Samples were centrifuges at 14,000 x g, 4 ᵒC, for 30 minutes. 
23. The supernatant was poured/pipetted off and DNA pellets were washed with 100 
µl of 90 % ethanol.  Samples were centrifuged again as in step 22. 
24. The supernatant was poured/pipetted off and DNA pellets were air dried. 
25. Purified oligonucleotides were resuspended in 100 µl of 1 M tris pH8. 
26. DNA concentrations were measured using a NanoDrop ND1000 
spectrophotometer (Thermo). 
 2.16.2 EMSA Probe Generation 
End-labelling top strand oligo with -32P ATP 
1. End labelling reactions were set up as indicated below. 
Top strand oligo (5 pmol/µl) 2 µl 
10X PNK buffer (NEB) 1.5 µl 
-32P ATP 5 µl 
T4 PNK (NEB) 0.5 µl 
H20 6 µl 
Total 15 µl 
2. Reactions were incubated at 37 ᵒC for 45 minutes, followed by 90 ᵒC for 5 minutes. 
Annealing of complementary oligonucleotides 
3. 30 pmol (6l) of unlabelled bottom strand oligo was added to the -32P ATP-
labelled top strand. 
4. 5 l of 10X Probe Annealing and Storage Buffer was added and reactions made to 
50 l with H20. 
5. Reactions were placed in a thermocycler and the following annealing programme 
was run. 
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Temperature Time 
90 ᵒC 3 minutes 
65 ᵒC 10 minutes 
37 ᵒC 10 minutes 
22 ᵒC 10 minutes 
4 ᵒC hold 
 
Removal of Excess -32P ATP 
6. Sepharose within Roche G25 Spin Columns (cat. no. 11273949001) was 
resuspended by inverting and buffer drained according to the manufacturer’s 
instructions. 
7. Columns were centrifuged twice at 1100 x g for 2 minutes at 4 ᵒC, flow through 
was emptied from the collection tube. 
8. The radiolabelled probe sample was loaded onto the sepharose column and 
eluted into a screw cap tube by centrifuging at 1100 x g for 4 minutes at 4 ᵒC. 
9. Excess unincorporated -32P ATP nucleotides are retained in the sepharose 
column. 
10. Radiolabelled probe DNA was stored at 4 ᵒC. 
2.16.3 In vitro transcription of transcription factor gene coding sequences 
In vitro transcription was performed using the mMessage mMachine T7 and T3 in vitro 
transcription kit (Ambion, cat. no’s AM1344 and AM1348 respectively) according to the 
manufacturers’ instructions.  Briefly, reactions were assembled as below. 
NTP/CAP  10 l 
10x reaction buffer 2 l 
Linear template DNA  1 g 
T7 enzyme mix  2 l 
RNasin  0.5 l 
Make to 20 l with H20 
Reactions were mixed thoroughly by pipetting and incubated at 37 ᵒC for 2 hours. 
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2.16.4 In vitro translation of transcription factor proteins 
In vitro translation of transcription factor proteins 
1. In vitro translation was performed using the Rabbit Reticulocyte Lysate System 
(Promega, product number L4960) according to manufacturers’ instructions.   For 
each protein translation two in vitro translation reactions were assembled, one 
incorporating 35S methionine into the synthesised protein to allow analysis of the 
size of protein product generated via polyacrylamide gel electrophoresis and 
phosphorimaging, the second synthesising non-radiolabelled cold protein for use 
in EMSA.  In vitro translation reactions were assembled as follows: 
 Radiolabelled IVT Non-radiolabelled IVT 
RNA substrate      1 µl    2 µl  
H20  4.5 µl 11 µl 
 Samples were incubated at 65 ᵒC for 5 minutes to denature RNA secondary 
 structure 
 RRL   17.5 µl 35 µl 
 RNasin Ribonuclease inhibitor (Promega)   0.5 µl   1 µl                                                                   
 Amino Acid Mix methionine- (1 mM)    0.5 µl   1 µl     
 Amino Acid Mixture leucine- (1 mM)                 - -                         1 µl     
  [35S] Methionine   2 µl     -- 
In vitro translation reactions were incubated at 30 ᵒC for 90 minutes and 
subsequently stored at -80 ᵒC. 
Preparation of Protein Samples for analysis by SDS-PAGE 
Radiolabelled in vitro translation samples were prepared for analysis by setting up 
reactions as described below. 
Radiolabelled in vitro translation reaction 2 µl 
2X LSB  5 µl 
H20  3 µl 
Samples were mixed and incubated at 100 ᵒC for 5 minutes, centrifuged briefly and used 
immediately in PAGE. 
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2.16.5 Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Gel Preparation 
1. Resolving gel casting solutions were prepared as shown below with APS being 
added last.  ~7.5 ml was pipetted carefully into gel casting cassettes.  The final 
acrylamide concentration of this solution is 10 % and was routinely used for all 
experiments.  The solution was overlaid with ~1 ml isopropanol and left to 
polymerise for 30 minutes at room temperature. 
40 % acrylamide (37.5 acrylamide:1 bis-acrylamide) 5 ml 
4X resolving buffer 5 ml 
H20  9.8 ml 
TEMED  10 µl 
10 % APS 100 µl 
2. The isopropanol layer was poured off and residual isopropanol removed by 
washing with H20.  Stacking gel casting solutions were prepared as shown below 
with APS being added last.  ~3 ml was pipetted on top of the resolving gel and a 10 
well plastic comb inserted.  The stacking gel was then left to polymerise for 30 
minutes at room temperature. 
40 % acrylamide (37.5 acrylamide:1 bis-acrylamide) 1.25 ml 
4X stacking buffer 2.5 ml 
H20  6.25 ml 
TEMED  10 l 
10 % APS 60 l 
Electrophoresis of Protein Samples 
3. Once polymerisation of the stacking gel was complete, the plastic comb and tape 
at the bottom of the cassette were removed and the wells were washed with H20 . 
4. Gel cassettes were fitted into the gel tanks, locked in place and submerged in 1X 
SDS-PAGE running buffer. 
5. Denatured protein samples were loaded into individual wells along with 5 l of 
PAGEruler Prestained Protein Ladder. 
6. Gels were run at 200 volts for 120 minutes. 
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Gel drying and imaging 
7. Once electrophoresis was complete, gel cassettes were opened and the stacking 
gel and resolving gel foot were removed. 
8. A piece of Whattman filter paper was placed on top of the gel and was peeled 
away from the remaining half of the gel cassette. 
9. The gel was then place on top of a further two pieces of Whattman filter paper 
and overlaid with clingfilm before being placed in the drying unit of a gel dryer 
which had been pre-heated to 80 ᵒC. 
10. The gel was left in the drying unit for ~30 minutes until completely dry and was 
then exposed to a phosphorimaging screen overnight. 
11. The phoshporimaging screen was scanned using a Fuji scanner the following day 
allowing visualisation of radiolabelled protein bands. 
2.16.6 Electrophoretic Mobility Shift Analysis (EMSA) 
Gel Preparation 
1. Glass plates were separated using 1 mm spacers, positioned at both edges and the 
base of the plates, and held in place with bulldog clips.  Gel casting solution was 
prepared as indicated below, with APS being added last.  ~ 20 ml of this solution 
was carefully pipetted into each gel casting unit and a 20 well plastic comb was 
inserted.  Gels were then left to polymerise for 1 hour at room temperature.  The 
final acrylamide concentration of these gels was 5 % and was routinely used for all 
EMSAs.  
40 % Acrylamide (29 Acrylamide:1 Bis-acrylamide) 6.25 ml 
5X TBE 10 ml 
H20 33.2 ml 
TEMED 50 l 
10 % APS 500 l 
2. Once gel polymerisation was complete, the bottom reservoir of a vertical gel tank 
(Whatman Biometra Model V15.17) was filled with 0.5 litres of 1X TBE buffer. 
3. The spacer was removed from the gel base and the gel cassette was fastened into 
the gel tank. 
4. The upper buffer reservoir of the gel tank was filled with 0.5 litres of 1X TBE buffer 
ensuring that the comb was submerged.  The comb was then carefully removed 
and wells were rinsed with 1X TBE buffer using a syringe. 
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5. Gels were pre-run for a minimum of 45 minutes at 120 volts prior to sample 
loading. 
Preparation of Probe +/- Competitor DNA  
6. DNA samples were prepared for addition to protein binding reactions as described 
below. 
Sonicated poly (dA.dT) 1 l 
Radiolabelled DNA probe (0.2 M) 0.05 l 
Cold specific competitor DNA (if required) (2 M) 0.25 l 
Make to 3 l with H20 
Preparation of Protein-DNA binding reactions 
7. Binding reactions were prepared follows. 
2X Binding Buffer 10 l 
DTT  (100 mM) 0.2 l 
10 % Triton X-100 0.5 l 
BSA (NEB, 10 mg/ml) 0.2 l 
VEZF1 in vitro translation OR 2 l 
Chick red blood cell nuclear extract 0.25 l 
Make to 15 2 l with H20 
8. 2 l of anti-VEZF1 antibody was added to reactions if required and all binding 
reactions were incubated on ice for 2 hours. 
9. Reactions were then incubated at room temperature for 15 minutes. 
10. 3 l of Probe +/- competitor DNA was added to each binding reaction, mixed and 
incubated at room temperature for 45 minutes. 
Gel Electrophoresis 
11. EMSA gels were loaded while running at 120 volts. 
12. Wells were rinsed again with 1X TBE using a syringe, and 10 l of protein/DNA 
binding reactions were loaded per well. 
13. 5 l of bromophenol blue loading buffer was loaded into well number 20 on the 
left hand edge of the gel to allow gel orientation. 
14. Gels were run at 120 volts for 2 hours. 
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Gel drying and imaging 
15. Once electrophoresis was complete, the gel unit was removed from the running 
tank and the uppermost glass plate removed. 
16. A piece of Whattman filter paper was place on top of the gel and used to separate 
the gel from the second glass plate. 
17. The gel was then placed on top of a further two pieces of Whattman paper and 
overlaid with clingfilm before gel drying using gel drying equipment. 
18. The gel was left in the drying unit for ~50 minutes and was then exposed to a 
phosphorimaging screen for ~40 hours. 
19. The phoshporimaging screen was scanned using a Fuji scanner allowing 
visualisation of radiolabelled probe DNA. 
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Chapter 3 
Profiling of VEZF1 DNA-binding events across the human 
genome in the human erythroid cell line K562 
3.1 Introduction 
VEZF1 is a highly conserved DNA-binding protein found in vertebrates. Vezf1-null mouse 
embryos exhibit an embryonic lethal phenotype resulting from severe haemorrhaging 
which is caused by a lack of vascular integrity (Kuhnert et al., 2005). Disruption of Vezf1 
also impairs vasculogenesis and haematopoeisis during embryonic stem cell 
differentiation (Zou et al., 2010). Despite its essential role in development, the gene 
targets of VEZF1 are relatively poorly characterised. VEZF1 binding sites have been 
identified within a small number of promoters (Lewis et al., 1988, Koyano-Nakagawa et 
al., 1994, Aitsebaomo et al., 2001, Dickson et al., 2010) and the chicken HS4 insulator 
element (Dickson et al., 2010). A preliminary VEZF1 ChIP-chip experiment in my 
supervisor’s research group previously identified 125 VEZF1 binding sites within 1 % of 
the human genome in K562 cells (section 1.9).  These sites included housekeeping and 
cell type-specific gene promoters in addition to gene distal enhancers and potential 
insulators (Strogantsev, 2009).  
In this study, I wish to gain a clearer understanding of the general gene regulatory process 
that VEZF1 is involved in. To achieve this, I begin by using ChIP-seq to profile the binding 
of VEZF1 across the human genome in a highly studied cell type. This profile can then be 
carefully studied to determine whether VEZF1 generally associates with transcription 
factor functions or has a more specialised role in regulating chromosome structure like 
other insulator-binding proteins.  
Prior to performing ChIP-seq, a cell type in which to profile VEZF1 genomic binding had to 
be selected. In line with the interests of my supervisor’s research group and that of my 
sponsor (the Medical Research Council (MRC)) in human gene regulation, a human cell 
type was selected. We decided to focus on a cell line rather than a primary tissue at this 
time as cell lines offer homogeneity and the potential to scale up cell numbers when 
developing new methodology. We decided to perform VEZF1 ChIP-seq analysis in the 
96 
 
human erythroid cell line K562. There were a number of reasons for this. Firstly, my 
supervisor’s research group has a long standing interest in erythroid gene regulation and 
had previously mapped VEZF1 binding to a portion of the genome in K562 cells using a 
ChIP-chip approach (section 1.9). This preliminary study will be used a reference when 
analysing VEZF1 ChIP-seq performance. The group have also generated a K562 cell line 
that expresses FLAG epitope-tagged recombinant VEZF1 at 50% of endogenous levels. 
This will allow for VEZF1 ChIP analysis with anti-FLAG antibodies, which will act as a 
control for potential chromatin enrichments that are not specific for VEZF1 when 
performing standard ChIP analysis with anti-VEZF1 antibodies. Another major factor 
which led to the choice of K562 cells was their status as an ENCODE tier 1 cell line.  
ENCODE research teams have characterised histone modifications, chromatin features 
and the binding profiles of many transcription factors across the whole K562 genome. 
This data is publically available, which therefore allows me to address my objectives of 
determining the chromatin state and co-binding transcription factors at VEZF1 sites in 
K562 cells without the need for extensive experimentation. 
The principal objectives of this chapter are to: 
1. Prepare crosslinked chromatin from K562 cells 
2. Perform VEZF1 ChIP and validate specific enrichments using QPCR 
3. Prepare and validate VEZF1 ChIP-seq libraries 
4. Align ChIP-seq reads to the human genome 
5. Identify peaks of VEZF1 binding in the K562 genome  
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3.2 Preparation of Crosslinked chromatin from K562 cells 
An optimised transcription factor ChIP protocol routinely used in the lab was followed for 
all ChIP experiments (section 2.5). The crosslinking of K562 cell cultures in exponential 
growth phase in warmed serum free media with 0.8 % formaldehyde for 5 minutes was 
previously determined to give optimal detection of DNA-binding proteins such as VEZF1 
(Strogantsev, 2009). The standard approach of 1 % formaldehyde for 10 minutes or longer 
may mask antibody-binding epitopes on DNA-binding proteins and may also impair 
chromatin sonication efficiency, resulting in reduced signal to background levels. 
Crosslinked chromatin was prepared and sonicated to an average fragment size of 200 – 
400 bp ready for immunoprecipitation (Figure 3.1).  
 
Figure 3.1 Shearing of K562 chromatin.  
Agarose gel electrophoresis of K562 chromatin after sonication to an average fragment 
size of 200 – 400 bp for use in ChIP.   
 
3.3 Validation of VEZF1 ChIP performance 
Chromatin preparations were pre-cleared with non-immune rabbit or mouse IgG and 
protein A or G agarose to remove any non-specific complexes.  For VEZF1 and control IgG 
ChIPs, chromatin from 1x107 cells was used per IP.  Three VEZF1 ChIPs were performed 
simultaneously and the final samples were combined for a final volume of 150 µl.  For 
FLAG ChIP the amount of chromatin was dropped to 5x106 cells per IP, two FLAG ChIPs 
were performed and the final samples were combined for a final volume of 100 µl.  The 
anti-VEZF1 antibody 3642 was used for the ChIP of endogenous VEZF1 from K562 cells 
(Dickson et al., 2010). The performance of VEZF1 ChIP in K562 cells was assayed by 
500 bp
100 bp
1000 bp
300 bp
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quantitative PCR (QPCR) using primers designed against regulatory elements previously 
identified to bind VEZF1 (Strogantsev, 2009).  Primer sets that detect the IL3 and EDN1 
promoters serve as negative control loci as VEZF1 is known not to bind these elements in 
erythroid cells.  The promoters of the broadly expressed genes STAG2, HISPPD2A and 
POLR3K, enhancers of the erythroid-specific gene TAL1 and a putative insulator at the 
FLNA locus were all enriched following VEZF1 ChIP (Figure 3.2).  A putative enhancer 
element within intron 3 of the FOXP4 gene was mildly enriched by VEZF1 ChIP. The IL3 
and EDN1 promoters were not enriched. These results are consistent with previous VEZF1 
ChIP-QPCR and ChIP-chip analyses in K562 cells (Strogantsev, 2009), so the VEZF1 ChIP 
was taken forward for ChIP-seq analysis. 
 
Figure 3.2 VEZF1 interacts with gene regulatory elements in K562 cells.  
QPCR analysis of regulatory element enrichment after VEZF1 ChIP.  The relative 
enrichment of each element over starting input chromatin after VEZF1 ChIP was 
normalised to that at the IL3 promoter. Error bars represent standard deviation between 
triplicate QPCR analyses of a VEZF1 ChIP.  
 
Agarose conjugated anti-FLAG antibodies were used to ChIP for recombinant VEZF1 from 
the K562 cell line D3/6, which expresses FLAG-tagged VEFZ1 protein at approximately half 
the level of endogenous wild type VEZF1 (Dan Li, unpublished data). A control K562 cell 
line S3F, which expresses the FLAG protein tag alone, was used to control for non-specific 
chromatin interactions with anti-FLAG agarose. QPCR analysis was used to show that the 
POLR3K and RFX5 gene promoters and the TAL1 +51 enhancer were all enriched following 
FLAG ChIP from the FLAG-VEZF1 expressing cell line D3/6 (Figure 3.3). No enrichment of 
the IL3 promoter was observed. No enrichment of VEZF1-associated regulatory elements 
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was observed with anti-FLAG ChIP in the control cell line S3F. These results are consistent 
with previous ChIP analysis with anti-VEZF1 antibodies in the parental K562 cells (Figure 
3.2) (Strogantsev, 2009). These results indicate that FLAG-tagged recombinant VEZF1 can 
interact with the same gene regulatory elements as endogenous VEZF1. The FLAG-VEZF1 
ChIP was therefore taken forward for ChIP-seq analysis. 
Figure 3.3 Recombinant VEZF1 can interact with the same gene regulatory elements as 
endogenous VEZF1. 
QPCR analysis of gene regulatory element enrichment following ChIP with anti-FLAG or 
non-immune IgG form K562 cell lines expressing FLAG-VEZF1 (D3/6) or FLAG only (S3F). 
The relative enrichment of each element over starting input chromatin after VEZF1 ChIP 
was normalised to that at the IL3 promoter. Error bars represent standard deviation 
between triplicate QPCR analyses of a VEZF1 ChIP. 
 
3.4 ChIP-seq Library Preparation 
ChIP-seq analysis was performed using the Illumina Genome Analyzer IIx platform at the 
University of Glasgow Polyomics Facility. The Illumina technology requires the 
preparation of a genomic DNA library where the enriched ChIP DNA fragments are ligated 
to adaptor oligonucleotides, PCR amplified and size selected prior to high throughput 
parallel DNA sequencing (introduction section 1.5.1.2). The standard Illumina method 
involves size selection prior to PCR amplification. It is known that sequencing of input 
ChIP-seq libraries tends to reveal increased read counts at DNaseI HSs (Vega et al., 2009, 
Liu et al., 2010).  This bias is believed to result from regions of euchromatin being more 
efficiently fragmented by sonication than regions of heterochromatin.  Size selection of 
small DNA fragments prior to PCR amplification during library preparation therefore 
preferentially biases towards sequencing of euchromatic genomic regions.  In order to 
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test for bias in my ChIP-seq samples the negative control IgG ChIP-seq track will be 
checked for enrichment above background levels at DNaseI HSs.  Size selection is also 
known to reduce the complexity of the library and increase the probability of the same 
fragments being amplified multiple times. Identical sequences are removed following 
sequencing as they may arise from PCR bias rather than genuine ChIP enrichment. This 
factor of library complexity is more of an issue when the experiment results in relatively 
low numbers of enrichment events, such as when a transcription factor specifically 
interacts with a few thousand elements, as compared with broadly distributed histones 
for example. In order to ensure maximal library complexity during ChIP-seq of 
transcription factors, we employ a rearranged library preparation procedure where PCR 
amplification is carried out prior to size selection on agarose gels (Dr David Vetrie 
personal communication).  The procedure uses 30 µl of ChIP DNA – which equates to 
three fifths of one ChIP reaction – and reagents from the NEBNext DNA Sample Prep 
Reagent Set 1 kit (E6000S) (New England Biolabs) and mostly follows the manufacturer’s 
recommendations (section 2.6).   
One sixth of the volume of each ChIP-seq library (5 µl) was diluted 1 in 10 and used as 
template in QPCR to determine whether enrichment patterns at genomic validation 
regions were comparable before and after library preparation.  Once again primer sets 
detecting the IL3 promoter served as a negative control for enrichment.  The STAG2 
promoter and TAL1 +51 enhancer elements remained enriched following ChIP-seq library 
preparation of the K562:VEZF1 ChIP sample (figure 3.4). However, the relative 
enrichments of the STAG2 promoter and TAL1 +51 enhancer altered following library 
preparation, probably due to size selection affecting the relative abundances of genomic 
fragments containing the QPCR primers.  The TAL1 +51 enhancer and RFX5 promoter 
remained enriched following ChIP-seq library preparation of the K562(D3/6):FLAG-VEZF1 
ChIP sample (figure 3.4).  The POLR3K promoter was slightly enriched compared to the IL3 
negative control in this library, however it appears that all three genomic validation 
regions tested by QPCR are less enriched relative to the IL3 control following library 
preparation than in ChIP samples prior to library preparation (figure 3.3). 
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Figure 3.4 Enrichment of regulatory elements is retained following ChIP-seq library 
preparation.   
QPCR analysis of regulatory element enrichment after library preparation using genomic 
DNA from VEZF1 ChIP in K562 cells and FLAG ChIP in a K562 cell line expressing FLAG-
VEZF1 (D3/6).  The relative enrichment of each element over starting input chromatin 
after VEZF1 ChIP-seq library preparation was normalised to that at the IL3 promoter. 
Error bars represent standard deviation between triplicate QPCR analyses of a VEZF1 
ChIP-seq library.      
Many groups prefer to check the fragment size distribution of their ChIP-seq libraries 
prior to sequencing. This is not a standard procedure at the Glasgow Polyomics Facility, 
who prefer to use a QPCR based library quantification assay as the primary determinant 
of library quality and quantity. Nevertheless, we ran a 1 µl aliquot of the K562:VEZF1 and 
K562:IgG on an Agilent Bioanalyzer using the Agilent High Sensitivity DNA Kit. Despite the 
size selection of ChIP DNA fragments from 200 – 300 bp, the analysis unexpectedly 
showed that the library fragments were quite broad, ranging from ~100 – over 1000 bp 
with a main fragment size of ~ 300 – 400 bp (Figure 3.5). A different ChIP-seq library 
prepared by the Polyomics Facility showed an expected banding around ~300 bp.  The 
differences in library appearance are probably a result of different practices in agarose gel 
extraction procedures during library preparation.  My libraries were gel purified using the 
Qiagen Qiaquick gel extraction kit using the manufacturers’ protocol, where agarose gel 
slices are heated at 50 ᵒC to promote melting. The Polyomics Facility prefers to complete 
agarose melting at room temperature. It appears that the heating of short DNA fragments 
in 5.5 M guanidine thiocyanate (QG buffer in the kit) promotes melting of the DNA 
fragments. A mixture of staggered and structured annealing products may form upon 
cooling. Such annealing products are of no concern for the Illumina sequencing as the 
libraries are denatured prior to cluster formation. However, it is clear that analysis of 
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sequencing libraries on an Agilent Bioanalyzer can be misleading unless precautions to 
avoid strand melting are taken. 
 
Figure 3.5 ChIP-seq library fragment size analysis. 
The size distributions of K562:VEZF1 and K562:IgG ChIP-seq library fragments were 
determined using an Agilent Bioanalyzer.  Gel (A) and electropherogram (B) results are 
shown for a positive control library prepared by the Polyomics Facility (lane 1) and for 
VEZF1 and IgG ChIP-seq libraries (lanes 2 and 3 respectively).  Electropherogram peaks at 
35 bp and 10,380 bp (B) correspond to size markers.  
The concentrations of correctly adapted fragments in ChIP-seq libraries were quantified 
using the SYBR QPCR KAPA library Quantification Kit from Illumina (KK4822) by the 
University of Glasgow Polyomics Facility (table 3.1).  An aliquot of each library was used to 
prepare a 20 µl solution at 1.5 nM for denaturation (table 3.1).  Denatured library 
samples were further diluted to 12 pM concentrations for loading on the flow cell. 
Sample Concentration Volume for 20 µl at 1.5nM 
K562:VEZF1 4.88 nM 6.1 µl 
K562:IgG 2.0 nM 15 µl 
K562(D3/6): 
FLAG-VEZF1 
16.57 nM 1.8 µl 
Table 3.1  ChIP-seq library quantification.  
The concentration of ChIP-seq libraries were quantified by QPCR and used to calculate the 
volume of each library required to prepare a 20 µl sample at 1.5 nM for denaturation. 
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3.5 VEZF1 ChIP-seq data quality 
The University of Glasgow Polyomics Facility performed single end sequencing of 76 bases 
in length for the K562:VEZF1, K562:IgG and K562(D3/6):FLAG-VEZF1 ChIP-seq 
preparations. The Facility provided FASTQ formatted files generated using CASAVA 
software. The performance of these sequencing runs was initially checked using the 
FastQC software (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc).  Firstly, it was 
clear that there was a good yield, with 34-40 million reads from each run (table 3.2). Most 
sequencing facilities report average yields of ~35 million reads per GAIIx run. The average 
quality of the reads was good and there is little or no adaptor sequence contamination. 
Sample Read length Read number Mean Q score Adaptor sequence 
K562:VEZF1 76 34,327,963 38 0.25% of total 
K562:IgG 76 34,978,434 38 No significant level 
K562(D3/6): 
FLAG-VEZF1 
76 40,327,215 38 No significant level 
Table 3.2 Illumina GAIIx sequencing performance.  
Data extracted from FastQC reports from 3 ChIP-seq runs. 
While the overall quality of each sequence run was very good, closer inspection of the 
quality scores at each base is required before deciding on how much of the 76 base 
sequence to include in genome alignment. Low quality scores towards the end of 
sequences may indicate incorrect base calls, leading to an inability to align to a reference 
genome. The FastQC programme produces a box-and-whisker histogram of quality (Q) 
score distribution for each base position in a sequence run.  FastQC analysis showed that 
the median sequence quality was in the very high range (Q scores of 28 – 40) for each 
position of the 76 base read length for each of the three ChIP-seq runs (Figure 3.6). 
However, it is clear that an increasing fraction of the reads have reduced quality after 
approximately 50 bases in read length, with reads in the 10th and 90th percentiles having 
poor quality scores (below 20). Sequences within the 20th – 80th range had poor quality 
scores after 70 bases in read length. This level of performance is considered to be very 
good for the Illumina GAIIx, but the FastQC analysis indicates that a proportion of reads 
might not match a reference genome if the full sequences are used for alignment. The 
general benchmark for high throughput sequencing quality is an average Q score of 30, 
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which represents a 1 in 1,000 probability of an incorrect base call. These sequencing runs 
fall below that threshold after ~60 bases. 
 
 
 
Figure 3.6 Illumina GAIIx sequencing per base quality. 
FastQC report of Q score per base call for VEZF1, IgG and VEZF1-FLAG ChIP-seq runs. 
Horizontal red lines show the median Q score for each base position and the connected 
blue line indicates the average quality score. Yellow boxes represent the 20th-80th quartile 
range, while black whiskers represent the 10th and 90th percentiles.  The background of 
these plots are divided into three sections where green, orange and red shading indicate  
Q score ranges considered to be of very good, reasonable or poor quality, respectively. 
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Sequences were aligned to the hg19 human reference genome using the Bowtie software 
package (Langmead et al., 2009). There are several short read alignment tools available, 
but we chose Bowtie due to its speed of data generation, memory efficiency and flexible 
options (Langmead, 2010).  Bioinformatic analyses of aligned ChIP-seq reads will rely on 
the quantitative differences in read density at enriched sites versus non-enriched 
background. It is therefore important to ensure that no reads create false positive 
enrichments. Thus, it is standard practice in the field to consider only uniquely aligned 
reads by using the bowtie setting “-m” to exclude multiply aligned reads. However, this 
comes at the expense of unique ChIP-seq reads that align to duplicated and repetitive 
genomic regions. Of these, we are interested in duplicated genomic regions and can 
selectively include them. Example duplicated genomic regions include the α and β-globin 
gene clusters. We therefore use the Bowtie setting “-m 3” to report any sequence that 
aligns to 1, 2 or 3 genomic locations. In cases where Bowtie finds two or three genomic 
locations for a particular sequence, it would randomly assign the sequence to one of 
these locations to avoid amplifying the read density at duplicated genomic regions. 
Alignments to repetitive sequences are excluded.   
Bowtie outputs a tab-delimited text file containing sequence alignments (SAM format), 
which is converted to a binary file (bam format) for subsequent bioinformatic 
applications. Bowtie also outputs a log file of the overall alignment performance. The 
alignment statistics from each alignment using the full 76 base sequences is shown in 
Table 3.3. 80% of the FLAG-VEZF1 ChIP-seq reads were aligned by Bowtie, so this 
alignment was taken forward for further analysis. However, only 31% and 44% of the 
VEZF1 and IgG ChIP-seq reads were aligned respectively. This is likely to be due to the 
reduced sequence quality at the 3’end of the VEZF1 and IgG ChIP-seq runs compared to 
the FLAG-VEZF1 run (Figure 3.6). 
The VEZF1 and IgG ChIP-seq reads that failed to align were re-aligned using Bowtie with 
the setting “-3 40”, which trims 3’ ends of the reads to consider only first 40 bases of 
sequence. This ensures that all of the sequence being considered is of very high quality, 
but this comes at the expense of complexity. We found that trimming of sequences 
allowed for much greater fraction of alignment of VEZF1 and IgG ChIP-seq reads (Table 
3.4). A further ~12 million VEZF1 reads were aligned following trimming, more than 
doubling the number of alignments. An addition 5.4 million IgG reads were also aligned 
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following trimming. Bowtie considers each sequence individually, so an additional step is 
made to filter out any identical sequences that may have arisen from PCR amplification. 
This removed 6-7% of the aligned reads from VEZF1 and IgG ChIP-seq runs, which our 
colleagues find typical fraction for good quality library preparations. However, 32% of the 
aligned reads from the FLAG-VEZF1 ChIP-seq run were removed due to clonal 
amplification. This is likely to be due to too low an amount of genomic DNA from the 
FLAG-VEZF1 ChIP entering into the library preparation.  
Sample Total reads Aligned reads 
(Reported) 
Failed to align Reads that align >3 sites 
(discarded) 
K562:VEZF1 34,327,963 10,503,949 
(30.60%) 
22,614,253 
(65.88%) 
1,209,761 
(3.52%) 
K562:IgG 34,978,434 15,299,779 
(43.74%) 
17,903,961 
(51.19%) 
1,774,694 
(5.07%) 
K562(D3/6): 
FLAG-VEZF1 
40,327,215 32,035,696 
(79.44%) 
5,176,858 
(12.84%) 
3,114,661 
(7.72%) 
 
Table 3.3 Alignment of ChIP-seq reads using Bowtie. 
Performance of Bowtie using the full 76 base sequences from each ChIP-seq run using the 
filter of multiply aligned reads –m3. 
Sample Total Aligned 
(76 bases) 
Aligned 
(40 bases) 
Combined Removed 
(PCR filter) 
Unique 
aligned 
K562:VEZF1 
 
34,327,963 
 
10,503,949 
(30.60%) 
11,996,579 
(53.05%) 
22,500,528 
 
1,260,562 
(5.6%) 
21,239,966 
 
K562:IgG 
 
34,978,434 
 
15,299,779 
(43.74%) 
5,410,839 
(30.22%) 
20,710,618 
 
1,530,108 
(7.4%) 
19,180,510 
 
K562(D3/6): 
FLAG-VEZF1 
40,327,215 
 
32,035,696 
(79.44%) 
- 
 
32,035,696 
 
10,363,304 
(32.3%) 
21,672,392 
 
 
Table 3.4 Unique aligned ChIP-seq reads after PCR filtering. 
Performance of Bowtie using the full 76 base sequence or trimmed to 40 bases (VEZF1 
and IgG samples only). Sequence alignments were combined and then screened for 
identical sequences (PCR filter).  
Following Bowtie alignment and PCR filtering, there were 19-22 million unique aligned 
reads from each ChIP-seq preparation. The depth of sequencing necessary to gain a full 
picture of the genomic interactions of a DNA binding protein largely depend upon the 
number of interaction sites, which is often unknown. Thorough analysis of ChIP-seq data 
generated by the ENCODE consortium has found that 20 million mapped reads is a good 
benchmark for ChIP-seq of a typical point-source DNA-binding factor. Enrichment peaks 
typically become saturated with additional sequencing depth, but new weak peaks 
continue to emerge with further sequencing  (Landt et al., 2012). For VEZF1, a preliminary 
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ChIP-chip analysis of VEZF1 binding to 1% of the K562 genome identified 125 sites 
(section 1.9). We would therefore expected ~20,000 VEZF1 genomic binding events in 
K562 cells when accounting for the whole genome size and improved resolution of 
neighbouring binding events. If only 50% of the mapped VEZF1 ChIP-seq reads were due 
to specific enrichment, we would still have ~500 reads per VEZF1 binding event on 
average.  
The .sam format alignment files produced by Bowtie were converted into binary .bam 
format files before conversion into plain text genome coordinate files of the .bed format 
to enable inspection on a genome browser. In order to visualise ChIP-seq data on a 
genome browser, the reads are first extended to 150 bases in length in order to more 
accurately represent the average size of the fragments present in the size selected ChIP 
library (200-300 bp – adaptors). The files were finally converted into .BigWig format files 
to enable rapid uploading and visualisation in the UCSC Genome Browser 
(http://genome.ucsc.edu/). During this conversion, the read counts that align to each 
genomic location were normalised for the total number of reads in the experiment to 
allow fairer comparison between datasets on the browser.  
The ChIP-seq data were visually inspected on the UCSC Genome Browser, a 
representative gene rich portion of chromosome 21 is shown in Figure 3.7. The VEZF1 
ChIP-seq track shows well defined peaks of enrichment.  These peaks are not present in 
the IgG negative control track, showing that these genomic sequence elements were 
specifically enriched by immunoprecipitation of VEZF1 protein. The FLAG-VEZF1 ChIP-seq 
track displays the same peaks of enrichment as the VEZF1 ChIP-seq track. As no additional 
enrichment peaks are seen in the VEZF1 track compared to the FLAG track, it can be 
concluded that the α-VEZF1 antibody used in VEZF1 ChIP-seq interacts with the VEZF1 
protein alone. The relative enrichment of the α-FLAG ChIP over background was weaker 
than that for the α-VEZF1 ChIP. This observation, coupled with the high levels of PCR 
clonality during library preparation for this ChIP (Table 3.4), suggests that further 
optimisation of α-FLAG ChIP would be required to increase IP yields if this approach was 
to be used again in future. 
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Figure 3.7 VEZF1 binding at specific elements revealed by ChIP-seq. 
UCSC genome browser view of ChIP-seq data mapped to human chr21 40,547,000-
40,831,000 (hg19). From top to bottom, tracks for VEZF1(K562), IgG(K562), FLAG-VEZF1 
(K562:D3/6) and DNaseI (K562) are shown. The VEZF1/IgG/FLAG data are normalised to 
library size, where a peak height of 6 equates to 120 overlapping reads. The K562 DNaseI-
seq (signal) track is from ENCODE accession wgEncodeEH000480 (Sabo et al., 2004).  
Below the tracks are UCSC annotated genes, where linked vertical blocks indicate protein-
coding exons and arrows indicate the direction of transcription.  
The VEZF1 peaks typically appear to be associated with the 5’ ends of the annotated 
genes. Consistent with this, VEZF1 ChIP-seq peaks correlate with peaks of DNaseI 
hypersensitivity (Figure 3.7). The promoter elements present at the 5’ ends of 
transcriptionally active genes are typically marked by DNaseI hypersensitive sites, 
suggesting that VEZF1 is bound at transcriptionally active promoters.  It is also evident 
that there are a number of DNaseI hypersensitive peaks which do not align to sites of 
VEZF1 enrichment.  The DNaseI track therefore provides further evidence that the VEZF1 
ChIP-seq has specifically detected VEZF1 genomic binding events and not just all highly 
accessible DNA elements such as those hypersensitive to DNaseI cleavage. 
I have shown that the α-VEZF1 ChIP-seq experiment resulted in high read quality and 
depth. Specific genomic sites with high levels of VEZF1 enrichment are evident, which are 
validated by similar enrichments in the α-FLAG ChIP-seq. I was therefore satisfied that the 
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VEZF1 ChIP-seq had identified genomic elements bound by VEZF1 and proceeded with 
bioinformatic analysis. 
3.6  Determination of VEZF1 binding events by peak finding 
A number of peak finding tools are available to identify regions of sequence enrichment 
from ChIP-seq data and thus identify specific sites of genomic interaction by a DNA-
binding factor. We have settled on using the MACS (Model-based Analysis of ChIP-Seq) 
programme to identify peaks of transcription factor binding as it tends to outperform 
other tools (Zhang et al., 2008). Most peak finding tools rely solely on a control 
experiment, such as the IgG control in this study, to estimate background biases in 
sequencing technology, chromatin structure effects and genome copy number variation. 
However, it is difficult to provide a truly representative control that has been sequenced 
to the same quality and depth, so many peak finding algorithms tend to result in many 
false positives and negatives. MACS takes advantage of the fact that enriched ChIP-seq 
reads show a bimodal pattern with Watson strand tags enriched upstream of binding and 
Crick strand tags enriched downstream. MACS empirically models these patterns to both 
improve peak calling accuracy and define precise peak summits (the binding sites). 
MACS peak finding on the VEZF1 ChIP-seq data was performed using settings that 
specified a bandwidth (chromatin fragment size) of 150 bp and an input sequence tag size 
of 40 bp.  These settings allowed MACS to identify 10,056 VEZF1 peaks. However, 
inspection of the MACS peaks on the genome browser revealed three fundamental 
problems. First, peak resolution was poor as peak coordinates were often much wider 
than the original apparent regions of enrichment (Figure 3.8 A, “MACS 40nt” track). 
Second, independent neighbouring peaks were often called as one peak (Figure 3.8 C and 
D). Third, many strong single peaks were not identified at all (Figure 3.8 B, “+20” and 
“+51” peaks).  These issues were largely overcome by instructing MACS to use an input 
sequence tag size of 25 bp (Figure 3.8 A – D, compare MACS 40 nt peak and MACS 25 nt 
peak tracks). This analysis identified 20,993 peaks. The majority of the VEZF1 enrichment 
peaks observed in the UCSC genome browser were detected and the size of the peaks 
were appropriately defined. 
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Figure 3.8 Performance of MACS peak calling of VEZF1 binding events. 
VEZF1 ChIP-seq enrichment profiles across four genomic loci (A – D) in K562 cells (top 
tracks).  The coordinates of peaks of VEZF1 enrichment identified using MACS using 25 or 
40 nucleotide sequence input sizes are shown beneath. The coordinates of separated 
peaks from 25nt MACS resolved by PeakSplitter (PS) are also shown. The single base peak 
summits from 25nt MACS and PeakSplitter are shown as vertical lines. UCSC annotated 
genes are shown in blue and the direction of transcription is indicated by arrows (bottom 
track). 
VEZF1
2.9
0
MACS 40nt peaks
MACS + PS summits
MACS 25nt peaks
MACS + PS peaks
MACS 25 nt summits
Scale:
C
h
r1
:1
5
1
,3
1
2
,4
8
6
-1
5
1
,3
2
2
,4
6
6
A.
6.6
0
VEZF1
MACS 40nt peaks
MACS 25 nt summits
MACS + PS summits
MACS 25nt peaks
MACS + PS peaks
Scale:
C
h
r1
:4
7
,6
4
4
,7
5
2
-4
7
,6
9
9
,8
7
5
B.
TAL1 +51 TAL1 +20 TAL1 +3 TAL1 
promoter
3.8
0
VEZF1
MACS 40nt peaks
MACS + PS summits
MACS 25nt peaks
MACS 25 nt summits
Scale:
C
h
rX
:1
5
3
,3
5
6
,6
7
9
-1
5
3
,3
6
9
,8
3
3
C.
Scale:
3.4
0
VEZF1
BRWD1Annotated Genes
MACS 40nt peaks
MACS 25nt peaks
MACS 25 nt summits
MACS + PS peaks
MACS + PS summits
C
h
r2
1
:4
0
,6
7
6
,2
9
6
-4
0
,6
9
5
,7
5
4
D.
111 
 
It was apparent however, that MACS was unable to resolve clustered VEZF1 peaks into 
independent peak calls (Figure 3.8 D).  This lack of resolution will interfere with 
subsequent bioinformatic analyses that rely on precise definition of VEZF1 binding site 
locations (the peak summits). PeakSplitter software (Salmon-Divon et al., 2010) was 
therefore employed to resolve individual peaks in a cluster and to identify peak summits.  
PeakSplitter resolved an additional 5,436 VEZF1 binding locations, which mostly appear to 
be at the 5’ends of genes that have multiple promoters (e.g., TAL1 and BRWD1 
promoters, Figure 3.8 B and D). 
Prior to further analyses, the VEZF1 peaks were ranked by sequence tag enrichment and 
obvious false positive peaks were removed. There were a total of 26,429 VEZF1 peaks 
following peak finding and splitting. The Seqmonk tool 
(http://www.bioinformatics.bbsrc.ac.uk/projects/seqmonk) was used to calculate the 
total number of sequence reads in the 50bp around each VEZF1 peak summit, expressed 
as reads per million (rpm) to normalise for total ChIP-seq library size.  This was also 
performed for corresponding genomic regions in the IgG ChIP-seq track.  The IgG rpm 
scores for each peak were subtracted from the corresponding VEZF1 scores, essentially 
normalising VEZF1 specific enrichments to IgG background levels. The VEZF1 peaks were 
ranked by normalised rpm scores. The lowest ranked peaks were inspected on the UCSC 
Genome Browser. It was found that “peaks” with a VEZF1-IgG rpm ratio of 2 or less were 
false positive peak calls. All of the VEZF1 peaks with ratios above 2 appeared to be 
discernible VEZF1 peaks, albeit weak, with no equivalent peak in the IgG track (not 
shown). We therefore decided at this stage to retain these weak VEZF1 sites for further 
analysis. 88 peaks were removed as false positives, leaving a total of 26,341 identified 
VEZF1 peaks in the K562 genome. 
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3.7  Discussion 
The aim of this chapter was to use ChIP-seq technology to profile VEZF1-DNA interactions 
in the K562 cell line on a genome-wide scale.  A previously optimised VEZF1 ChIP protocol 
was followed and QPCR validation showed VEZF1 ChIP to be reproducible as enrichment 
patterns correlated highly between this and previous VEZF1 ChIP experiments in K562. 
ChIP-seq libraries were generated using genomic ChIP DNA in order to prepare ChIP-
enriched DNA for next generation sequencing on the Illumina GAIIX platform.  During 
library preparation adaptor oligonucleotides were ligated to either end of ChIP-DNA 
fragments to allow hybridisation to complimentary primers on the surface of the 
sequencing flow cell.  Adaptor-ligated DNA fragments were enriched by PCR amplification 
and fragments of 200 – 300 bp were size selected following agarose gel electrophoresis.  
PCR amplification was performed prior to size selection in order to maintain maximal 
library complexity and reduce the likelihood of clonal PCR amplification leading to 
discarded sequence reads.  Size selection was performed for fragments of 200 – 300 bp as 
sequences of this length are recommended for optimal cluster formation, larger fragment 
sizes may result in sequence clusters overlapping which will prevent bases from being 
accurately called during sequencing resulting in the loss of ChIP-seq reads.   
Following their preparation ChIP-seq libraries were validated by QPCR to ensure that 
ChIP-enriched genomic regions remained so after library preparation.  While informative, 
this analysis can be misleading as it relies on the binding sites of primer pairs being 
present on the same DNA fragment.  Prior to library preparation a wide variety of DNA 
fragment sizes are present in ChIP DNA however following size selection during library 
preparation the relative abundances of DNA fragments that contain both binding sites for 
a pair of QPCR primers is likely to be altered and may affect the enrichment value 
generated by QPCR. 
We tried to validate the size distribution of ChIP-seq libraries as being 200 – 300 bp in 
length using the Agilent Bioanalyzer and were surprised to find that the fragment sizes of 
these libraries ranged from ~100 – over 1000 bp.  We believe this unexpected fragment 
size distribution to be an artefact which occurred during the extraction of size-selected 
library DNA from agarose gel fragments.  It is believed that, during the heating of agarose 
gel slices at 50 ᵒC in Qiagen’s QG buffer, DNA fragments within the gel slice may have 
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undergone some denaturation and that staggered or structured DNA products may have 
then formed upon cooling.  It therefore appears that, if ChIP-seq library size is to be 
validated using an Agilent Bioanalyzer, the gel slice should be dissolved at room 
temperature. 
During the alignment of VEZF1 and IgG ChIP-seq reads to the human reference genome, 
66 % and 51 % of full length reads respectively failed to align.  It was considered that 
these failed alignments likely resulted from mis-called bases at the 3’ end of sequence 
reads.  The reads which failed to align were therefore trimmed to 40 bp by removing the 
3’ 36 bases, following which 53 % and 30 % of trimmed VEZF1 and IgG sequence reads 
respectively were successfully aligned to the reference genome.  It should be noted 
however that cropping sequence reads increases the likelihood of these reads aligning to 
multiple sites within the reference genome which, as described previously, can lead to 
their being discarded or randomly assigned to one of the possible alignment sites (section 
3.5).  It is therefore apparent that a balance between sequence length and base call 
accuracy must be met in order to achieve the most possible sequence read alignments. 
Peak finding using the MACS programme identified 20,993 VEZF1 enrichment peaks 
across the reference genome.  It was evident however, that MACS was unable to resolve 
groups of clustered peaks into independent peak calls.  PeakSplitter software was 
therefore employed to resolve independent clustered peaks identifying a further 5,436 
VEZF1 peaks.  Based on these findings, the combined use of MACS and PeakSplitter is 
recommended for maximal resolution of ChIP-seq peaks. 
On first inspection, VEZF1 enrichment peaks appear to align with DNase I hypersensitive 
sites, as would be expected for a sequence-specific transcription factor.  As a number of 
DHSs do not correlate with VEZF1 peaks, we are confident that VEZF1 ChIP has specifically 
enriched VEZF1-associated elements and not highly accessible DNA elements in general.  
As VEZF1 peaks appear to be mostly situated at the 5’ ends of genes, future analyses 
should investigate the relationship of VEZF1 peak sites to TSSs, promoter-associated 
epigenetic modifications and nucleosome depleted regions.  VEZF1 enrichment peaks at 
several known enhancer elements were observed by manual inspection of the VEZF1 
ChIP-seq track (data not shown), future analyses should therefore also address whether 
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there is a general association between VEZF1 binding and enhancer elements or whether 
these events are rare.  
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Chapter 4 
VEZF1 interacts with core promoters and cell-type specific 
enhancers 
4.1 Introduction 
 
In this chapter, I wish to gain a clearer understanding of the general gene regulatory 
processes that VEZF1 is involved in. To achieve this, I carefully studied the VEZF1 ChIP-seq 
profile in K562 cells to determine whether VEZF1 generally functions as a transcription 
factor or a more specialised chromosome structure factor like other insulator-binding 
proteins. The principal objectives of this chapter are to: 
1. Determine the genomic distribution of VEZF1 binding with respect to genes and 
gene regulatory elements. 
2. Determine the chromatin state(s) at elements bound by VEZF1. 
3. Identify transcription factors that co-bind to gene regulatory elements with VEZF1. 
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4.2 The genomic distribution of VEZF1 binding with respect to 
genes and gene regulatory elements 
4.2.1 VEZF1 binding at genes 
VEZF1’s role in mediating barrier activity at the chicken HS4 insulator element has lead us 
to hypothesise that VEZF1 ChIP-seq may reveal binding at many novel insulator elements, 
which would be typically located in intergenic regions.  However, our initial inspection of 
the VEZF1 ChIP-seq profile in the UCSC Genome Browser indicated that VEZF1 was 
frequently associated with the 5’ end of genes (section 3.5). The locations of the 26,341 
VEZF1 peak summits identified in chapter 3, which I refer to as VEZF1 sites, were 
therefore compared to the RefSeq gene annotation using the web based ChIP-seq data 
analysis site Nebula (http://nebula.curie.fr/) (Boeva et al., 2012). This analysis reveals that 
only ~16 % of VEZF1 sites locate to intergenic regions (Figure 4.1).  Strikingly, it was 
observed that 55.6% of VEZF1 sites were located within 500 bp of transcription start sites 
(TSS), 33% upstream and 23.6% downstream, while a further 13% of VEZF1 sites locate to 
the first annotated intron.  Thus, more than two thirds of VEZF1 sites are gene promoter 
proximal and locate to potential gene regulatory elements. 
Figure 4.1 VEZF1 binding at genes. 
The fraction of VEZF1 sites (ChIP-seq peak summits) mapping to annotated genes as 
reported by the Nebula tool. VEZF1 sites located within 500 bp upstream or downstream 
of transcription start sites (TSS) are indicated as TSS UP and DOWN, respectively. VEZF1 
sites located within 500 bp downstream of transcription end sites (TES) are indicated as 
TES DOWN. The intergenic category includes VEZF1 sites that do not reside within genes 
or within 500 bp of their start or end. 
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4.2.2 VEZF1 binding at promoters 
The high degree of VEZF1 association with promoters, led me to ask whether VEZF1 
binding events are distributed across promoters akin to cis-regulatory factors or whether 
VEZF1 resembles a general transcription factor that is closely associated with TSS. The 
Nebula gene annotation of all VEZF1 peak locations was used to plot VEZF1 peaks with 
respect to the nearest annotated TSS.  This analysis shows the highest density of VEZF1 
peaks localise to the area around TSSs (Figure 4.2).  This observation strongly suggests 
that VEZF1 is a general transcription factor with a likely role in gene promoter regulation. 
 
 
Figure 4.2 VEZF1 ChIP-seq peaks are enriched in the region of TSSs.   
Distribution of VEZF1 ChIP-seq peaks with respect to nearest annotated RefSeq gene TSS. 
A) VEZF1 peak numbers in 1 kb windows up to 50 kb either side of a TSS. B) VEZF1 peak 
numbers in 20bp windows up to 1 kb either side of a TSS. 
 
In order to take a closer look at VEZF1 enrichment at gene TSS and to compare different 
ChIP-seq datasets, further analyses were performed using the seqMINER tool (Ye et al., 
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2011).  SeqMINER allows ChIP-seq read density to be plotted relative to a set of chosen 
‘peaks’.  Firstly, the density of all VEZF1, FLAG-VEZF1 and IgG ChIP-seq reads were plotted 
relative to the 26,341 VEZF1 peak summits identified in chapter 3 (Figure 4.3).  As 
expected, VEZF1 ChIP-seq reads accumulated in a sharp symmetrical bell-shaped 
distribution over the defined VEZF1 peak summits (Figure 4.3).  The FLAG-VEZF1 reads 
showed the same enrichment at the VEZF1 ChIP-seq peak summits, albeit with a lower 
signal to noise ratio due to lower ChIP yield, as discussed previously. The IgG negative 
control reads showed the background level of reads generated from non-specific ChIP 
enrichment (Figure 4.3). This analysis further demonstrates that peak finding accurately 
identified VEZF1 binding sites, that the α-VEZF1 and α-FLAG-VEZF1 ChIPs identify the 
same sites and that there are few/no false positive peaks contaminating the identified 
collection of peaks. 
 
Figure 4.3 VEZF1 and FLAG-VEZF1 ChIP-seq read densities are maximal at the sites of 
VEZF1 ChIP-seq peaks.   
SeqMINER analysis of VEZF1 (red), FLAG-VEZF1 (green) and IgG (blue) ChIP-seq read 
densities in regions 5 kb either side of all the 26,341 VEZF1 peak summits identified in 
chapter 3. Mean read densities (reads/500 bp windows) were normalised to total aligned 
read count for each ChIP-seq library. 
The distribution of VEZF1, FLAG-VEZF1 and IgG ChIP-seq reads was then compared to the 
location of all RefSeq annotated gene TSSs.  VEZF1 ChIP-seq reads accumulate directly 
over TSSs (Figure 4.4) correlating with the similar analysis performed using Nebula (Figure 
4.2).  FLAG ChIP-seq read distribution was very similar but with a lower signal to noise 
ratio.  As before the IgG plot serves as a negative control showing the distribution of non-
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specifically enriched reads (Figure 4.4).  It is apparent from this data that VEZF1 is highly 
associated with gene transcription start sites. 
 
Figure 4.4 VEZF1 and FLAG ChIP-seq read densities are maximal at TSSs.   
seqMINER analysis mapped ChIP-seq read densities relative to distance from TSSs.  VEZF1 
ChIP-seq reads from K562 cells and FLAG ChIP-seq reads from D3/6 K562 cells were 
maximal at TSSs.  Sequence reads from the negative control IgG ChIP in K562 cells were 
not substantially enriched at VEZF1 peaks.  Mean read densities (reads/50 bp windows) 
were normalised to total aligned read count for each ChIP-seq library. 
4.3 The chromatin states at elements bound by VEZF1 
4.3.1 The ENCODE ChromHMM chromatin state map 
While the comparison of VEZF1 peaks to gene annotation can give a quick overview of 
VEZF1 gene association, it lacks key information about gene regulation. The gene 
annotation does not take account of alternative promoter usage in different cell types, 
nor does it include information relating to enhancer, silencer or insulator element 
locations. Indeed, the majority of distal gene regulatory elements remain to be identified 
and annotated (Dunham et al., 2012). We were therefore interested in comparing the 
locations of VEZF1 peak summits with the ChromHMM chromatin state map for K562 
cells defined by the ENCODE project (Ernst and Kellis, 2010, Ernst et al., 2011). This map 
defines predicted promoter, transcribed, enhancer, insulator and heterochromatin states 
from high quality ChIP-seq datasets for H3K27ac, H3K27me3, H3K36me3, H3K4me1, 
H3K4me2, H3K4me3, H3K9ac, H3K20me1 and CTCF (section 1.5.3). Prior to comparison 
with all the VEZF1 peaks, we compared the K562 ChromHMM track on the UCSC browser 
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to the TAL1 gene locus, which has multiple well characterised promoters and enhancers. 
(Figure 4.5). The ChromHMM model accurately calls the alternative TAL1 promoters p1a 
and p1b, the strong erythroid-specific enhancer +51. The haematopoietic stem cell 
enhancers +18.5 and +20 are correctly called, despite being weak in K562 cells. The +3 
element is called as a strong promoter. It appears that the ChromHMM model will be 
useful in predicting gene regulatory functions that associate with VEZF1 sites at genomic 
locations that otherwise lack functional characterisation. 
 
Figure 4.5 The ChromHMM chromatin state map accurately calls known regulatory 
regions of the TAL1 locus in K562 cells. 
UCSC genome browser view of VEZF1 ChIP-seq data mapped to human chr1 47,645,000-
47,700,000 (hg19). VEZF1 ChIP-seq peaks and peak summits are represented by black 
boxes and vertical black lines respectively.  The K562 ChromHMM chromatin state track is 
from ENCODE accession wgEncodeEH000790 (Ernst and Kellis, 2010, Ernst et al., 2011). 
Below the tracks is the UCSC gene annotation, where linked vertical blocks indicate 
protein-coding exons and arrows indicate the direction of transcription. 
4.3.2 The chromatin state distribution of VEZF1 sites 
The 26,341 VEZF1 peak summits defined in chapter 3 were overlapped with the ENCODE 
HMM chromatin state map for K562 cells using the genomic intersection tool in Galaxy 
(http://galaxyproject.org/) (Taylor et al., 2007).  Single base peak summits were used to 
prevent the counting of more than one chromatin state per VEZF1 peak and should most 
accurately reflect the chromatin events at VEZF1 binding sites. This analysis revealed a 
striking association between VEZF1 binding and genomic elements that carry the 
chromatin hallmarks of promoters that are strong (11,284 sites), weak (3,042) or poised 
(293 sites) (Figure 4.6 A). Collected together, 55.4% of all the identified VEZF1 sites locate 
to promoter-associated elements (Figure 4.6 B). This is consistent with 55.6% of VEZF1 
sites being located within 500 bp of transcription start sites (section 4.2.1).  
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Figure 4.6  VEZF1 ChIP-seq peaks are highly associated with gene regulatory elements. 
A) The overlap between 26,341 VEZF1 peaks and 15 ChromHMM chromatin states for 
K562 cells (ENCODE UCSC accession wgEncodeEH000790). B) Summary of the chromatin 
states at VEZF1 sites, where all ChromHMM-defined classes of promoter were grouped 
together as were enhancers, transcribed genes and repetitive elements. 
Furthermore, there is also a striking association between VEZF1 and genomic elements 
that carry the chromatin hallmarks of enhancers that are strong (3,963 + 810 sites) or 
weak (3,102 + 775 sites). Collected together, 32.8% of all the identified VEZF1 sites locate 
to 8,650 enhancer-associated elements (Figure 4.6 B). There were only minor associations 
with other chromatin state types. Only 85 sites locate to regions of transcriptional 
elongation, suggesting that VEZF1 does not play a major role in transcriptional pausing 
(section 1.8). There is a weak association with other genomic elements including 
insulator-like elements, to which only 249 out of the total 26,341 VEZF1 peaks mapped. 
We have noticed from genome browsing that many CTCF sites overlap other chromatin 
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states, especially enhancer states (not shown). The very low degree of overlap between 
VEZF1 peaks and the “insulator” chromatin state therefore under-reports the true levels 
of association between VEZF1 and CTCF.  
4.3.3 Chromatin features at promoter-associated VEZF1 elements 
The levels of various chromatin features at 14,619 VEZF1 peaks that overlap promoter-
associated chromatin states (section 4.3.2) were analysed using seqMINER.  The aim of 
this analysis was to both validate the promoter-associated chromatin state and to look at 
the relationship between VEZF1 ChIP-seq peaks and adjacent chromatin. In order to 
achieve this, ChIP-seq and DNase-seq read alignment files were downloaded from the 
UCSC genome browser. These data sets were loaded into seqMINER and the read density 
from 5 kb upstream to 5 kb downstream of the 14,619 VEZF1 peaks was determined. The 
average read profiles were standardised to allow comparison between different ChIP-seq 
experiments.  
This analysis showed that there are high levels of the histone H3 modifications H3K4me3 
and H3K27ac and the variant histone H2A.Z at promoter-associated VEZF1 elements 
(Figure 4.7). Conversely, H3K27me3 and H3K9me3, both associated with repressive 
chromatin, are not enriched. The H3K4me1 histone modification is present at low levels 
at promoter-associated VEZF1 peaks. These findings are entirely consistent with the 
chromatin signatures observed at transcriptionally active gene promoters (section 1.3.7). 
Interestingly, the levels of H2A.Z, H3K4me3 and H3K27ac are all depleted at the centre of 
the VEZF1 peaks (Figure 4.7) suggesting that VEZF1 binding sites are situated within 
nucleosome depleted regions (NDRs). These observations closely correlate with VEZF1 
binding in close proximity to transcription start sites (section 4.2.2), which are 
characteristic NDRs (Lee et al., 2004, Iyer, 2012, Struhl and Segal, 2013). 
 
123 
 
 
Figure 4.7 Chromatin signatures of promoter-associated VEZF1 peaks. 
VEZF1 sites locate within nucleosome depleted regions of active promoters in K562 cells. 
Mean read density profiles of H3K4me1 (wgEncodeEH000046), H3K4me3 
(wgEncodeEH000048), H2A.Z (wgEncodeEH001038), H3K27ac (wgEncodeEH000043), 
H3K27me3 (wgEncodeEH000044) and H3K9me3 (wgEncodeEH001040) ChIP-seq  from 5 
kb upstream to 5 kb downstream of the 14,619 VEZF1 peak summits that overlap 
ChromHMM promoter states. Standardised read counts represent Z-scored read densities 
in 50 bp windows. 
 
Next, we studied the relationship between VEZF1 binding and the average transcription 
state at gene TSS. We made use of Affymetrix cDNA microarray data for K562 cells from 
our colleague Dr. David Vetrie, which identified a total of 11,714 genes as being 
expressed . We use the RefSeq coordinates for these genes in SeqMINER, such that the 
analysis focussed on their annotated TSS with the bodies of all the genes oriented to the 
right hand side of the TSS. Consistent with previous reports (section 1.3.7), this analysis 
found that the TSS of active genes are flanked by nucleosomes enriched in H2A.Z, 
H3K4me3 and H3K27ac (Figure 4.8 B). The consistent depletion in histone protein 
enrichment directly over the TSS denotes the nucleosome depleted region (NDR) which is 
found at the TSSs of active genes (Segal et al., 2006, Lee et al., 2007b). RNA polymerase II 
was observed to bind at the TSS of these genes, providing further indication of active 
gene transcription at these gene promoters (Figure 4.8 A). Furthermore, RNA-seq levels 
were elevated into the gene bodies, with high enrichments immediately downstream of 
the TSS.  The H3K36me3 histone modification, which marks regions of active gene 
transcription, was also enriched within the bodies of expressed genes (figure 4.8 B).  
These observations are entirely consistent with the transcriptional activity of the 11,714 
selected genes.  VEZF1 ChIP-seq reads were seen to form a peak directly over these active 
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TSSs (Figure 4.8 A). It is apparent that VEZF1 binds at the nucleosome depleted TSSs of 
actively expressed genes in K562 cells. 
 
 
 
Figure 4.8  Chromatin signature over the TSS of actively expressed genes. 
VEZF1 binds at the nucleosome depleted TSSs of actively expressed genes in K562 cells. 
Mean read density profiles from 5 kb upstream to 5 kb downstream of the TSS of 11,714 
transcriptionally active genes in K562 cells. (A) VEZF1 and RNA Polymerase II 
(unphosphorylated CTD) ChIP-seq (wgEncodeEH000727), DNase-seq 
(wgEncodeEH000484) and RNA-seq (wgEncodeEH000484). (B) H3K4me1 
(wgEncodeEH000046), H3K4me3 (wgEncodeEH000048), H2A.Z (wgEncodeEH001038), 
H3K27ac (wgEncodeEH000043), H3K27me3 (wgEncodeEH000044), H3K9me3 
(wgEncodeEH001040) and  H3K36me3 (wgEncodeEH000045)ChIP-seq are shown. 
Standardised read counts represent Z-scored read densities in 50 bp windows. 
4.3.4 Relationship between VEZF1 binding to promoters and gene 
 expression 
In order to determine whether VEZF1 binding at gene promoters is associated with their 
transcriptional levels, VEZF1 ChIP-seq read density at TSS was compared to gene 
expression levels. Rather than plot average enrichment levels of ChIP-seq reads, as shown 
above, SeqMINER was used to generate heatmaps where each TSS is presented 
individually. 11,714 TSS were ordered by associated gene expression level, with the most 
highly expressed genes at the top of the heatmap plots and lowest expressers at the 
bottom. K562 RNA-seq data from the ENCODE project was plotted to validate the 
ordering by gene expression levels determined by Affymetrix microarrays. It can be seen 
from the resulting heatmap that RNA-seq reads are enriched in the proximity of the TSS 
for most of the elements analysed, with especially high levels for the top one third of 
expressed genes (Figure 4.9). RNA-seq reads also align to the gene bodies of the most 
expressed genes, with more RNA-seq reads at the most highly expressed genes. 
Furthermore, the levels of RNA polymerase II, open chromatin (FAIRE) and the promoter-
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associated histone marks H3K4me3, H3K27ac and H2A.Z are all highest at the most 
expressed genes, with gradual decreases down to the lowest expressed genes (Figure 
4.9). The levels of VEZF1 enrichment correlate directly with gene expression as the most 
highly expressed genes are those that are most highly enriched by VEZF1 (Figure 4.9).  
These data also show VEZF1 enrichment to directly correlate with RNA pol II enrichment 
and with levels of active chromatin marks.  VEZF1 enrichment levels were most directly 
comparable to the degree of open chromatin determined by the FAIRE-seq assay. 
Together, these data demonstrate that VEZF1 binding at gene TSSs is closely associated 
with the chromatin opening and transcription activity of gene promoters. 
 
Figure 4.9 VEZF1 binding at TSS is associated with chromatin opening and transcription. 
Read density profiles of RNA-seq (wgEncodeEH000484), ChIP-seq of VEZF1, RNA 
Polymerase II (unphosphorylated CTD) (wgEncodeEH000727), H3K27ac 
(wgEncodeEH000043), H3K4me3 (wgEncodeEH000048) and H2A.Z (wgEncodeEH001038) 
with DNase-seq (wgEncodeEH000484) and FAIRE-seq (wgEncodeEH000531) from 5 kb 
upstream to 5 kb downstream of the TSS of 11,714 transcriptionally active genes in K562 
cells. Read densities are shown as a heat map where red is highest and white is lowest. 
Reade densities for the 11,714 TSS are arranged as a stack and ordered by the expression 
level of the associated gene (RMA value from Affymetrix cDNA microarray analysis). 
4.3.5 Chromatin features at enhancer-associated VEZF1 elements 
The comparison of VEZF1 ChIP-seq peaks with the ENCODE ChromHMM chromatin state 
maps for K562 cells found that VEZF1 bound at 8,650 elements that carry the chromatin 
hallmarks of enhancer elements (section 4.3.2). I wished to study the chromatin features 
at VEZF1 sites associated with gene distal enhancers. We found that 2,205 of the 
ChromHMM enhancer-like elements were located within 1kb of an annotated TSS. We 
therefore analysed the levels of various chromatin features at the 6,355 enhancer-
associated VEZF1 sites >1kb from a TSS using seqMINER.  
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The average read profile for H3K4me1 ChIP-seq showed this modification to be enriched 
in the nucleosomes at the enhancer-associated VEZF1 peaks (Figure 4.10). This is in 
contrast to the lack of H3K4me1 enrichment at promoter-associated VEZF1 sites and TSS 
(Figures 4.7 and 4.8). In addition, the H3K27ac modification was also found to be highly 
enriched at the enhancer sites (Figure 4.10). This chromatin profile of high 
[H3K27ac/H3K4me1] is consistent with previous studies of enhancer-associated histone 
modifications (section 1.3.7). H3K27ac enrichment at enhancer elements has been shown 
to differentiate active from poised enhancers (Creyghton et al., 2010).  The high level of 
H3K27ac present at VEZF1-enriched enhancers therefore indicates the active state of 
these enhancer elements. H3K4me3 and the histone variant H2A.Z was also enriched at 
the VEZF1 enhancer sites, but there was no apparent enrichment of the repressive 
histone modifications H3K9me3 and H3K27me3 (Figure 4.10).   
It is interesting to note that the levels of H3K4me1, H4K4me3, H3K27ac and H2A.Z are 
enriched in the nucleosomes either side of the VEZF1 peak, but are depleted over the site 
of VEZF1 binding (Figure 4.10). This profile strongly indicates that enhancers bound by 
VEZF1 also contain nucleosome depleted regions much like promoter elements. 
 
Figure 4.10 Chromatin signatures of enhancer-associated VEZF1 peaks. 
VEZF1 sites locate within nucleosome depleted regions of active enhancers in K562 cells. 
Mean read density profiles of H3K4me1 (wgEncodeEH000046), H3K4me3 
(wgEncodeEH000048), H2A.Z (wgEncodeEH001038), H3K27ac (wgEncodeEH000043), 
H3K9me3 (wgEncodeEH001040) and H3K27me3 (wgEncodeEH000044) and ChIP-seq  
from 5 kb upstream to 5 kb downstream of the 6,355 VEZF1 peak summits that overlap 
ChromHMM enhancer states located >1kb from an annotated TSS. Standardised read 
counts represent Z-scored read densities in 50 bp windows. 
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4.4 Co-binding transcription factors at VEZF1 sites 
4.4.1. Co-binding of VEZF1 with general transcription factors at promoters 
Gene regulatory elements tend to include clusters of transcription factor binding sites 
that act in concert to regulate chromatin remodelling, transcription complex loading and 
activity. I wished to gain some insight into which transcription factors share potential 
physical and functional relationships with VEZF1. The locations of all 26,321 VEZF1 ChIP-
seq peaks or the 14,619 promoter-associated peaks were therefore compared to 
transcription factor binding site (TFBS) peaks collated from the ENCODE project. It was 
most practical to start by comparing VEZF1 peaks to the full ENCODE version 2 release of 
transcription factor ChIP-seq peaks. It should be cautioned that while this list contains 
~2.7 million identified TFBS, it is not specific to K562 cells. A window of 200 bp around 
each VEZF1 peak summit was generated and analysed for overlap with any ENCODE TFBS 
using the genomic intersection tool in Galaxy (http://galaxyproject.org/) (Taylor et al., 
2007). The incidences of overlapping peaks were added and expressed as a percentage of 
VEZF1 binding events (Table 4.1).  
This analysis found that VEZF1 binding frequently overlapped the binding of many well 
characterised general transcription factors. RNA polymerase II is the factor that most 
frequently interacts with VEZF1 elements, with an overlap with 93% of promoter-
associated and 73% of all VEZF1 binding events (Table 4.1). TFIID components TAF1 and 
TBP and the transcription elongation factor pTEFb complex component cyclin T2 (CCNT2) 
all frequently interact with elements bound by VEZF1. These frequencies of overlap with 
general transcription factors are consistent with VEZF1 binding at sites of transcription 
initiation, such as gene TSS. The remainder of the factors that most frequently interact at 
VEZF1 sites are typically transcription factors with broad functions like, CMYC, EGR1, 
FOS/JUN, SP1, USF and YY1. GATA1, GATA2 and TAL1 are tissue-specific transcription 
factors that regulate erythroid-specific genes and are expressed in K562 cells. These 
factors were found to associate with between 3,800 and 4,500 VEZF1 elements (Table 
4.1). Interestingly, these elements do not appear to be associated with promoter 
elements. 
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All 26428 sites 
 
All 14619 promoters 
Rank Factor Overlaps Fraction 
 
Rank Factor Overlaps Fraction 
1 POL2 19164 72.5% 
 
1 POL2 13521 92.5% 
2 TAF1 16309 61.7% 
 
2 TAF1 13027 89.1% 
3 HEY1 15049 56.9% 
 
3 HEY1 12375 84.7% 
4 EGR-1 14107 53.4% 
 
4 E2F6 10399 71.1% 
5 E2F6 13543 51.2% 
 
5 EGR-1 10093 69.0% 
6 ELF1 12873 48.7% 
 
6 ELF1 9563 65.4% 
7 ZBTB7A 12507 47.3% 
 
7 SIN3A 9408 64.4% 
8 TBP 11892 45.0% 
 
8 TBP 9339 63.9% 
9 SIN3A 11140 42.2% 
 
9 ZBTB7A 9170 62.7% 
10 C-MYC 10659 40.3% 
 
10 C-MYC 8313 56.9% 
11 CCNT2 10095 38.2% 
 
11 E2F1 8189 56.0% 
12 E2F1 9673 36.6% 
 
12 CCNT2 7468 51.1% 
13 YY1 8899 33.7% 
 
13 YY1 7102 48.6% 
14 CTCF 8593 32.5% 
 
14 GABP 6174 42.2% 
15 GABP 8368 31.7% 
 
15 CTCF 6097 41.7% 
16 SP1 7926 30.0% 
 
16 HMGN3 5939 40.6% 
17 HMGN3 7695 29.1% 
 
17 NFKB 5795 39.6% 
18 IRF1 7455 28.2% 
 
18 IRF1 5772 39.5% 
19 MAX 7240 27.4% 
 
19 SP1 5761 39.4% 
20 NFKB 7182 27.2% 
 
20 MAX 5405 37.0% 
21 USF-1 6850 25.9% 
 
21 POL2(Ser2p) 5389 36.9% 
22 PAX5 6569 24.9% 
 
22 PAX5 5374 36.8% 
23 ETS1 6445 24.4% 
 
23 ETS1 5259 36.0% 
24 NRSF 6182 23.4% 
 
24 USF-1 4619 31.6% 
25 POL2(Ser2p) 6118 23.1% 
 
25 MXI1 4156 28.4% 
26 ZNF263 5512 20.9% 
 
26 ZNF263 4088 28.0% 
27 PU.1 5308 20.1% 
 
27 NRSF 3987 27.3% 
28 MXI1 5262 19.9% 
 
28 CHD2 3844 26.3% 
29 USF1 5145 19.5% 
 
29 TAF7 3559 24.3% 
30 CEBPB 5073 19.2% 
 
30 POU2F2 3541 24.2% 
31 CHD2 4690 17.7% 
 
31 NRF1 3489 23.9% 
32 P300 4676 17.7% 
 
32 AP-2γ 3467 23.7% 
33 HDAC2 4655 17.6% 
 
33 E2F4 3465 23.7% 
34 AP-2γ 4507 17.1% 
 
34 ZNF143 3309 22.6% 
35 GATA1 4481 17.0% 
 
35 PU.1 3225 22.1% 
36 RAD21 4470 16.9% 
 
36 CEBPB 3118 21.3% 
37 POU2F2 4382 16.6% 
 
37 TCF12 3014 20.6% 
38 JUND 4377 16.6% 
 
38 JUND 2952 20.2% 
39 TCF12 4192 15.9% 
 
39 E2F1 2895 19.8% 
40 EBF1 4154 15.7% 
 
40 RAD21 2876 19.7% 
41 TAF7 4076 15.4% 
 
41 CTCFL 2873 19.7% 
42 ZNF143 4056 15.3% 
 
42 TCF4 2873 19.7% 
43 NRF1 4034 15.3% 
 
43 EBF1 2872 19.6% 
44 E2F4 4006 15.2% 
 
44 P300 2843 19.4% 
45 TCF4 3901 14.8% 
 
45 RFX5 2648 18.1% 
46 C-FOS 3857 14.6% 
 
46 HDAC2 2616 17.9% 
47 TAL1 3769 14.3% 
 
47 GTF2F1 2598 17.8% 
48 GATA2 3747 14.2% 
 
48 SRF 2535 17.3% 
49 CTCFL 3639 13.8% 
 
49 ZEB1 2512 17.2% 
50 SMC3 3579 13.5% 
 
50 C-FOS 2447 16.7% 
 
Table 4.1  Overlap between VEZF1 and other transcription factor binding events. 
Incidences of ChIP-seq peaks for VEZF1 (peak summits expanded to 200bp) that overlap 
with other factors, as defined by the ENCODE project (EncodeRegTfbsClusteredV2). The 
top 50 factors that most frequently overlap all 26,341 (left) or the 14,619 promoter-
associated VEZF1 binding events (right) are shown. Known erythroid-specific transcription 
factors are highlighted in red. 
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An initial goal of this study was to identify novel insulator elements. The initial analysis of 
the overlap between VEZF1 peaks in K562 cells with CTCF peaks identified in all studies 
found 8,593 overlapping events (Table 4.1). In order to look more accurately at the 
potential co-binding of VEZF1 and CTCF in K562 cells, 26,341 VEZF1 peaks were compared 
with 31,849 CTCF peaks from K562 cells (wgEncodeEH002797, FDR>2). It was found that 
2,759 VEZF1/CTCF sites overlapped when 200 bp around each peak summit was used. 
Most of these are promoter-associated, but 578 are gene distal. Some of these may be 
insulators akin to the chicken HS4 element. 
In order to determine the relationship between VEZF1 and general transcription factor 
binding at TSS, the ChIP-seq read densities of these factors in K562 cells were profiled 
using seqMINER. The TSSs of 11,714 genes that are transcriptionally active in K562 cells 
were arranged by associated gene expression level as before. We selected SP1, YY1, 
CMYC, ELF1, EGR1, HMGN3, TBP and TAF1 for this analysis along with the 
unphosphorylated transcription initiation form of RNA polymerase II. These factors were 
chosen as they are well characterised and each bind to different classes of DNA sequence 
element at core promoters. It is evident from this analysis that VEZF1 enrichment of 
active gene promoters directly correlates with the levels of other general transcription 
factors (Figure 4.11). All of these factors are found to be most greatly enriched around 
the TSS of highly expressed genes with enrichment levels falling in conjunction with 
decreasing gene expression levels (Figure 4.11).  
In order to gain an understanding of the average spatial position of each factor relative to 
TSS, the mean read density profiles of each factor in K562 cells were calculated. This 
analysis showed that while the average ChIP-seq profile of VEZF1 overlaps that of general 
transcription factors at TSS, the position of maximal enrichment differs for each factor 
(Figure 4.12).  The maximal point of enrichment of each factor relative to the TSS was 
calculated and these values are presented in table 4.2. 
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Figure 4.11 VEZF1 binds alongside other general transcription factors at 
transcriptionally active gene promoters. 
Read density profiles of VEZF1, RNA Polymerase II (unphosphorylated CTD) 
(wgEncodeEH000727), SP1 (wgEncodeEH001578), YY1 (wgEncodeEH001623), ELF1 
(wgEncodeEH001619), EGR1 (wgEncodeEH001646), HMGN3 (wgEncodeEH001863), TAF1 
(wgEncodeEH001582), TBP (wgEncodeEH001825) and CMYC (wgEncodeEH002800) ChIP-
seq from 5 kb upstream to 5 kb downstream of the TSS of 11,714 transcriptionally active 
genes in K562 cells. Read densities are shown as a heat map where red is highest and 
white is lowest. Read densities for the 11,714 TSS are arranged as a stack and ordered by 
the expression level of the associated gene (RMA value from Affymetrix cDNA microarray 
analysis). 
 
Figure 4.12 Transcription factor binding profiles at TSS. 
Mean read density profiles of VEZF1, RNA Polymerase II (unphosphorylated CTD) 
(wgEncodeEH000727), SP1 (wgEncodeEH001578), YY1 (wgEncodeEH001623), ELF1 
(wgEncodeEH001619), EGR1 (wgEncodeEH001646), HMGN3 (wgEncodeEH001863), TAF1 
(wgEncodeEH001582), TBP (wgEncodeEH001825) and CMYC (wgEncodeEH002800) ChIP-
seq from 1.5 kb upstream to 1.5 kb downstream of RefSeq TSS. Standardised read counts 
represent Z-scored read densities in 15 bp windows. 
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Table 4.2 Average binding positions of transcription factors at gene promoters. 
The positions of maximal mean ChIP-seq read density for VEZF1 and general transcription 
factors relative to transcription start sites (rounded to 5 bp). 
 
4.4.2 Co-binding of VEZF1 with transcription factors at enhancers 
The sets of transcription factors which operate at gene distal enhancers tend to differ 
from those which function at core promoters. In order to gain insight into which 
transcription factors might operate with VEZF1 at enhancers, the locations of 8,650 
enhancer-associated VEZF1 ChIP-seq peaks (section 4.3.2) were compared to 
transcription factor binding site peaks collated from the ENCODE project. The analysis 
was performed as described in the previous section, where the incidences of overlapping 
peaks were added and expressed as a percentage of VEZF1 binding events (Table 4.3).  
 
This analysis found that VEZF1 binding at enhancer-associated elements frequently 
overlapped the binding of many well characterised general transcription factors. Similar 
to promoters, RNA polymerase II is the factor that most frequently interacts with VEZF1 
enhancer sites, with an overlap 76% at enhancer-associated VEZF1 elements (Table 4.3). 
The binding of general transcription factors such as EGR1, TAF1, TBP, cyclin T2 (pTEFb), 
CMYC, SP1, USF1 and YY1 is also a regular feature (27-55% frequency) at enhancer-
associated VEZF1 elements. It should be noted that 2,205 of the 8,560 elements with 
enhancer-like chromatin states studied here locate within 1kb of an annotated TSS 
(section 4.3.5). Much of the overlap with general transcription factors may therefore be a 
result of TSS activity. In contrast to promoter-associated elements (Table 4.1), the tissue-
TF Base position at which read density is at maximum
SP1 -65 bp
EGR1 -40 bp
VEZF1 -35 bp
ELF1 -15 bp
CMYC -15 bp
TBP +15 bp
YY1 +20 bp
HMGN3 +20 bp
TAF1 +40 bp
RNAPII +85 bp
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specific transcription factors GATA1, GATA2 and TAL1 were found to bind at a subset of 
25-30% of VEZF1 enhancers (Table 4.3).  
8650 enhancers 
Rank Factor Overlaps Fraction 
1 POL2 6598 76.3% 
2 EGR1 4723 54.6% 
3 TAF1 4335 50.1% 
4 ZBTB7A 4133 47.8% 
5 E2F6 3899 45.1% 
6 ELF1 3887 44.9% 
7 HEY1 3697 42.7% 
8 CCNT2 3328 38.5% 
9 TBP 3245 37.5% 
10 C-MYC 2800 32.4% 
11 TAL1 2608 30.2% 
12 GABP 2585 29.9% 
13 SP1 2529 29.2% 
14 USF-1 2417 27.9% 
15 CTCF 2409 27.8% 
16 SIN3A 2360 27.3% 
17 JUND 2359 27.3% 
18 YY1 2307 26.7% 
19 NRSF 2296 26.5% 
20 HMGN3 2293 26.5% 
21 GATA2 2260 26.1% 
22 E2F1 2216 25.6% 
23 GATA1 2196 25.4% 
24 IRF1 2184 25.2% 
25 PU.1 2120 24.5% 
26 MAX 2093 24.2% 
27 HDAC2 2079 24.0% 
28 CEBPB 2001 23.1% 
29 E2F6 1903 22.0% 
30 P300 1855 21.4% 
31 NFKB 1696 19.6% 
32 CJUN 1597 18.5% 
33 ETS1 1583 18.3% 
34 CFOS 1567 18.1% 
35 ZNF263 1566 18.1% 
36 PAX5 1501 17.4% 
37 RAD21 1421 16.4% 
38 EBF1 1357 15.7% 
39 MXI1 1322 15.3% 
40 USF1 1317 15.2% 
41 TCF12 1293 14.9% 
42 AP-2γ 1246 14.4% 
43 TCF4 1150 13.3% 
44 JUNB 1147 13.3% 
45 CHD2 1146 13.2% 
46 SMC3 1141 13.2% 
47 FOXA1 1137 13.1% 
48 POL2(Ser2p) 1102 12.7% 
49 FOSL1 1092 12.6% 
50 USF2 1079 12.5% 
Table 4.3 Overlap between VEZF1 and other transcription factor binding events at 
enhancers. 
Incidences of ChIP-seq peaks for VEZF1 (peak summits expanded to 200bp) that overlap 
with other factors, as defined by the ENCODE project (EncodeRegTfbsClusteredV2). The 
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top 50 factors that most frequently overlap 8,650 enhancer-associated VEZF1 binding 
events are shown. Known erythroid-specific transcription factors are highlighted in red. 
 
We wished to look more closely at the relationship between VEZF1 and transcription 
factors associated with enhancer activity (P300, BRG1, CEBPβ) and erythroid-specific gene 
regulatory elements (GATA1, TAL1, NFE2 and BACH1) (Fujiwara et al., 2009, Hu et al., 
2011). SeqMINER clustering of ChIP-seq read densities for these factors were profiled at 
6,355 enhancer-like VEZF1 elements located >1kb from an annotated TSS. The analysis 
was set to identify 10 clusters, each of which reveals groups of elements with different 
transcription factor associations. VEZF1 was found to bind with comparable intensity to 
all of the 6,355 elements studied (Figure 4.13). P300, a histone acetyltransferase 
responsible for depositing H3K27ac marks (Jin et al., 2011), is bound at all of the VEZF1 
enhancers (Figure 4.13) which is consistent with the high level of H3K27ac at these 
elements (Figure 4.10). The VEZF1 enhancers are also bound by RNA polymerase II.    
 
Figure 4.13 VEZF1 and erythroid transcription factor co-binding at enhancer elements. 
Read density profiles of TAL1 (wgEncodeEH001824), GATA1 (wgEncodeEH000638), BRG1 
(wgEncodeEH000724), VEZF1, P300 (wgEncodeEH002834), NFE2 
(wgEncodeEH000624),RNA Polymerase II (unphosphorylated CTD) (wgEncodeEH000727), 
CEBPβ (wgEncodeEH002346) and BACH1 (wgEncodeEH002846) ChIP-seq from 5 kb 
upstream to 5 kb downstream of 6,355 VEZF1 peak summits that both overlap 
ChromHMM enhancer states and are located >1kb from annotated TSS. Read densities 
are shown as a heat map where red is highest and white is lowest.  
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The binding of the other factors studied varies, where four patterns of binding are 
observed. The first group totalling 1,280 elements (clusters 6-9, Figure 4.13) appear to be 
TSS as judged by the high levels of RNA pol II extending from the VEZF1 peak summits. 
However, an interesting group of 1,586 elements (clusters 1 and 5, Figure 4.13) are bound 
by the erythroid-specific transcription factors GATA1, TAL1 and NFE2 in addition to the 
enhancer associated transcription factors P300, BRG1 and CEBPβ. GATA1 and TAL1 are 
known to frequently co-operate at erythroid gene regulatory elements in a TAL1-
Erythroid-Complex (TEC) (Wadman et al., 1997). A third group of 1,356 elements is also 
bound by TAL1 at low levels (clusters 2 and 10, Figure 4.13), but generally lacks binding of 
GATA1, NFE2, CEBPβ or BACH1. Finally, a group of 2,133 elements (clusters 3 and 4) lacks 
binding of any of the cell-type specific transcription factors studied, indicating that 
VEZF1’s association with enhancer elements is probably not exclusive to erythroid-
specific elements. 
 
The mean ChIP-seq read density profiles for the transcription factors studied were 
compared between all 6,355 TSS-distal VEZF1 enhancers and the 1,586 “TEC enhancers” 
identified from clustering. This analysis showed that the GATA1, TAL1, P300 and BRG1 
transcription factors were all substantially enriched at the TEC enhancers compared to all 
the TSS-distal VEZF1 enhancers studied (Figure 4.14). The levels of NFE2, CEBPβ and RNA 
polymerase II were also substantially increased. Taken together, these findings indicate 
that the 1,586 elements identified in this analysis are bound by erythroid-specific 
transcription factors, probably collectively as a TEC complex. These elements have 
enhancer-associated chromatin signatures and are bound by known enhancer factors 
such as P300, BRG1 and CEBPβ. Consistent with this, the 1,586 element group includes 
the well characterised erythroid-specific enhancers of the TAL1 (+51 element), HBA (-8, -
33 and -40 elements) and HBB (HS1, HS2 and HS3 elements) genes. 
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   All 6355 1586 TEC sites 
 
 
 
Figure 4.14 Transcription factor binding at 1,586 erythroid enhancer elements. 
Mean read density profiles of TAL1 (wgEncodeEH001824), GATA1 (wgEncodeEH000638), 
BRG1 (wgEncodeEH000724), VEZF1, P300 (wgEncodeEH002834), NFE2 
(wgEncodeEH000624),RNA Polymerase II (unphosphorylated CTD) (wgEncodeEH000727), 
CEBPβ (wgEncodeEH002346) and BACH1 (wgEncodeEH002846) ChIP-seq 5 kb either side 
of either 6,355 TSS VEZF1 enhancers or 1,586 TEC-VEZF1 enhancers. Standardised read 
counts represent Z-scored read densities in 50 bp windows. The peak maxima for each 
read profile is tabulated. Increases in transcription factor enrichment in the TEC enhancer 
group are highlighted red. 
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4.5 Discussion 
The aim of this chapter was to gain further insight into the types of regulatory processes 
that VEZF1 is involved in.  This was to be accomplished by determining: i) the locations of 
VEZF1 binding sites relative to genes and gene regulatory elements, ii) the chromatin 
states at VEZF1-bound elements and iii) the TFs which co-bind with VEZF1. 
As discussed in chapter 3, peak finding following VEZF1 ChIP-seq identified a total of 
26,341 VEZF1 enrichment peaks across the K562 genome.  Analysis of the locations of 
these peaks relative to the RefSeq human genome annotation and the ChromHMM 
chromatin state map for the K562 cell line revealed a striking correlation between VEZF1 
binding and promoter and enhancer regulatory elements, with 55 % of VEZF1 peaks 
(14,619 peaks) locating to promoters and 33% (8,650 peaks) locating to enhancers.  
Furthermore, the distribution of VEZF1 ChIP-seq reads at promoter elements is highly 
concentrated around TSSs and was found to peak at an average distance of -35 bp from 
the TSS of VEZF1-associated promoters.  These findings indicate a role for VEZF1 in the 
regulation of gene expression. 
VEZF1 peaks map to NDRs at both promoter and enhancer elements.  The promoter-
associated NDRs to which VEZF1 maps are highly enriched on either side by the active 
chromatin marks H2A.Z, H3K4me3 and H3K27ac and are depleted in the repressive 
H3K27me3 and H3K9me3 marks.  The enhancer-associated NDRs to which VEZF1 maps 
are also surrounded by nucleosomes enriched in the active chromatin marks H2A.Z and 
H3K4me3 as well as H3K27ac and H3K4me1 which are reported as being markers of 
active enhancer elements.  VEZF1-associated enhancers are also depleted in repressive 
histone modifications.  The association of VEZF1 with the TSSs of genes that are actively 
expressed in K562 cells combined with the finding that levels of VEZF1 enrichment at 
active TSSs positively correlate with gene expression levels, RNA pol II enrichment and 
levels of active chromatin marks, further supports a link between VEZF1 binding and 
active gene expression. 
Analysis of VEZF1 co-binding factors identified RNA pol II as the TF which most frequently 
interacts with VEZF1-associated promoter elements.  This analysis also revealed VEZF1-
bound promoters to be co-occupied with a number of general TF proteins whose level of 
enrichment positively correlate with those of VEZF1.  However a major limitation of this 
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analysis lies in the source of the TFBS locations.  The full ENCODE version 2 release of TF 
ChIP-seq peaks was used to identify sites of TF binding proximal to VEZF1 ChIP-seq peaks, 
however this release contains the locations of ~2.7 million TFBSs identified by ChIP-seq of 
119 TFs across 77 cell types and is therefore not specific to binding events in K562 cells.  A 
proportion of the ‘co-binding’ events between VEZF1 and general TFs is therefore likely to 
be misleading as these proteins may bind the same genomic element but in different cell 
types.  This co-binding screen is also limited by the accuracy of peak calling within the 
ChIP-seq data sets used to generate the ENCODE version 2 release of TFBSs.  Examination 
reveals peak calling in many tracks to be accurate, but there is evidence of false positive 
and false negative peak calling and poor peak definition in some datasets.  Such poor 
peak calling performances may affect the identification of sites of co-occupancy with 
VEZF1 and other TFs.  This co-occupancy analysis was useful as an initial screen to identify 
proteins which may co-bind with VEZF1 at different types of genomic element.  
Unfortunately, it is not possible to extract K562-specific TFBS data from the ENCODE 
version 2 release of TFBSs.  Further investigation will be required to study the co-
occupancy of VEZF1 and specific proteins of interest across the K562 cell genome.  In 
order to achieve this, publicly available ChIP-seq reads for factors of interest should be 
aligned to the hg19 human reference genome and peak calling performed using MACS 
and PeakSplitter softwares.  Enrichment overlaps between VEZF1 and factors of interest 
can then be studied and the juxtaposition of binding motifs investigated.  This type of 
analysis can be used to reveal co-operativity between TFs at specific types of genomic 
elements.  
A similar analysis of VEZF1 co-binding factors at enhancer elements identified RNA pol II 
as being the TF which most frequently interacts with VEZF1-associated enhancers.  A 
number of general TFs were also revealed to bind genomic DNA near VEZF1 peaks as 
were the tissue-specific TFs GATA1, GATA2 and TAL1.  A group of 1,586 VEZF1 enrichment 
peaks were discovered to associate with enhancer elements which appear to be bound by 
the TEC complex.  The TEC is an erythroid cell-specific TF complex which functions to 
regulate expression of a group of erythroid-specific genes (Wadman et al., 1997, Lahlil et 
al., 2004, Xu et al., 2007, Dhami et al., 2010).  This group of VEZF1-enriched TEC-
associated enhancers were co-occupied by the erythroid-specific gene regulatory 
elements GATA1, TAL1, NFE2 and BACH1 in addition to the general active enhancer 
associated TFs BRG1, P300 and CEBPβ.   
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It can be concluded from the findings presented in this chapter that VEZF1 primarily binds 
NDRs within active promoter and enhancer elements.  Levels of VEZF1 enrichment are 
seen to positively correlate with those of co-binding TFs and a specific subgroup of VEZF1-
associated enhancers appears to be comprised of TEC-associated erythroid specific 
enhancer elements. 
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Chapter 5 
Definition of a VEZF1 DNA-binding consensus motif 
5.1  Introduction 
In chapter 3, ChIP-seq analysis identified 26,341 peaks of VEZF1 enrichment across the 
genome of human K562 cells. While the average width of the VEZF1 ChIP-seq peaks 
identified by MACS analysis was 433 bp, the analysis did generate peak summits where 
VEZF1 is most likely to bind. However, the specific DNA motifs with which VEZF1 interacts 
remain undefined. The bioinformatic analysis of chromatin and gene regulatory events at 
VEZF1 peaks presented in Chapter 4 found that ~55% of VEZF1 sites locate to TSSs at 
promoters, while ~33% of sites locate to enhancers. Around 1,600 of these enhancers are 
bound by erythroid-specific factors. A previous ChIP analysis of VEZF1 binding in different 
cell types found VEZF1 enrichment at housekeeping promoters in all cell types studied, 
whereas VEZF1 binding at erythroid-specific promoters and enhancers was restricted to 
erythroid cells (section 1.9) (Strogantsev, 2009). The fact that VEZF1 interacts with 
different regulatory element types and that binding can be either constitutive or cell-type 
specific suggests that VEZF1 may interact with different DNA motifs. 
Chicken VEZF1 has been found to interact with multiple sites within the β-globin gene 
locus in vitro. Originally known as Beta Globin Protein 1 (BGP1), chicken VEZF1 interacts 
with a minimum of seven dG.dC bases within a long homopolymeric string upstream of 
the βA globin gene promoter in vitro (Lewis et al., 1988, Clark et al., 1990) and has also 
been shown to interact with three sites within the HS4 β-globin insulator. One of these 
sites, FI, contains a homopolymeric 9(dG.dC) string, but the FIII and FV sites each have 
two shorter dG.dC runs (Dickson et al., 2010). The binding of human VEZF1 to DNA 
elements in the core promoters of the IL3 and EDN1 genes have also been characterised. 
These sites are G-rich, but also lack a minimum of seven contiguous dG.dC bases (Koyano-
Nakagawa et al., 1994, Aitsebaomo et al., 2001).  The VEZF1 binding motifs identified in 
these studies are shown in Table 5.1. It is clear that while there is a relationship between 
these motifs, no clear binding site consensus can be identified from this small number of 
sites.  
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Table 5.1 VEZF1 binding motifs identified in previous studies. 
dG nucleotides within VEZF1 binding motifs are shown in red.  Refer to text for 
references. 
 
The analysis of enriched DNA motifs within VEZF1 ChIP-seq peaks should allow the 
definition of a robust consensus sequence. Studies in this chapter therefore aim to: 
 Determine a consensus DNA binding site motif, or motifs, for VEZF1 from ChIP-seq 
data using bioinformatic tools 
 Identify putative VEZF1 recognition motifs within ChIP peaks 
 Analyse the relative DNA-binding affinity of VEZF1 in vitro 
 Develop a model of VEZF1 DNA-binding affinity and its relationship to gene 
regulatory mechanisms 
 
Genomic Element VEZF1-binding motif
β-Adult promoter CGGGGGGGGGGGGGGGGT
HS4 FI CTTTGGGGGGGGGCTGTC
HS4 FIII TCGGGGATGCGGGGGGAG
HS4 FV TGGGGGATACGGGGAAAA
IL3 promoter GGCGGGGGGAGGTGGTGG
EDN1 promoter GACAAATGGGGGTGAGAT
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5.2 ab initio prediction of VEZF1 DNA-binding specificity 
VEZF1 contains six Cys2-His2 (C2H2) zinc finger (ZF) domains, but no other recognisable 
DNA-binding motifs. Protein structure studies and mutagenesis have resulted in the 
development of a generic C2H2 DNA-binding model, which maps the exact interactions 
between nucleotides and specific ZF domain residues (Pavletich and Pabo, 1991, Elrod-
Erickson et al., 1998). This model, in combination with the experimentally defined 
sequence specificity of C2H2 factors allows for ab initio prediction of the DNA-binding 
specificity of uncharacterised C2H2 proteins.  
We firstly compared the VEZF1 protein sequence to a straightforward C2H2 code based 
on mutagenic studies of EGR1 (zif268) (Wolfe et al., 2000). This analysis predicted that the 
optimal recognition sequence for VEZF1 would be gTGGGGgGGGCGGC (Figure 5.1B). Most 
C2H2 domains studied have a canonical arrangement of tandem C2H2 domains. Given 
that ZF1 of VEZF1 has a non-canonical spacing with respect to the other ZF domains 
(figure 5.1A), the model might not accurately predict the potential specificity of this 
domain. The specificity of ZF2-ZF6 would therefore be gTGGGGgGGG. Next, we used a 
more sophisticated ab initio prediction tool that used a probabilistic model built from 455 
C2H2 protein–DNA pairs from the TRANSFAC 7.3 database of experimentally defined 
sequence specificities (Kaplan et al., 2005). This analysis found that the optimal 
recognition sequence for VEZF1 would be GGGGgGGGcg (Figure 5.1C). Both of these 
predictions are highly convergent and indicate that an optimal VEZF1 recognition motif 
consists of homopolymeric strings of eight dG.dC bases.  It is apparent from both models 
that the probability of a central guanosine base is weaker than the surrounding bases. 
This suggests that the central base position is not as critical for VEZF1 binding as 
surrounding positions and that other bases might be tolerated at this position.   
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Figure 5.1  VEZF1 is predicted to prefer a homopolymeric deoxyguanosine motif.   
A) The amino acid sequence of human VEZF1, C2H2 domains are highlighted in red. B) 
Prediction of the preferred DNA binding specificity of VEZF1 derived from comparison to a 
C2H2 DNA recognition code (Wolfe et al., 2000). C) Prediction of the preferred DNA 
binding specificity of VEZF1 derived from a probabilistic model 
(http://compbio.cs.huji.ac.il/Zinc, (Kaplan et al., 2005)). 
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5.3 Identification of enriched DNA sequence motifs at VEZF1 
ChIP-seq peak summits 
The discovery of regulatory DNA motifs, such as TF binding motifs, has been a major focus 
of biologists and bioinformaticians over recent years.  The identification of TF binding 
motifs is important to achieving a better understanding of the regulatory mechanisms in 
which TFs function.    The great number of computational motif discovery tools that have 
been developed and are publicly available for use reflects the complexity of the challenge 
that creating these tools poses.   With the advent of ChIP-seq and other high throughput 
sequencing techniques, motif discovery tools are required which are capable of efficiently 
processing the huge amounts of data generated by these techniques. 
5.3.1 Motif discovery using MEME 
MEME (Multiple EM for Motif Elicitation) is the most commonly used motif discovery tool 
due to its ease of use via the MEME web portal (http://meme.nbcr.net/meme/, 
(Machanick and Bailey, 2011) . MEME was used to search for enriched DNA sequence 
motifs of up to 30 bp in length within the 100 bp surrounding VEZF1 ChIP-seq peak 
summits.  Prior to motif discovery, the 26,341 VEZF1 ChIP-seq peak summits were ranked 
by read enrichment levels normalised against non-immune IgG ChIP-seq enrichments at 
the same genomic locations.  
Motif discovery was performed for groups of 1000 VEZF1 ChIP-seq peaks based on their 
peak strength. MEME analysis was performed on (1) the 1000 most highly enriched VEZF1 
peaks followed by peaks ranked 5000-6000 (2), 10,000-11,000 (3), 15,000-16,000 (4), 
20,000-21,000 (5) and 25,000-26,000 (6). The aim was identify the most optimal VEZF1 
motif from the top 1000 VEZF1 peaks followed by potentially divergent motifs as VEZF1 
enrichments decrease. Eight sequence motifs were generated for each group. The highest 
ranking motif was found in 70 to 80 % of the 1000 elements tested in most of the groups 
of peaks (Figure 5.2). The additional motifs discovered were unlikely to represent VEZF1 
motifs as they were found in a minor fraction of elements tested (4.8 % of input on 
average, not shown). 
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Figure 5.2  Motif discovery using MEME identifies G-rich motifs.   
Motif discovery was performed using the 100 bp of DNA sequence surrounding VEZF1 
ChIP-seq peaks as input for MEME.  Sequences were analysed in groups of 1000 based on 
relative ChIP-seq enrichment levels.  Weblogo presentations of the discovered position 
weight matrices of base enrichment are shown, where the height of each letter indicates 
the relative occurrence of nucleotides in enriched motifs. 
 
The most highly represented DNA motifs identified by MEME for each group of 1000 
VEZF1 ChIP-seq peaks analysed are G-rich. A common pattern of gGGnGGgg was apparent 
within groups 2, 3, 4 and 5, however this pattern is less apparent within the motifs 
discovered from groups 1 or 6 (Figure 5.2). Most of the DNA motifs discovered by MEME 
are very long in length when compared to previously characterised VEZF1 binding sites 
Found 717 timesGroup 1
VEZF1 peaks 1 - 1000
Found 838 timesGroup 2
VEZF1 peaks 5,000 – 6,000
Found 670 timesGroup 3
VEZF1 peaks 10,000 – 11,000
Found 798 timesGroup 4
VEZF1 peaks 15,000 – 16,000
Found 581 timesGroup 5
VEZF1 peaks 20,000 – 21,000
Found 255 timesGroup 6
VEZF1 peaks 25,000 – 26,000
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(Table 5.1) or the motif predicted from the protein amino acid sequence (Figure 5.1). The 
DNA motif discovered from the 1000 most enriched VEZF1 sites is largely comprised of a 
long string of poorly enriched G bases that are consistently underlain by A bases (Figure 
5.2, group 1). I am therefore concerned that MEME has had difficulty in aligning 
discovered G-rich motifs when forming a consensus. Another unexpected finding from 
these MEME analyses was that no obvious motif change was apparent between the 
highest and lowest VEFZ1-enriched sites. 
Further constraints of the MEME programme are that it is very slow in performing motif 
finding analyses and that the MEME-ChIP tool actually only uses 600 sequences to 
generate a motif, i.e. in analyses where 1000 DNA sequences are used as input MEME-
ChIP randomly selects 600 sequences and uses them to perform its analysis, this may lead 
to specific motifs being missed or under-/over-reported. 
 
5.3.2 Motif discovery using POSMO 
5.3.2.1 Motif discovery in all VEZF1 ChIP-seq peaks 
We decided to make use of the recently developed motif discovery programme POSMO 
as it has been reported to be more efficient than iterative discovery tools like MEME (Ma 
et al., 2012).  POSMO incorporates two advances over existing motif discovery methods. 
First is that POSMO uses a motif occurrence model that reflects the fact that transcription 
factor motifs typically cluster around ChIP-seq peak summits. This approach is 
computationally efficient, permitting analysis of full ChIP-seq datasets in minutes. Second, 
POSMO incorporates a word clustering that improves the alignment of discovered motifs 
when forming position weight matrices (PWMs) that describe a discovered motif. 
 
POSMO can be used to search for motifs of 7 to 9 bp in length with the width of the DNA 
sequence around ChIP-seq peak summits set by the user.  Following comparisons of 
different settings combinations it was concluded that using a 200 bp window around 
ChIP-seq peak centres for motif finding generated the most consistent results between 8-
mer and 9-mer motif searches and subsequent analyses were performed searching for 9-
mer motifs in a 200 bp window around VEZF1 peaks.  Figure 5.3 shows the most 
represented 8 and 9-mer motifs discovered by POSMO analyses of a 200 bp window 
surrounding all of the total 26,341 VEZF1 ChIP-seq peak summits.  Similar to outputs of 
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the prediction models and MEME analysis, homopolymeric strings of dG residues were 
apparent with a central residue (position 6 in the POSMO web logos) being less prevalent 
(Figure 5.3). Strikingly, POSMO discovered a far greater number of motif occurrences than 
MEME, with an average of approximately two occurrences for each VEZF1 peak. 
 
Figure 5.3  Motif discovery using POSMO identifies homopolymeric dG.dC motifs.  
Overrepresented motifs of 8 or 9 nucleotides in length were identified within a 200 bp 
window surrounding 26,341 VEZF1 ChIP-seq peak summits.  The most frequently 
occurring motifs are shown along with the number of times each motif was found.  
Weblogo presentations of the discovered position weight matrices of base enrichment 
are shown, where the height of each letter indicates the relative occurrence of 
nucleotides in enriched motifs. 
 
5.3.2.2 Motif discovery within groups of VEZF1 ChIP-seq peaks ranked by 
read enrichment 
POSMO was used to discover motifs within groups of VEZF1 ChIP-seq peaks based on 
their peak strength. POSMO analysis was performed on (1) the 250 most highly enriched 
VEZF1 peaks, (2) the top 1000 peaks, (3) peaks ranked 8001-9000 and (4) peaks ranked 
20,000-21,000. The aim was to identify the most optimal VEZF1 motif from the most 
enriched VEZF1 peaks followed by potentially divergent motifs as VEZF1 enrichments 
decrease. These analyses discovered highly enriched GGGGNGGGG motifs in all of the 
groups of VEZF1 sites, but the relative weight of each G base altered with decreasing 
VEZF1 enrichment (Figure 5.4). The primary motif discovered within the 250 most 
9-mer motif search; 200 bp width
8-mer motif search; 200 bp width
Found 62,456 times
Found 50,434 times
A.
B.
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enriched VEZF1 sites appears as a homopolymeric run of 9(dG.dC) (Figure 5.4A). This 
motif matches the high affinity VEZF1 sites found at the chicken βA-globin promoter and 
the HS4 insulator FI site (Table 5.1) (Dickson et al., 2010). 
 
The motifs within the top 1000 peaks can be homopolymeric but may consist of two 
shorter stretches of dG residues flanking an A or C residue shown at position 5 of the web 
logo (Figure 5.4B).  The VEZF1 motifs within peaks of intermediate enrichment (ranked 
8,000-9,000) no longer appear to be homopolymeric but consist of two highly conserved 
stretches of four G residues which were separated by either a C or an A nucleotide (Figure 
5.4C).  Finally, the most frequently occurring motif identified within VEZF1 peaks of lower 
enrichment (ranked 20,000-21,000) consist of two highly conserved stretches of four G 
residues which were separated by an A base (Figure 5.4D). 
The abundance of the discovered motifs at VEZF1 ChIP-seq peak summits indicates that 
multiple target sites can be found at the most highly enriched elements. The most 
frequently occurring motif from the 250 highest enriched VEZF1 sites was found 571 
times in these 200 bp elements. Likewise, the most frequently occurring motif generated 
using the top 1000 sites was found 1941 times in those elements. However, the best 
motif found from 1000 intermediate sites was found approximately once per element on 
average.  Interestingly, the motif that occurred most often in 1000 sites of weaker VEZF1 
enrichment was only found 392 times in these elements.  These observations indicate 
that decreasing enrichment levels correlate with VEZF1 binding to increasingly 
degenerate DNA motifs. 
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Figure 5.4  VEZF1 binding motifs differ in correlation with levels of VEZF1 enrichment.   
DNA sequence motifs identified by POSMO as being enriched within 200 bp sequences 
surrounding VEZF1 ChIP-seq peak summits. VEZF1 sites were ranked based on ChIP-seq 
read enrichments and groups of 250 or 1000 elements studied, as shown.  The most 
frequently occurring motif from each group is presented along with the number of times 
each motif was found.  Weblogo presentations of the discovered position weight matrices 
of base enrichment are shown, where the height of each letter indicates the relative 
occurrence of nucleotides in enriched motifs. 
 
 
5.3.2.3  Motif discovery in VEZF1 ChIP-seq peaks that overlap promoter or 
enhancer HMM chromatin states 
Comparison of VEZF1 ChIP-seq peak summit locations with the ChromHMM chromatin 
state map for K562 cells (Ernst et al., 2011) identified 14,619 VEZF1 sites that overlap with 
VEZF1 Peaks 1 - 250
Found 571 times
VEZF1 Peaks 1 – 1000
Found 1941 times
VEZF1 Peaks 8,000 – 9,000
Found 1093 times
VEZF1 Peaks 20,000 – 21,000
Found 392 times
A.
B.
C.
D.
149 
 
promoter states and 8,560 sites that overlap with enhancer states (section 4.3.2).  
POSMO motif discovery was performed on these different groups of VEZF1 sites to 
determine whether VEZF1 interacts with different motifs when performing different gene 
regulatory tasks. Similar to the motifs found at the highest affinity VEZF1 sites described 
above, the most frequent motif at all promoter-associated VEZF1 sites appears as a 
homopolymeric run of 9(dG.dC) (Figure 5.5A). In order to identify VEZF1 binding site 
motifs associated with enhancers, we excluded 2,205 elements that were located within 
1kb of an annotated TSS from the analysis. We also excluded a further 1,280 elements 
that strongly resembled TSSs in SeqMINER cluster analysis due to the high levels of RNA 
polymerase II (clusters 6-9, Figure 4.13). The most frequent motif discovered at 3,489 TSS 
distal enhancer-associated elements consists of two highly conserved stretches of four G 
residues which were separated by an A or T base (Figure 5.5B). This enhancer motif is 
reminiscent of that discovered for 1000 weak VEZF1 sites (figure 5.4D), however these 
enhancer-associated sites have the same distribution of read enrichment as for all VEZF1 
sites (not shown). It therefore appears that VEZF1 interacts with a divergent motif 
gGGGwGGGg at enhancers.  
 
 
150 
 
 
Figure 5.5  VEZF1 interacts with divergent motifs at enhancer-associated elements. 
DNA sequence motifs identified by POSMO as being enriched within 200 bp sequences 
surrounding VEZF1 ChIP-seq peak summits. 14,619 promoter-associated (A) and 3,489 
TSS-distal enhancer-associated (B) VEZF1 sites were analysed. The most frequently 
occurring motif from each group is presented along with the number of times each motif 
was found.  Weblogo presentations of the discovered position weight matrices of base 
enrichment are shown, where the height of each letter indicates the relative occurrence 
of nucleotides in enriched motifs. 
 
5.4 Identification of putative VEZF1 recognition motifs within 
 ChIP peaks 
POSMO DNA sequence motif discovery analyses indicate that VEZF1 interacts with 
GGGGNGGGG motifs. However, the relative enrichment of guanosine bases at the edge of 
the motif and the base at the centre of the motif alter depending on the strength or 
regulatory function of VEZF1 sites. The most highly enriched sites tend to contain 
homopolymeric 9(dG.dC) motifs, while weak sites tend to contain divergent gGGGaGGGg 
motifs (section 5.3.2.2). Enhancer sites, which can have high, intermediate or low levels of 
VEZF1 ChIP-seq read enrichment, harbour a gGGGwGGGg motif that is similar to that 
enriched at weak VEZF1 sites (section 5.3.2.3). We need to determine whether the 
divergent motifs identified are true VEZF1 binding motifs and whether there are 
differences in VEZF1’s DNA-binding affinity for homopolymeric 9(dG.dC) versus 
gGGGwGGGg sequence motifs. 
As this phase of work started before VEZF1 ChIP-seq analysis was complete, putative 
VEZF1 binding elements were identified within 125 VEZF1 ChIP-chip peaks (section 1.9).  
A GGGGNGGGG motif discovered from these 125 VEZF1 binding sites was identified as a 
putative binding motif (Figure 5.6). The ChIP-chip peaks had an average size of 400 bp, so 
Promoter-associated 
VEZF1 motifs
Found 43,341 times
Enhancer-associated VEZF1 
motifs
Found 3198 times 
A.
B.
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multiple putative VEZF1 binding elements were identified within many of the peaks. The 
aim of the experiment was to increase our understanding of VEZF1 specificity, so a variety 
of putative VEZF1 target elements were selected that contained either homopolymeric 
dG strings or two shorter dG strings with a central dC, dT or dA base (Table 5.2). The 
target elements were identified from ChIP-chip peaks that had been validated by 
independent ChIP assays in 9 different cell types (Strogantsev, 2009). 
 
Figure 5.6  Enriched sequence motif identified in 125 VEZF1 ChIP-chip peaks. 
The most enriched DNA sequence motif identified by MEME within 125 VEZF1 ChIP-chip 
peaks (Strogantsev, 2009). Weblogo presentations of the discovered position weight 
matrix of base enrichment are shown, where the height of each letter indicates the 
relative occurrence of nucleotides in enriched motifs.  
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VEZF1 site Sequence Cell type 
Controls 
  No competitor 
 HS4 FI TGGGGGCTTTGGGGGGGGGCTGTCCCCGTG Broad 
HS4 F1aaa1 TGGGGGCTTTGGGGGTTTGCTGTCCCCGTG Broad 
HS4 FIII CTCGGGGATGCGGGGGGAGCGCCGGACCGG Broad 
G string nnnnnnnnnnnGGGGGGGGGnnnnnnnn 
 EDN1 proA CCCCTATTAGAGTGGGGGTAAACAGCTC Vascular* 
TAL1 pro1bA GGGGGGGGCGGTGGGGGGGCATTTTCCG Myeloid* 
HMGN1 proA GGCGCCCGGGGGGGGGGGGGGGGCCCCG Broad 
STAG2 proA GCCACCCATGGGGGGGGGGGGTCTCCGG Broad* 
GC nnnnnnnnnnGGGGCGGGGnnnnnnnn 
 EHD1 16A GGGGTAATGGGGGGCGGGGCGGGGGGC Broad 
DNMT3B proB GGGGAACGGGGGGGCGGGGACGAGGGA Broad 
HBA p380 GTGCCAGGCCGGGGCGGGGGTGCGGGC Erythroid* 
FLNA int GGGGTGGGATGGGGCGGGGCCATCCAG Broad* 
TAL1 pro1bB GGCGGCAGCCGGGGCGGGGGCGTCCGT Myeloid* 
FLNA IRA TGCCGAGGCGGGGGCGGGGCGTGGAGG Broad* 
MECP2 proB CCCTTGCCGGGGGGCGGGGGTCAGGGG Broad* 
BRWD1 pro CGGCGCGGGGGGGGCGGGGGGCGGGGG Broad* 
HBA p40 TTATGCTTGGGGCGCGGGGGCACGCCG Erythroid* 
HBA p177 GGGTGCACGCGGGGCGGGGGCCAGGAC Erythroid* 
GT nnnnnnnnnnGGGGTGGGGnnnnnnnn 
 GMCSF +30B GTGGGTGGGGGGGGTGGGGAAAGGGGT Lymphoid* 
RFX pro AAGTGGAGCGGGGGTGGGGCGGGGTAG Broad* 
GMCSF +30A CCTGCCTCTAGGGGTGGGGTAGGTGAG Lymphoid* 
FLNA IRC GGCTCCCGGGGGGGTGGGTGGTGGCGC Broad* 
POLR3K pro CGCGCCGGGGGGGGTGGGGCGGCTGCG Broad 
HBB HS3GT CAGGGAGGGTGGGGTGGGGTCAGGGCT Erythroid* 
CKMT C AAGGCCGGGGGCGGTGGGGGAGTGGCT Broad* 
HBB HS2 CCAGAAGGCGGGGGTGGGGCACTGACC Erythroid 
CKMT A TGCGCCAGGAGGGGTGGGGCTGGAGTC Broad* 
GA nnnnnnnnnnGGGGAGGGGnnnnn 
 TAL1 +3 AGGCGGGTGGGGGGAGGAGGGGGTA Myeloid* 
IL3 proP GGCAAGGCGGGGGGAGGTGGTGGTG Lymphoid* 
HBA HS14 GGGGCCGGGGGCGGAGGGGGCCAGA Broad* 
IL3 proD CTGGGAGCTGGGGGAGGGGCTGGCC Lymphoid* 
MECP2 proA GGGGAGGACGGGGGAGGGGGGAGGT Broad* 
GMPPA GGGGCCGGGGGCGGAGGGGGCCAGA Broad* 
TAL1 +51 CCCAGGGCCTGGGGAGGGGGAGCCT Erythroid* 
DNMT3B proA GGGAGTGGGTGGGGAGGGGGCGGTG Broad 
TAL1 +20 CTGGTCCAAAGGGGAGGGGAGGAGT Myeloid* 
IL3 -37 TGATTTTGTGGGGGAGGTTGTTTGA Lymphoid* 
HBZ pro GGTCAGGTGAGGGGAGGGGGCTGCA Erythroid* 
HBA HS40 TCCTGTGGGGGTGGAGGTGGGACAA Erythroid 
HBB pro TCCCAGGAGCAGGGAGGGCAGGAGC Erythroid 
GnnG nnnnnnnnnGGGGnnGGGGnnnnnnnnnn 
 CKMT B GGAGTGGCTGGGGCTGGGGGCGGTATCGG Broad* 
HBG pro AGATAGTGTGGGGAAGGGGCCCCCAAGAG Erythroid 
FLNA IRB CGCGTCTGGGGGGTCGTGGGGAAGCAGGG Broad* 
 
Table 5.2.  Putative VEZF1 binding motifs identified at validated ChIP elements.  
Predicted VEZF1 binding motifs are underlined and associated dG nucleotides are shown 
in red.  The cell type specificity of VEZF1 binding for many sites (asterisks) was previously 
determined (Strogantsev, 2009). The cell type specificity of other elements is inferred 
from ENCODE chromatin state maps. 
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5.5 Analysis of the in vitro relative DNA-binding affinity of VEZF1  
Electrophoretic mobility shift analyses (EMSA) were employed to validate whether the 
putative VEZF1 recognition sites are indeed bound by VEZF1 in vitro.  EMSA involves the 
formation of protein:DNA complexes in solution followed by electrophoresis on native 
polyacrylamide gels. The short double-stranded DNA oligonucleotides are radiolabelled to 
allow the visualisation of both bound and unbound DNA. Unbound DNA probe migrates 
quickly, whereas the binding of protein would shift, or retard, the mobility of the labelled 
DNA. The mobility of the protein:DNA complexes are a function of size, shape and charge. 
EMSA was chosen as this assay allows the direct visualisation of distinct protein:DNA 
complexes, this avoiding the need for purified VEZF1.  However, the assay is limited by its 
relatively low throughput capacity and the fact that the in vitro nature of the system 
makes it difficult to replicate in vivo binding events, where post-translational 
modifications and cooperativity with co-binding factors are difficult to reproduce. 
 
A two stage approach to studying the relative affinity of VEZF1 towards the panel of 
putative recognition sites identified in section 5.4 was taken. In the first stage, the 
putative target sites were used as non-labelled competitors of VEZF1 binding to a labelled 
positive control site. Footprint I from the chicken HS4 insulator element was used as the 
positive control site. FI contains a homopolymeric 9(dG.dC) motif that is specifically 
recognised by VEZF1 (Dickson et al., 2010). Substitution of guanosine bases in the FIaaa1 
mutant (Table 5.2) disrupts VEZF1 binding, thus forming a negative control.  In the second 
stage, any motifs meriting further investigation were directly labelled for use as probes in 
EMSA assays. 
 
5.5.1 Production of recombinant VEZF1 protein 
Recombinant VEZF1 protein was produced by in vitro translation using rabbit reticulocyte 
lysate. This in vitro translation system can rapidly produce sufficient quantities of full 
length mammalian proteins for EMSA that have correct protein folding. Full length VEZF1 
cannot be produced in bacteria due to insolubility arising from improper folding (Adam 
West, unpublished observation). A cDNA encoding chicken VEZF1 was previously cloned 
into the pCITE4b plasmid (Dickson et al., 2010). Chicken VEZF1 is 98.5% identical with 
human VEZF1, with identical DNA binding residues in the C2H2 zinc finger domains. The 
154 
 
pCITE4b-GgVEZF1 plasmid contains chicken VEZF1 cDNA cloned downstream of a T7 
expression promoter and a CITE element which functions to enhance the efficiency of in 
vitro translation (Figure 5.7). Recombinant full length VEZF1 was produced following in 
vitro transcription and translation. SDS-PAGE analysis of 35S-methionine labelled 
translations showed the production of a polypeptide of the expected size of 64kDa for full 
length VEZF1, with some truncation products (Figure 5.8). 
 
 
Figure 5.7 The pCITE4b-GgVEZF1 plasmid.   
Scaled map of pCITE4b-GgVEZF1 showing the T7 promoter from where transcription 
initiates, the CITE element which functions to enhance in vitro translation efficiency and 
the chicken VEZF1 coding sequence.  The plasmid was linearised with Bgl II prior to in 
vitro transcription to prevent unproductive read-through transcription. 
 
T7 promoter
CITE
VEZF1
Poly(A)
T7 terminator
Bgl II
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Figure 5.8  In vitro translation of full length VEZF1. 
Phosphorimaged radiogram showing 35S methionine-labelled in vitro translated proteins 
from VEZF1, luciferase or no cRNAs electrophoresed on an SDS-PAGE gel.  The expected 
size of full length VEZF1 (64 kDa) is indicated by an arrow.   
5.5.2 Establishment of EMSA assays 
The EMSA assay was established as previously described (Dickson et al., 2010), using 32P 
end-labelled HS4 FI double stranded 40-mer oligonucleotide as the probe DNA. The probe 
was incubated with either chicken red blood cell nuclear extract or in vitro translated 
VEZF1 and the resulting protein:DNA complexes electrophoresed using 5% (29:1 Ac:Bis) 
native PAGE in 1X TBE. The initial performance of the EMSA assay was disappointing as 
the unbound DNA probe failed to resolve as a discrete band near the dye front. Instead, 
the unbound probe often appeared as a retarded smear (Figure 5.9). The formation of 
complexes with in vitro translated recombinant VEZF1 was also much weaker than 
anticipated. The smearing of the DNA probe was variable in nature and some days 
extended up to the well. This problem had not been previously observed with this 
protocol. 
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Figure 5.9  Improper resolution of DNA probes during initial EMSA assays.   
Phosphorimaged radiogram of native PAGE analysis of 32P-labelled HS4-FI probe 
incubated with no protein (lane1), red blood cell nuclear extract (lane 2) or in vitro 
translated VEZF1 (lane 3). The well is at the top and the dye front is at the bottom of this 
and subsequent EMSA images. Retarded protein:DNA complexes of the mobility expected 
for full length VEZF1 are indicated by an arrow.  
The replacement of PAGE buffers, EMSA reagents and DNA probe purification reagents 
failed to identify a cause for poor probe resolution during PAGE. It was considered that 
the high GC content of the FI oligonucleotides may support mis-annealing, resulting in 
staggered or structured multimers of varying lengths, which may account for the retarded 
mobility of the free probe.  The conditions for the annealing of the top and bottom 
strands were adjusted from a gradual cooling from 90 degrees Celsius at one degree per 
minute to a stepped programme of 90, 65, 37 and 22 degrees on a thermocycler. There 
was also concern that repeated freeze-thawing of prepared probe DNA was promoting 
strand separation as the smearing consistently deteriorated with time after probe 
preparation.  DNA probe preparations were therefore stored at 4 rather than 20 degrees.   
The formation of complexes between in vitro translated recombinant VEZF1 and the FI 
probe was initially weaker than anticipated. Reduced yield from the in vitro translation of 
complementary RNAs can occur if the RNA contains secondary structures. It was notable 
that a number of truncated VEZF1 polypeptides were produced in the original in vitro 
translation. cRNAs were therefore incubated at 65 ᵒC for 5 minutes immediately prior to 
their addition into in vitro translation reactions.  
Free probe: HS4 FI
Protein:
1 2 3
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EMSA analysis of VEZF1 interaction with the HS4 FI probe was repeated following the 
above protocol adjustments. The combination of stepwise probe annealing and freeze-
thaw avoidance resulted in probe DNA resolution as a discrete band towards the dye 
front (Figure 5.10). Efficient complex formation between FI and full length VEZF1 from the 
optimised in vitro translation can now also be observed (Figure 5.10, lane 3). The addition 
of polyclonal antibodies raised against the C-terminus of VEZF1 resulted in a “supershift” 
of full length recombinant VEZF1:DNA complexes to slower migrating complexes (Figure 
5.10, compare lanes 3 and 4). Faster migrating complexes that formed with in vitro 
translated VEZF1 are not supershifted, presumably because they contain C-terminal 
truncation products of VEZF1. A portion of the complexes between nuclear proteins 
extracted from chicken red blood cells and the FI probe are also supershifted by anti-
VEZF1 antibodies (Figure 5.10, compare lanes 1 and 2). It has previously been shown that 
a mixture of VEZF1, SP1, SP3 and other related factors in nuclear extracts can form 
complexes with the FI site in vitro (Dickson et al., 2010). These results are entirely 
consistent with previous published observations, so the optimised EMSA assay is suitable 
for studying VEZF1 interactions with putative binding motifs identified from ChIP peaks. 
 
Figure 5.10  Optimised EMSA analysis of VEZF1 DNA binding. 
Radiogram of native PAGE analysis of 32P-labelled HS4-FI probe incubated with red blood 
cell nuclear extract (lanes 1 and 2) or in vitro translated VEZF1 (lanes 3 and 4). Retarded 
protein:DNA complexes of the mobility expected for full length VEZF1 are indicated by an 
arrow. Faster migrating DNA complexes with truncated in vitro translations of VEZF1 are 
indicated by asterisks. Supershifted VEZF1:DNA complexes with anti-VEZF1 antibodies 
(supplemented in lanes 2 and 4) are indicated (SS). 
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5.5.3 Competition EMSA analysis of VEZF1 binding to putative target sites 
40 bp double stranded oligonucleotides containing 49 putative VEZF1 binding sites were 
prepared without radiolabelling. These sites include the 39 sites described in Table 5.2 
plus a further 10 sites that subsequently failed independent ChIP validation, as discussed 
later. A 50 fold excess of each “cold” competitor was individually added to radiolabelled  
HS4-FI probe prior to incubation with recombinant VEZF1. The complexes from these 49 
EMSA reactions were analysed over four PAGE gels. We only have capacity to run two 
large format PAGE gels at any one time, so a panel of control binding reactions were 
included to monitor consistency and ensure comparability between gels.  
Addition of a 50-fold excess of cold HS4-FI efficiently competes for VEZF1 interaction with 
radiolabelled FI (Figure 5.11A, compare lanes 3 and 5). FI contains a homopolymeric 
9(dG.dC) motif that is specifically recognised by VEZF1 (Dickson et al., 2010). Substitution 
of guanosine bases in the FIaaa1 mutant (Table 5.2) disrupts VEZF1 binding. Addition of a 
50-fold excess of cold F1aaa1 has a minimal competition effect on VEZF1 interaction with 
radiolabelled FI (Figure 5.11A, compare lanes 3, 5 and 6). These controls show that 
competition EMSAs can be used to profile the relative DNA-binding affinity of VEZF1 for 
putative binding sites relative to its affinity for HS4-FI. 
It is evident from the four EMSA gels that a number of the putative VEZF1 binding 
sequences compete for VEZF1 binding to the HS4 FI sequence (Figures 5.11 and 5.12).  In 
order to generate a quantitative competition score for each VEZF1 binding sequence, the 
intensity of the VEZF1-FI specific complex bands were quantified from the 
phosphorimage.  The VEZF1-FI specific band intensities for each competition were 
normalised to that of the specific band without competition to generate a score of the 
percentage of VEZF1-HS4 FI band remaining after competition with each DNA sequence 
tested.  This analysis was performed for all competitor sequences used in the EMSA 
screen. The IGF2, NRXN, SPA1, GMCSF pro, LYL1 and EHD17 sequences were removed 
from the analysis at this stage as it became apparent that these ChIP-chip peaks failed to 
show reproducible VEZF1 enrichment in the independent ChIP-seq or ChIP-qPCR assays.
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Figure 5.11 Competition EMSA analysis of VEZF1 interaction with putative binding motifs.   
Radiogram of native PAGE analysis of 32P-labelled HS4-FI probe incubated with red blood cell nuclear extract (lanes 1 and 2) or in vitro translated VEZF1 
(lanes 3-38). Retarded protein:DNA complexes of the mobility expected for full length VEZF1 are indicated by arrows. Faster migrating DNA complexes 
with truncated in vitro translations of VEZF1 are indicated by asterisks. Supershifted VEZF1:DNA complexes with anti-VEZF1 antibodies (supplemented 
in lanes 2 and 4) are indicated (SS). 50 fold excess of the non-labelled competitor DNAs indicated above each lane were added in lanes 5-19 and 21-38. 
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Figure 5.12 Competition EMSA analysis of VEZF1 interaction with putative binding motifs.   
Radiogram of native PAGE analysis of 32P-labelled HS4-FI probe incubated with red blood cell nuclear extract (lanes 1 and 2) or in vitro translated VEZF1 
(lanes 3-39). Retarded protein:DNA complexes of the mobility expected for full length VEZF1 are indicated by arrows. Faster migrating DNA complexes 
with truncated in vitro translations of VEZF1 are indicated by asterisks. Supershifted VEZF1:DNA complexes with anti-VEZF1 antibodies (supplemented 
in lanes 2 and 4) are indicated (SS). 50 fold excess of the non-labelled competitor DNAs indicated above each lane were added in lanes 5-19 and 21-30. 
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The competition scores for the HS4 FI and HS4 FIaaa1 mutant control competitors on all 
four EMSA gels was found to be consistent. The 50 fold excess cold HS4 FI sequence 
reproducibly competed VEZF1 binding to radiolabelled FI by 93 to 94 % across all four 
EMSA gels (Figure 5.13).  The FIaaa1 mutant competed by 22 to 41% across all four EMSA 
gels. This level of reproducibility indicates that competition EMSAs are a reliable way of 
screening for the relative affinity of putative VEZF1 binding sequences. 
 
 
 
 
Figure 5.13  Competition scores for the HS4 FI 
and HS4 FI mutant sequences were consistent 
between the four EMSA competition gels. 
The competition scores for each of the 39 putative VEZF1 binding sequences were 
compared to the types of sequence motif represented (Figure 5.14). The scores were 
categorised based on a comparison to the high affinity VEZF1 site HS4-FI (“strong”) and 
the FIaaa1 mutant which disrupts the majority of VEZF1 binding (“very weak”). Each of 
the four elements containing homopolymeric G strings are efficient competitors for 
VEZF1 binding (Figure 5.14, G-string group).  Conversely, the sequences containing SP1 
consensus GC boxes are typically weak competitors for VEZF1 binding (Figure 5.14, GC 
group).   Sequences containing GA or GT motifs compete for VEFZ1 binding with variable 
affinity (Figure 5.14, GA and GT groups). It is not immediately apparent from looking at 
the sequence motifs why some GA or GT motifs are apparently higher affinity VEZF1 
binding sequences than others (Table 5.3). However, it is clear that most of the weakest 
competitor sequences (classed as “very weak” or “negative”) diverge from the VEZF1 
consensus sequence (Table 5.3).
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Figure 5.14  Putative VEZF1 binding sequences compete for VEZF1 binding with different efficiencies. 
Quantification of VEZF1’s relative affinity for putative binding sequences. The intensities of the complexes formed between full length recombinant 
VEZF1 and the HS4 FI sequence (from the gels shown in Figures 5.11 and 5.12) for each competition experiment were normalised to no competitor to 
form a percentage competition value. The competition scores have been defined as ‘strong’ (80 – 100 % competition), ‘moderate’ (60 – 80 % 
competition), ‘weak’ (40- 60 % competition), ‘very weak’ (20 – 40 % competition) or ‘negative’ (0 – 20 % competition).  Competition data are grouped 
based on the class of sequence motif found in each competitor. 
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VEZF1 site Sequence % comp Score Selected 
Controls 
   
 
No competitor 0 negative  
HS4 FI TGGGGGCTTTGGGGGGGGGCTGTCCCCGTG 93.9 strong  
HS4 F1aaa1 TGGGGGCTTTGGGGGTTTGCTGTCCCCGTG 33.0 very weak  
HS4 FIII CTCGGGGATGCGGGGGGAGCGCCGGACCGG 91.3 strong  
G string nnnnnnnnnnnGGGGGGGGGnnnnnnnn 
  
 
EDN1 proA CCCCTATTAGAGTGGGGGTAAACAGCTC 97.2 strong YES 
TAL1 pro1bA GGGGGGGGCGGTGGGGGGGCATTTTCCG 96.8 strong YES 
HMGN1 proA GGCGCCCGGGGGGGGGGGGGGGGCCCCG 95.9 strong YES 
STAG2 proA GCCACCCATGGGGGGGGGGGGTCTCCGG 87.6 strong YES 
GC nnnnnnnnnnGGGGCGGGGnnnnnnnn 
  
 
EHD1 16A GGGGTAATGGGGGGCGGGGCGGGGGGC 89.8 strong YES 
DNMT3B proB GGGGAACGGGGGGGCGGGGACGAGGGA 68.3 moderate YES 
HBA p380 GTGCCAGGCCGGGGCGGGGGTGCGGGC 56.4 weak  
FLNA int GGGGTGGGATGGGGCGGGGCCATCCAG 55.6 weak YES 
TAL1 pro1bB GGCGGCAGCCGGGGCGGGGGCGTCCGT 49.9 weak  
FLNA IRA TGCCGAGGCGGGGGCGGGGCGTGGAGG 47.2 weak  
MECP2 proB CCCTTGCCGGGGGGCGGGGGTCAGGGG 46.6 weak  
BRWD1 pro CGGCGCGGGGGGGGCGGGGGGCGGGGG 21.2 very weak  
HBA p40 TTATGCTTGGGGCGCGGGGGCACGCCG 19.5 negative  
HBA p177 GGGTGCACGCGGGGCGGGGGCCAGGAC 0 negative  
GT nnnnnnnnnnGGGGTGGGGnnnnnnnn 
  
 
GMCSF +30B GTGGGTGGGGGGGGTGGGGAAAGGGGT 92.5 strong  
RFX pro AAGTGGAGCGGGGGTGGGGCGGGGTAG 84.0 strong  
GMCSF +30A CCTGCCTCTAGGGGTGGGGTAGGTGAG 81.0 strong  
FLNA IRC GGCTCCCGGGGGGGTGGGTGGTGGCGC 79.5 moderate YES 
POLR3K pro CGCGCCGGGGGGGGTGGGGCGGCTGCG 74.2 moderate YES 
HBB HS3GT CAGGGAGGGTGGGGTGGGGTCAGGGCT 60.8 moderate YES 
CKMT C AAGGCCGGGGGCGGTGGGGGAGTGGCT 52.8 weak  
HBB HS2 CCAGAAGGCGGGGGTGGGGCACTGACC 46.2 weak YES 
CKMT A TGCGCCAGGAGGGGTGGGGCTGGAGTC 43.4 weak  
GA nnnnnnnnnnGGGGAGGGGnnnnn 
  
 
TAL1 +3 AGGCGGGTGGGGGGAGGAGGGGGTA 93.0 strong YES 
IL3 proP GGCAAGGCGGGGGGAGGTGGTGGTG 93.0 strong YES 
HBA HS14 GGGGCCGGGGGCGGAGGGGGCCAGA 84.2 strong  
IL3 proD CTGGGAGCTGGGGGAGGGGCTGGCC 82.9 strong  
MECP2 proA GGGGAGGACGGGGGAGGGGGGAGGT 78.8 moderate YES 
GMPPA GGGGCCGGGGGCGGAGGGGGCCAGA 73.3 moderate  
TAL1 +51 CCCAGGGCCTGGGGAGGGGGAGCCT 67.3 moderate YES 
DNMT3B proA GGGAGTGGGTGGGGAGGGGGCGGTG 63.5 moderate  
TAL1 +20 CTGGTCCAAAGGGGAGGGGAGGAGT 60.4 moderate  
IL3 -37 TGATTTTGTGGGGGAGGTTGTTTGA 58.8 weak  
HBZ pro GGTCAGGTGAGGGGAGGGGGCTGCA 46.7 weak  
HBA HS40 TCCTGTGGGGGTGGAGGTGGGACAA 36.6 very weak  
HBB pro TCCCAGGAGCAGGGAGGGCAGGAGC 11.0 negative  
GnnG nnnnnnnnnGGGGnnGGGGnnnnnnnnnn 
  
 
CKMT B GGAGTGGCTGGGGCTGGGGGCGGTATCGG 43.5 weak  
HBG pro AGATAGTGTGGGGAAGGGGCCCCCAAGAG 39.6 very weak  
FLNA IRB CGCGTCTGGGGGGTCGTGGGGAAGCAGGG 36.2 very weak  
Table 5.3.  The competition scores of putative VEZF1 binding sequences. 
Predicted VEZF1 binding motifs are underlined and associated stretches of dG nucleotides 
are shown in red.  Scores from EMSA competition assays are shown and those sequences 
selected for use as probe in subsequent EMSAs are indicated. 
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5.5.4 Direct EMSA analysis of VEZF1 binding to putative target sites 
It is inferred from competition EMSAs that a reduction in the formation of complexes 
between VEZF1 and the radiolabelled HS4 FI probe is due to interaction of VEZF1 with 
non-labelled competitor DNA sequences.  In order to directly demonstrate that VEZF1 
interacts with the putative binding sequences, 15 sequences were selected for use as 
radiolabelled probes in a second series of EMSAs (Table 5.3).  A series of six binding 
reactions were set up using each probe sequence.  The first four reactions test whether 
endogenous proteins in chicken red blood cell nuclear extract interact with the test 
sequence, whether any resulting complexes contain VEZF1 (supershift with anti-VEZF1 
antibodies) and whether they have the same DNA sequence specificity as reported for 
VEZF1 (competition with F1 and F1aaa1). The latter two reactions test whether 
recombinant VEZF1 interacts with the test sequence. The same concentration of DNA 
probes and proteins were used in all the direct EMSA experiments below. 
5.5.4.1 Direct EMSA analysis of VEZF1 binding to G string sequences 
Four sequences that contain G strings were analysed for VEZF1 binding by direct EMSA 
(Table 5.3). Competition analysis demonstrated that the EDN1 proA, TAL1 pro1bA, 
HMGN1 proA and STAG2 proA sequences are all efficient competitors for VEZF1 binding 
(section 5.5.3). All four elements contain homopolymeric G strings. Direct EMSA analysis 
shows that VEZF1 does indeed interact with each of these elements, but that different 
relative affinities for each site can be observed (Figure 5.15). It is apparent that the TAL1 
pro1bA element is the highest affinity site for recombinant VEZF1, followed by HMGN1 
proA and EDN1 proA, then STAG2 proA (Figure 5.15, compare lane 5 in each panel).  
Incubation with anti-VEZF1 antibodies results in inhibition of binding of full length VEZF1 
or supershifted VEZF1:DNA complexes for each of these elements (Figure 5.15, compare 
lanes 5 and 6 in each panel). The relative binding of recombinant VEZF1 to each of the G 
string motifs correlates with the competition scores for each sequence.  The three highest 
affinity sequences EDN1, TAL1p1bA and HMGN1 all achieved competition scores of 96 – 
97 %, whereas the weaker STAG2 sequence scored a lower competition value of 87 % 
(Table 5.3). 
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Figure 5.15 VEZF1 interacts with novel G string sequences found at VEZF1 ChIP peaks. 
Radiograms of native PAGE analysis of 32P-labelled EDN1 pro (panel A), TAL1 pro1bA (panel B), HMGN1 proA (panel C) and STAG2 (panel D) probes 
incubated with red blood cell nuclear extract (lanes 1 to 2) or in vitro translated VEZF1 (lanes 5 and 6). Retarded protein:DNA complexes of the mobility 
expected for full length VEZF1 are indicated by arrows. Faster migrating DNA complexes with truncated in vitro translations of VEZF1 are indicated by 
asterisks. Supershifted VEZF1:DNA complexes with anti-VEZF1 antibodies (supplemented in lanes 2 and 6) are indicated (SS). 50 fold excess of the non-
labelled competitor DNAs indicated above each lane were added in lanes 3 and 4. 
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The results of direct EMSA analysis of nuclear extract protein interactions with each of 
the G string sequences are more complex to interpret. All of the G string sequences form 
complexes of a mobility expected for full length VEZF1, but different degrees of complex 
formation are observed. The STAG2 proA element is the highest affinity site for nuclear 
proteins, followed by HMGN1 proA, TAL1 p1bA and EDN1 pro (Figure 5.15, compare lane 
1 in each panel). The complexes that form with each of the four sequences are specific for 
the G string motifs as they are efficiently competed by the G string containing FI site, but 
much less so by the FIaaa1 mutant (Figure 5.15, compare lanes 1, 3 and 4 in each panel). 
Supershift analysis indicates that VEZF1 is present in each of the complexes between the 
G string sequences and nuclear extract proteins, but that other proteins also bind to 
these sequences (Figure 5.15, compare lanes 1 and 2 in each panel). The majority of the 
complexes formed between nuclear proteins and the TAL1 pro1bA or HMGN1 proA 
sequences are supershifted by anti-VEZF1 antibodies, indicating that VEZF1 is the main 
constituent of these complexes. This observation is consistent with the high affinity of 
recombinant VEZF1 for these elements. VEZF1 appears to be a minor constituent of the 
complexes formed between nuclear proteins and the EDN1 proA and STAG2 proA 
sequences, this is consistent with the lower affinity of recombinant VEZF1 for the STAG2 
proA element compared to the TAL1p1bA and HMGN1 proA sequences. 
Taken together, it can be concluded that VEZF1 interacts with the G string sequences 
EDN1 proA, TAL1 pro1bA, HMGN1 proA and STAG2 proA. The relative DNA-binding 
affinity of VEZF1 for the EDN1 proA, TAL1 pro1bA and HMGN1 proA sites is comparable to 
that of the HS4 FI element. Binding to the STAG2 proA element is lower. Other nuclear 
proteins with similar specificity and EMSA mobility also interact with each of these G 
string sequences in vitro. This was previously observed for the HS4 FI element, which can 
also be bound by SP1 and SP3 in vitro (Dickson et al., 2010). 
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5.5.4.2 Direct EMSA analysis of VEZF1 binding to GC motif sequences 
Three sequences that contain GC motifs akin to the SP1 consensus binding motif were 
analysed for VEZF1 binding by direct EMSA. Competition analysis demonstrated that 
sequences like FLNA int are typically weak competitors for VEZF1 binding, although two 
sequences with longer G strings, EHD1 16A and DNMT3B proB, were stronger competitors 
(Table 5.3).   Direct EMSA analysis shows that recombinant VEZF1 does interact with the 
DNMT3B proB sequence with high affinity, but little or no binding of VEZF1 is observed at 
the EHD1 16A or FLNA int sequences (Figure 5.16, compare lane 5 in each panel). All of 
the GC sequences form strong complexes with nuclear proteins. These are of a mobility 
expected for full length VEZF1, but supershift analyses indicate that very little VEZF1 is 
present in these complexes (Figure 5.16, compare lanes 1 and 2 in each panel). It is likely 
that other transcription factors such as the SP1 family proteins are present in these 
complexes. 
Taken together, the competition and direct EMSA analyses demonstrate that unlike 
homopolymeric G string sequences, VEZF1 does not efficiently recognise isolated 
GGGGCGGGG motif sequences in vitro. Direct VEZF1 binding to the multiple GC sequence 
EHD1 16A was not observed, in contradiction to the efficient competition previously 
observed with this sequence (Table 5.3). VEZF1 does interact with the GC sequence 
DNMT3B proB reasonably well, but it should be noted that there is a homopolymeric 
7(dG.dC) string in this sequences with a further short G string a three bases away (Table 
5.3). Mutagenesis experiments would be required to determine whether VEZF1 is 
interacting with the GC motif in DNMT3B proB or the separated G strings. 
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Figure 5.16 VEZF1 interaction with GC sequences found at VEZF1 ChIP peaks is variable. 
Radiograms of native PAGE analysis of 32P-labelled EHD 16A (panel A), DNMT3B B (panel B) and FLNA int (panel C) probes incubated with red blood cell 
nuclear extract (lanes 1 to 2) or in vitro translated VEZF1 (lanes 5 and 6). Retarded protein:DNA complexes of the mobility expected for full length 
VEZF1 are indicated by arrows. Faster migrating DNA complexes with truncated in vitro translations of VEZF1 are indicated by asterisks. Supershifted 
VEZF1:DNA complexes with anti-VEZF1 antibodies (supplemented in lanes 2 and 6) are indicated (SS). 50 fold excess of the non-labelled competitor 
DNAs indicated above each lane were added in lanes 3 and 4. 
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5.5.4.3 Direct EMSA analysis of VEZF1 binding to GT motif sequences 
Four GT motif sequences that had moderate or weak competition activity were analysed 
for VEZF1 binding by direct EMSA. The binding of recombinant VEZF1 to the FLNA IRC and 
POLR3K pro sequences was weak. Furthermore, there was no apparent binding of 
recombinant VEZF1 to the HBB HS3GT or HBB HS2 sequences (Figure 5.17, compare lane 
5 in each panel). All of the GT sequences form strong complexes with nuclear proteins. 
These are of a mobility expected for full length VEZF1, but supershift analyses show that 
while VEZF1 is present in these complexes, other factors probably make up the majority 
of the complexes (Figure 5.17, compare lanes 1 and 2 in each panel).  
Taken together, the competition and direct EMSA analyses demonstrate that unlike 
homopolymeric G string sequences, VEZF1 does not efficiently recognise isolated 
GGGGTGGGG motifs in vitro. A previous direct EMSA study in our research group found 
that VEZF1 strongly interacts with the GT motif sequence GMCSF +30B under the same 
experimental conditions for direct EMSA shown here (Adam West, unpublished 
observations). The GMCSF +30B sequence does include a homopolymeric 8(dG.dC) string 
with a further short G string one base away (Table 5.3). Mutagenesis experiments would 
be required to determine whether VEZF1 is interacting with the GT motif in GMCSF +30B 
or the separated G strings. 
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Figure 5.17 VEZF1 interactions with GT sequences found at VEZF1 ChIP peaks are variable. 
Radiograms of native PAGE analysis of 32P-labelled FLNA IRC (panel A), POLR3K pro (panel B), HBB HS3GT (panel C) and HBB HS2 (panel D) probes 
incubated with red blood cell nuclear extract (lanes 1 to 2) or in vitro translated VEZF1 (lanes 5 and 6). Retarded protein:DNA complexes of the mobility 
expected for full length VEZF1 are indicated by arrows. Faster migrating DNA complexes with truncated in vitro translations of VEZF1 are indicated by 
asterisks. Supershifted VEZF1:DNA complexes with anti-VEZF1 antibodies (supplemented in lanes 2 and 6) are indicated (SS). 50 fold excess of the non-
labelled competitor DNAs indicated above each lane were added in lanes 3 and 4. 
+ + + +
+ +
+ +
+
+
- -
----
----
- - ---
- ----
FLNA IRC
1 2 3 4 5 6
79 %
RBC NX:
VEZF1 IVT:
α-VEZF1:
WT :
mut :Cold DNA 
competitor
Proteins
Competitor score:
Free probe
+ + + +
+ +
+ +
+
+
- -
----
----
- - ---
- ----
HBB HS2
1 2 3 4 5 6
46 %
+ + + +
+ +
+ +
+
+
- -
----
----
- - ---
- ----
POLR3K pro
1 2 3 4 5 6
74 %
+ + + +
+ +
+ +
+
+
- -
- -
----
--
- - ---
- ----
HBB HS3GT
1 2 3 4 5 6
61 %
A. B. C.
SS SS SS SS
D.
171 
 
5.5.4.4 Direct EMSA analysis of VEZF1 binding to GA motif sequences 
Four GA motif sequences that had strong or moderate competition activity were analysed 
for VEZF1 binding by direct EMSA. Strong binding of recombinant VEZF1 to the TAL1 +3 
and IL3 proP was observed, however little or no VEZF1 binding was observed at the 
MeCP2 proA and TAL1 +51 sequences (Figure 5.18, compare lane 5 in each panel). All of 
the GA sequences tested form complexes with nuclear proteins. Supershift analyses show 
that VEZF1 is a major constituent of the complexes formed with the TAL1 +3 and IL3 proP 
sequences. VEZF1 accounts for approximately half of the complexes formed with MeCP2 
proA, but is a minor component of complexes formed with TAL1 +51 (Figure 5.18, 
compare lanes 1 and 2 in each panel).  
Taken together, the competition and direct EMSA analyses demonstrate that VEZF1 can 
efficiently recognise isolated GGGGAGGGG motifs in vitro. However, not all sequences 
that contain isolated GGGGAGGGG motifs are bound efficiently by VEZF1 in vitro. It is 
difficult to determine why VEZF1 has preference for one GGGGAGGGG sequence over 
another in vitro. It is possible that bases which flank the GGGGnGGGG motif discovered 
from ChIP-seq studies play a role. The high affinity TAL1 +3 and IL3 proP sequences do 
contain additional flanking G bases, unlike TAL1 +51 (Table 5.3). 
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Figure 5.18 VEZF1 interaction with GA sequences found at VEZF1 ChIP peaks is variable. 
Radiograms of native PAGE analysis of 32P-labelled TAL1 +3 (panel A), IL3 proB (panel B), MECP2 proA (panel C) and TAL1 +51 (panel D) probes 
incubated with red blood cell nuclear extract (lanes 1 to 2) or in vitro translated VEZF1 (lanes 5 and 6). Retarded protein:DNA complexes of the mobility 
expected for full length VEZF1 are indicated by arrows. Faster migrating DNA complexes with truncated in vitro translations of VEZF1 are indicated by 
asterisks. Supershifted VEZF1:DNA complexes with anti-VEZF1 antibodies (supplemented in lanes 2 and 6) are indicated (SS). 50 fold excess of the non-
labelled competitor DNAs indicated above each lane were added in lanes 3 and 4. 
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5.6 Integration of EMSA and ChIP-seq data 
The EMSA experiments described in this chapter were designed using VEZF1 ChIP-chip 
data from a previous study. The ~400 bp size of ChIP-chip peaks may result in the 
selection of sequence motifs for EMSA analysis that are not actually bound by VEZF1 in 
vivo. ChIP-seq analysis now provides data that can map in vivo sites of VEZF1 binding at 
higher resolution than ChIP-chip. It is expected that for most VEZF1 binding events, the 
distribution of ChIP-seq reads will follow a Gaussian distribution around a binding event, 
where the summit of a given peak of enriched reads would closely indicate the site of 
VEZF1 binding. Working on this assumption, the distance between each putative VEZF1 
binding motif studied relative to the nearest VEZF1 ChIP-seq peak summit was calculated 
(Table 5.4). 
This review shows that the majority of the sequences selected for EMSA analyses map 
directly to VEZF1 ChIP-seq peaks, apparently confirming that the putative VEZF1 binding 
DNA motifs identified from analysis of ChIP-chip data were indeed bound by VEZF1.  The 
EDN1 proA sequence does not overlap a ChIP-seq peak in K562 cells as VEZF1 binding to 
this site is specific to vascular cell types (Strogantsev, 2009). Likewise, VEZF1 binding at 
the three IL3 sequences studied is specific to lymphoid cell types. 11 of the 39 elements 
selected for EMSA analysis are located more than 100 bp from the nearest VEZF1 ChIP-
seq peak summit and are unlikely to represent the true in vivo targets of VEZF1 at these 
elements. These include the G string element STAG2 proA and the multiple GC elements 
EHD1 16A and BRWD1 pro (Figure 5.19). Each of these elements had lower affinity for 
recombinant VEZF1 than expected from their sequences. 
Some of the putative VEZF1 binding sequences studied in EMSA analyses derive from well 
characterised gene enhancer elements. Included among these are the TAL1 erythroid 
enhancer element TAL1 +51, and the β-globin LCR enhancer elements HBB HS2 and HBB 
HS3. Close inspection of the genomic location of these sequence elements show that they 
are located at the centre of the VEZF1 ChIP-seq peaks identified at these loci (Figure 
5.20). The inability of VEZF1 to interact with these elements when isolated in vitro suggest 
that VEZF1 may require cooperative interactions with co-binding factors when interacting 
with these enhancer elements in vivo. This is consistent with a previous ChIP analysis 
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which showed that VEZF1 binding at these enhancers was restricted to erythroid cell 
types (Strogantsev, 2009).  
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VEZF1 site Sequence 
Distance 
to peak  
Competition 
EMSA 
Direct 
EMSA 
G string 
 
   
EDN1 proA CCCCTATTAGAGTGGGGGTAAACAGCTC No peak strong strong 
TAL1pro1bA GGGGGGGGCGGTGGGGGGGCATTTTCCG 0 bp strong strong 
HMGN1 proA GGCGCCCGGGGGGGGGGGGGGGGCCCCG 57 bp strong strong 
STAG2 proA GCCACCCATGGGGGGGGGGGGTCTCCGG 308 bp strong moderate 
GC 
 
   
EHD1 16A GGGGTAATGGGGGGCGGGGCGGGGGGC 578 bp strong weak 
DNMT3B proB GGGGAACGGGGGGGCGGGGACGAGGGA 80 bp moderate strong 
HBA p380 GTGCCAGGCCGGGGCGGGGGTGCGGGC 181 bp weak - 
FLNA int GGGGTGGGATGGGGCGGGGCCATCCAG 160 bp weak weak 
TAL1pro1bB GGCGGCAGCCGGGGCGGGGGCGTCCGT 0 bp weak - 
FLNA IRA TGCCGAGGCGGGGGCGGGGCGTGGAGG 0 bp weak - 
MECP2 proB CCCTTGCCGGGGGGCGGGGGTCAGGGG 270 bp weak - 
BRWD1 pro CGGCGCGGGGGGGGCGGGGGGCGGGGG 402 bp very weak - 
HBA p40 TTATGCTTGGGGCGCGGGGGCACGCCG 121 bp negative - 
HBA p177 GGGTGCACGCGGGGCGGGGGCCAGGAC 0 bp negative - 
GT 
 
   
GMCSF +30B GTGGGTGGGGGGGGTGGGGAAAGGGGT 48 bp strong - 
RFX pro AAGTGGAGCGGGGGTGGGGCGGGGTAG 70 bp strong - 
GMCSF +30A CCTGCCTCTAGGGGTGGGGTAGGTGAG 10 bp strong - 
FLNA IRC GGCTCCCGGGGGGGTGGGTGGTGGCGC 41 bp moderate weak 
POLR3K pro CGCGCCGGGGGGGGTGGGGCGGCTGCG 24 bp moderate weak 
HBB HS3GT CAGGGAGGGTGGGGTGGGGTCAGGGCT 30 bp moderate negative 
CKMT C AAGGCCGGGGGCGGTGGGGGAGTGGCT 63 bp weak - 
HBB HS2 CCAGAAGGCGGGGGTGGGGCACTGACC 0 bp weak negative 
CKMT A TGCGCCAGGAGGGGTGGGGCTGGAGTC 435 bp weak - 
GA 
 
   
TAL1 +3 AGGCGGGTGGGGGGAGGAGGGGGTA 80 bp strong moderate 
IL3 proP GGCAAGGCGGGGGGAGGTGGTGGTG No peak strong strong 
HBA HS14 GGGGCCGGGGGCGGAGGGGGCCAGA 364 bp strong - 
IL3 proD CTGGGAGCTGGGGGAGGGGCTGGCC No peak strong - 
MECP2 proA GGGGAGGACGGGGGAGGGGGGAGGT 15 bp moderate weak 
GMPPA GGGGCCGGGGGCGGAGGGGGCCAGA 298 bp moderate - 
TAL1 +51 CCCAGGGCCTGGGGAGGGGGAGCCT 0 bp moderate negative 
DNMT3B proA GGGAGTGGGTGGGGAGGGGGCGGTG 0 bp moderate - 
TAL1 +20 CTGGTCCAAAGGGGAGGGGAGGAGT 30 bp moderate - 
IL3 -37 TGATTTTGTGGGGGAGGTTGTTTGA No peak weak - 
HBZ pro GGTCAGGTGAGGGGAGGGGGCTGCA 34 bp weak - 
HBA HS40 TCCTGTGGGGGTGGAGGTGGGACAA 10 bp very weak - 
HBB pro TCCCAGGAGCAGGGAGGGCAGGAGC No peak negative - 
GnnG 
 
   
CKMT B GGAGTGGCTGGGGCTGGGGGCGGTATCGG 85 bp weak - 
HBG pro AGATAGTGTGGGGAAGGGGCCCCCAAGAG No peak very weak - 
FLNA IRB CGCGTCTGGGGGGTCGTGGGGAAGCAGGG 255 bp very weak - 
 
Table 5.4 The distance of putative VEZF1 binding motif to the nearest ChIP-seq peak.  
The VEZF1 binding motifs studied by EMSA analyses are shown.  The distance of each 
sequence motif from the nearest VEZF1 ChIP-seq peak summit in K562 cells is shown 
alongside the scoring of the relative binding to recombinant VEZF1 in EMSA assays.  
Distances of >100 bp to the nearest VEZF1 ChIP-seq peak summit and negative direct 
EMSA scores are shown in blue. 
 
 
 
176 
 
Figure 5.19  Some EMSA sequences do not locate to VEZF1 ChIP-seq peak summits. 
UCSC Genome browser views of VEZF1 ChIP-seq profiles from K562 cells at the (A) STAG2 
(B) EHD1 and (C) BRWD1 loci. ChIP-seq peaks and summits identified by MACS and 
PeakSplitter analysis (section 3.6) are shown in black below the ChIP-seq track. UCSC 
annotated genes are shown in blue and the direction of transcription is indicated by 
arrows (bottom track). The location of 40 bp sequences selected for EMSA analyses are 
indicated above the ChIP-seq track in red. Genomic locations (hg19) are indicated. 
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Figure 5.20  Enhancer-associated VEZF1 binding motifs locate to VEZF1 ChIP-seq peaks.  
UCSC Genome browser views of VEZF1 ChIP-seq profiles from K562 cells at the TAL1 +51 
enhancer (A) and HBB HS2 and HS3 enhancers (B). ChIP-seq peaks and summits identified 
by MACS and PeakSplitter analysis (section 3.6) are shown in black below the ChIP-seq 
track. UCSC annotated genes are shown in blue and the direction of transcription is 
indicated by arrows (bottom track). The location of 40 bp sequences selected for EMSA 
analyses are indicated above the ChIP-seq track in red. Genomic locations (hg19) are 
indicated. 
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5.7 Discussion  
The aims of this chapter were to use VEZF1 ChIP-seq data to define a VEZF1 consensus 
binding motif or motifs, to analyse the relative DNA binding affinity of VEZF1 for putative 
VEZF1-binding motifs in vitro, and to develop a model of DNA binding affinity and its 
relationship to gene regulatory mechanisms.  A small number of VEZF1 binding sites have 
been identified and characterised in the published literature, these DNA motifs are 
consistently G-rich.  A minimum stretch of seven contiguous dG.dC bases is required for 
VEZF1 binding to the chicken βA promoter (Clark et al., 1990).  Consistent with this, 
putative VEZF1 consensus binding sites generated by prediction tools consist of 
homopolymeric runs of eight dG.dC bases (Figure 5.1).  Most validated VEZF1 binding 
sites however lack this homopolymeric run of dG bases and consist of G-rich motifs 
interspersed with A, C or T bases (table 5.1).  It is apparent therefore that while VEZF1 
clearly interacts with G-rich DNA elements, no clear consensus binding motif can be 
identified from this small collection of DNA binding sites.    
It was discovered that the performance of different motif discovery tools can be greatly 
variable.  Initial motif discovery performed by MEME using VEZF1 ChIP-seq data 
discovered G-rich motifs as being most highly represented as expected, however these 
motifs were very long in length and the majority of G residues within them were poorly 
conserved.  This unexpected finding raised great concern regarding the ability of MEME to 
accurately align G-rich sequences during motif discovery.  A second motif finding tool, 
POSMO, discovered far more believable enriched DNA motifs.  POSMO consistently 
discovered DNA motifs of ~9 highly conserved bases as being enriched within VEZF1 ChIP-
seq peaks.  Outside these 9 bases no sequence conservation is apparent indicating that 
enriched putative protein-binding motifs were accurately aligned and representative 
PWMs generated.   
VEZF1 motif discovery by POSMO using the most highly enriched ChIP-seq sites found 
homopolymeric G string sequences to be the most frequently occurring motifs.  POSMO 
analysis also showed that decreasing VEZF1 enrichment correlates with binding to 
increasingly degenerate motifs which consist of two runs of four G bases separated by an 
A or C residue.  Homopolymeric 9(dG) motifs were found to be highly enriched at VEZF1-
associated promoters while a gGGGA/TGGGg motif was discovered to occur with greatest 
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frequency at VEZF1-associated enhancers.  These findings indicate that VEZF1 generally 
binds high affinity homopolymeric DNA motifs at promoters and weaker more divergent 
motifs at enhancers. 
Consistent with the results of POSMO motif discovery, VEZF1 was found to consistently 
form strong interactions with homopolymeric G string motifs in vitro by a series of 
competition and direct EMSAs.  VEZF1 interacted weakly with GC motifs and formed 
interactions of variable strength with GA and GT motifs.  It is also noteworthy that most 
of the weakest VEZF1 binding sites diverge from the GGGGNGGGG consensus motif.   
Some putative VEZF1-binding motifs, which mapped directly to VEZF1 ChIP-seq peaks, 
were unable to interact with VEZF1 when isolated in vitro, these included the erythroid-
specific enhancer elements TAL1+51, HBB HS2 and HBB HS3.  The TAL1+51-associated 
VEZF1 ChIP-seq peak ranked within the top 13 % of all 26,429 VEZF1 ChIP-seq peaks, 
while HBB HS2- and HS3-associated peaks ranked within the top 32 % and 81 % of peaks 
respectively.  The sequence motifs of these putative VEZF1-binding elements correlate 
with the enhancer-associated divergent VEZF1 motif identified by POSMO motif discovery 
(figure 5.5).  Failure of VEZF1 to interact with these motifs in vitro may indicate that 
additional co-binding factors are required for VEZF1 binding to these sites in vivo.  Such 
co-factors may include components of the TEC complex, which were found to interact 
with VEZF1-enriched erythroid-specific enhancer elements in chapter 4 (section 4.4.2). 
The HBB HS2 and HS3 elements are components of the human β-globin locus control 
region (LCR), which regulates the erythroid and developmental-specific expression of the 
human β-globin genes.  The functional core of HS2 has been mapped to a 375 bp 
fragment which contains a number of protein binding sites (Reddy and Shen, 1991).  The 
putative VEZF1 binding GT motif that we have identified within the HS2 element is 
footprinted in vivo in K562 cells (Ikuta and Kan, 1991), however deletion of this element 
has been reported to have little effect on HS2 enhancer function (Sorrentino et al., 1990).  
The functional core of HS3 maps to a 225 bp region which contains six footprinted 
elements in erythroid cells (Philipsen et al., 1990, Strauss and Orkin, 1992).  The putative 
VEZF1-binding GT motif that we have identified within the HS3 element is located within 
footprint II.  Mutational analyses of HS3 in the murine erythroleukemia cell line Hu11, 
which contains a portion of the human chromosome 11 that includes the human β-globin 
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locus, have shown the putative VEZF1-binding motif to be essential for HS3 activity 
(Philipsen et al., 1993).  Two consensus GATA motifs, which are located within footprint I 
and footprint III and flank the putative VEZF1 site, are also essential for HS3 activity 
(Philipsen et al., 1993).  These GATA sites are located at a distance of 19 bp 5’ and 17 bp 
3’ of the VEZF1 site.  These findings support the hypothesis that co-binding of erythroid-
specific factors may mediate VEZF1 binding to erythroid-specific sites. 
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Chapter 6 
The relationship between VEZF1, promoter DNA methylation and 
transcription of the chicken β-globin genes 
6.1 Introduction 
VEZF1 has previously been reported to interact with gene regulatory elements at the 
chicken β-globin locus. VEZF1 is the factor originally identified as Beta Globin Protein 1 
(BGP1), which binds to a long homopolymeric G-string upstream of the βA gene promoter 
in vitro (Lewis et al., 1988, Dickson et al., 2010).  VEZF1 has also been shown to bind to 
three G-string sequences within the HS4 insulator element in vitro and in vivo (Dickson et 
al., 2010).  The binding of VEZF1 at gene regulatory elements across the chicken β-globin 
locus in primary chick erythrocytes was previously profiled by ChIP-qPCR (Figure 6.1, 
Ruslan Strogantsev, unpublished data). This analysis was performed in circulating 
nucleated erythrocytes from 5 day old embryos, which are reported to express the 
embryonic β-globin genes ρ and ε, and 10 day embryos, which are reported to express 
the βA gene. It was found that VEZF1 interacts with the HS4 insulator in both 5 and 10 day 
erythrocytes. Interestingly, VEZF1 was found to interact with the β-globin gene promoters 
in a stage-specific manner. VEZF1 binding is observed at the ρ and ε promoters only in 5 
day erythrocytes, the stage at which they are expressed. Conversely, VEZF1 interacts with 
the βA promoter only when it is expressed in 10 day erythrocytes. VEZF1 is also found to 
interact with the HS2 and βA/ε enhancer elements at both stages. These results show that 
VEZF1 binding to gene regulatory elements can be regulated during development and 
that binding to gene promoters correlates with their expression.  
 
VEZF1 binding to each of the three sites in the HS4 element is essential for the barrier 
activity of this insulator. Deletion of any one VEZF1 binding site from HS4 results in an 
accumulation of DNA methylation and silencing of a transgene flanked by mutant 
insulators (Dickson et al., 2010).  Further support of a role for VEZF1 as a regulator of DNA 
methylation is provided by evidence that VEZF1 binding sites in the hamster APRT gene 
promoter are sufficient to protect this CpG island from de novo DNA methylation or to 
direct demethylation of a pre-methylated APRT CGI upon integration into the genome of 
mouse ES cells (Dickson et al., 2010). Given the apparent relationship between VEZF1 
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binding and protection against DNA methylation, it is of interest to investigate whether 
the DNA methylation status of the ρ and βA promoters changes during erythroid 
development and how this correlates with VEZF1 binding and gene expression. 
 
Figure 6.1 VEZF1 interactions at the β-globin locus during chick erythroid development. 
(A) Schematic of the chicken globin gene locus.  ChIP-qPCR analysis of VEZF1 interactions 
(red) with DNA elements across the chicken β-globin gene cluster and surrounding loci in 
(B) 5 day chicken embryonic erythrocytes or (C) 10 day chicken embryonic erythrocytes.  
IgG ChIP-qPCR is included as a negative control for non-specific immunoprecipitation of 
DNA sequences (blue).  Error bars reflect standard deviation between triplicate technical 
replicates (Dr Ruslan Strogantsev, unpublished data).  
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The studies in this chapter aim to address the following: 
1) Determine the expression of VEZF1 and the β-globin genes in circulating 
erythrocytes during chicken embryonic development 
2) Profile the genomic binding of VEZF1 in circulating chicken embryonic 
erythrocytes during chicken embryonic development 
3) Identify the specific DNA motifs bound by VEZF1 at β-globin gene regulatory 
elements 
4) Examine the affinity of VEZF1 for putative binding sequences found at β-globin 
gene promoters. 
5) Study the relationship between VEZF1 binding, promoter DNA methylation and 
transcription of the ρ and βA genes. 
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6.2 The expression of VEZF1 and the β-globin genes in circulating 
erythrocytes during chicken embryonic development 
In order to understand the regulation of VEZF1 binding and DNA methylation of the β-
globin genes, the expression of VEZF1 and each of the β-globin genes needed to profiled 
in our erythrocyte preparations. Circulating erythrocytes were isolated from chick 
embryos that had been incubated for between 5 and 10 days post fertilisation. The mRNA 
levels of ρ, ε, βH and βA globin were determined at different stages of erythrocyte 
development (Figure 6.2). The “embryonic” β-globin genes ρ and ε are reported to be 
highly expressed at day 5 and progressively repressed throughout the process of 
embryonic development (Bruns and Ingram, 1973, Sheng, 2010).  The expression of these 
genes in our erythrocyte preparations correlate with this pattern.  ρ globin expression at 
day 5 is 204-fold greater than β-actin (ACTB) and increases to a peak of 897-fold above 
ACTB at day 6.  ρ globin expression progressively silences during later stages of erythroid 
development, falling to 34-fold expression above ACTB at day 10.  ε globin expression 
followed a very similar pattern.  ε globin mRNA levels were 532-fold above ACTB at day 5 
with expression peaking at 1136-fold at day 6.  ε globin also progressively silences during 
later stages of erythroid development, falling to 43-fold expression above ACTB at day 10. 
Conversely, the expression of the “adult” β-globin genes βH and βA are reported to be 
unexpressed in chick embryos at day 5 post-fertilisation.  Expression of the βA gene 
increases progressively throughout the course of embryonic development until it is 
strongly expressed at day 10.  Expression of the βH gene also occurs throughout chick 
embryonic development but reaches only very low expression levels in 10 day 
erythrocytes (Bruns and Ingram, 1973, Sheng, 2010).  The expression of these genes in 
our erythrocyte preparations correlate with this pattern (Figure 6.2). The expression of βA 
globin in erythrocytes increased from only 0.9-fold relative to ACTB in 5 day erythrocytes 
to a peak of 1043-fold above ACTB in 10 day erythrocytes. βH globin expression levels 
followed a similar pattern, but at a much lower level than βA, rising from 0.06-fold relative 
to ACTB at day 5 to 17.5-fold at day 10.  
These gene expression analyses confirm that the developmentally regulated switching of 
β-globin gene expression in our embryonic erythrocyte preparations matches those 
previously reported (Bruns and Ingram, 1973, Sheng, 2010). 
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Figure 6.2 β-globin gene expression in embryonic chicken erythrocytes.   
Quantitative RT-PCR analysis of β-globin mRNA levels in erythrocytes isolated from 
chicken embryos between day 5 and 10 post fertilisation. β-globin mRNA levels were 
normalised to those of ACTB in each preparation.  Error bars represent standard deviation 
between three technical PCR replicates. The expression profile is representative of 
erythrocyte preparations from three independent clutches. 
Embryonic stage-specific binding of VEZF1 was previously observed at the β-globin 
promoters but not at the HS4 insulator, so it is important to understand whether the 
expression of VEZF1 changes during the period of embryogenesis studied. RT-PCR analysis 
shows that VEZF1 mRNA levels are relatively unchanged in circulating erythrocytes 
between 5 and 10 days post fertilisation (Figure 6.3). 
 
Figure 6.3 VEZF1 gene expression in embryonic chicken erythrocytes.     
Quantitative RT-PCR analysis of VEZF1 mRNA levels in erythrocytes isolated from chicken 
embryos between day 5 and 10 post fertilisation. VEZF1 levels were normalised to those 
of ACTB in each preparation.  Error bars represent standard deviation between three 
technical PCR replicates.  
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6.3 The genomic binding of VEZF1 in circulating chicken 
embryonic erythrocytes during chicken embryonic 
development 
It is important to determine the exact sequences bound by VEZF1 in vivo during 
development in order to gain a clear understanding of how VEZF1 binding may be 
regulated. VEZF1 may interact with divergent low affinity sequences at stage-specific sites 
and therefore rely on cooperative interactions with co-binding transcription factors. 
Alternatively, VEZF1 binding sequences may be selectively masked by stage-specific 
nucleosome positioning, for example. ChIP-seq analysis should define VEZF1 binding 
events more accurately than the ChIP-QPCR method we have previously employed. This 
analysis would also allow the identification of stage-specific binding events at other gene 
loci, such as the α-globin gene cluster. 
6.3.1 Preparation of crosslinked chromatin from embryonic erythrocytes 
1x108 circulating embryonic erythrocytes were collected from 5 and 10 day embryos and 
formaldehyde crosslinked chromatin was prepared using previously optimised conditions 
(2.5). Sonication of chromatin purified from 5 day erythrocytes yielded fragments with an 
average size of ~400 – 700 bp, while sonication of chromatin from 10 day erythrocytes 
yielded fragments with an average size of ~300 – 600 bp (Figure 6.4). Fragmented 
chromatin from 5x106 5 and 10 day erythrocytes was used per ChIP. VEZF1 ChIPs from 
both preparations were performed in duplicate and pooled. 
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Figure 6.4 Sonication of chick erythrocyte chromatin.   
Agarose gel electrophoresis of 5 and 10 day embryonic chick erythrocyte chromatin after 
sonication for use in ChIP. 
6.3.2 Validation of VEZF1 ChIP performance and library preparations 
The enrichment of previously identified VEZF1 binding targets following VEZF1 ChIP was 
validated using QPCR analysis. The HS4 insulator element was found to be bound by 
VEZF1 in both 5 and 10 day erythrocytes (Figure 6.5). VEZF1 was also bound at the ρ-
globin promoter in 5 day erythrocytes, but not at the βA-globin promoter. Conversely, 
VEZF1 was bound at the βA-globin promoter in 10 day erythrocytes, but not at the ρ-
globin promoter. These results are consistent with previous findings in the West 
laboratory (Figure 6.1). No VEZF1 binding was observed within the condensed chromatin 
region upstream of the β-globin gene locus. These analyses show that genomic elements 
bound by VEZF1 in erythrocytes were isolated efficiently by VEZF1 ChIP and that stage-
specific binding patterns were still being identified. One third of each ChIP DNA pool was 
used in ChIP-seq library preparation. 
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Figure 6.5 Validation of VEZF1 ChIP from embryonic erythrocytes.   
QPCR analysis of β-globin gene locus sequences following VEZF1 ChIP in (A) 5 day and (B) 
10 day embryonic erythrocytes.  Primer sets targeting the condensed chromatin 5’ of HS4, 
the HS4 insulator, the ρ promoter and the βA promoter were used for the analysis. The 
relative enrichment of each element after VEZF1 ChIP was normalised to that of starting 
input chromatin.  Error bars represent standard deviation between triplicate QPCR 
analyses of a VEZF1 ChIP. 
VEZF1 ChIP-seq libraries were validated for the enrichment of previously identified VEZF1 
binding targets using QPCR analysis. This analysis confirmed that HS4 insulator sequences 
remain highly enriched in the VEZF1 ChIP-seq libraries from 5 and 10 day erythrocytes 
(Figure 6.6). The ρ-globin promoter also remains highly enriched in the 5 day erythrocyte 
library, but the enrichment of βA promoter sequences appear to be lost following library 
preparation from 10 day erythrocytes. The apparent alteration in relative enrichments 
may be due to issues relating to sequence representation or PCR bias during library 
preparation. However, it may simply be due to the location of the QPCR primer set 
relative to the true VEZF1 binding event(s) at the βA promoter. The initial QPCR on the 
VEZF1 ChIP has a full range of sonicated chromatin fragment sizes to detect from, 
whereas the ChIP-seq libraries are size selected, so QPCR primer sets need to overlap the 
VEZF1 binding peak quite accurately. Given that we are unsure of the true VEZF1 binding 
event(s) at the βA promoter and that the enrichments of the HS4 insulator remain 
consistently high, we decided to proceed with sequencing of both the VEZF1 ChIP-seq 
libraries from 5 and 10 day erythrocytes. 
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Figure 6.6 Validation of VEZF1 ChIP-seq library preparations.   
QPCR analysis of β-globin gene locus sequences following VEZF1 ChIP in (A) 5 day and (B) 
10 day embryonic erythrocytes.  Primer sets targeting the condensed chromatin 5’ of HS4, 
the HS4 insulator, the ρ promoter and the βA promoter were used for the analysis. The 
relative enrichment of each element after VEZF1 ChIP-seq library preparation was 
normalised to that of starting input chromatin.  Error bars represent standard deviation 
between triplicate QPCR analyses of a VEZF1 ChIP. 
The VEZF1 ChIP-seq libraries from 5 and 10 day embryonic erythrocytes were given to the 
University of Glasgow Polyomics Facility for sequencing on an Illumina GAIIx sequencer.  
The concentration of correctly adapted fragments in each ChIP-seq library was quantified 
using the SYBR QPCR KAPA library Quantification Kit from Illumina (KK4822) by the 
University of Glasgow Polyomics Facility (Table 6.1).  An aliquot of each library was used 
to prepare a 20 µl solution at 1.5 nM for denaturation (Table 6.1).  Denatured library 
samples were further diluted to 12 pM concentrations for loading on the flow cell. 
Sample Concentration Volume for 20 µl at 1.5nM 
5 day:VEZF1 6.93 nM 4.3 µl 
10 day:VEZF1 6.78 nM 4.4 µl 
Table 6.1 ChIP-seq library quantifications.  
The concentration of ChIP-seq libraries were quantified by QPCR and used to calculate the 
volume of each library required to prepare a 20 µl sample at 1.5 nM for denaturation. 
 
6.3.3 Chicken VEZF1 ChIP-seq data quality 
The performance of the Illumina sequencing was assessed using FastQC.  Both of the 
VEZF1 ChIP-seq runs yielded around 47 million reads, with high average qualities and no 
adaptor sequence contamination (Table 6.2) 
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Sample Read length Read number Mean Q score Adaptor sequence 
5 day:VEZF1 73 46,891,117 39 No significant level 
10 day:VEZF1 76 47,534,861 39 No significant level 
Table 6.2 Illumina GAIIx sequencing performance.  
Data extracted from FastQC reports from 2 ChIP-seq runs. 
The box-and-whisker plots of phred quality scores throughout each sequencing run show 
that the median sequence quality remains within the very good range throughout the 
length of both sequence runs (Q scores of 28 – 40) (Figure 6.7). However, the base calls of 
sequences in the 10th and 90th percentiles have poor Q scores after ~64 bases. These 
results indicate that very good performance levels have been achieved in these 
sequencing runs, although a proportion of full length reads may not align to the chicken 
reference genome due to lower Q scores at the 3’ ends of some reads. 
191 
 
Figure 6.7 Illumina GAIIx sequencing per base quality. 
FastQC report of Q score per base call for 5 day and 10 day VEZF1 ChIP-seq runs. 
Horizontal red lines show the median Q score for each base position and the connected 
blue line indicates the average quality score. Yellow boxes represent the 20th-80th quartile 
range, while black whiskers represent the 10th and 90th percentiles.  The background of 
these plots are divided into three sections where green, orange and red shading indicate  
Q score ranges considered to be of very good, reasonable or poor quality, respectively. 
Full length ChIP seq reads were aligned to the galGal4 chicken reference genome by the 
Bowtie software package using the “-m3” command to allow for alignment to the 
duplicated globin genes.  71% and 74% of VEZF1 ChIP-seq reads from the 5 and 10 day 
preparations were successfully aligned to the chicken reference genome (Table 6.3). 
Unfortunately, 80 % of VEZF1:5 day aligned reads and 84% of 10 day aligned reads were 
removed as they were not unique, leaving 6,438,091 unique aligned reads from 5 day 
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VEZF1 ChIP-seq and 5,725,147 unique aligned reads from 10 day VEZF1 ChIP-seq.  The 
apparent high clonality in these libraries is likely to be due to too low an amount of VEZF1 
ChIP DNA entering the library preparation. We will seek to sonicate chromatin to a lower 
average fragment size in future to increase the concentration of fragments that fall within 
the Illumina library size selection. 
Sample Total reads Aligned reads 
(Reported) 
Failed to 
align 
Removed   
(PCR filter) 
Unique 
aligned 
5 
day:VEZF1 
46,891,117 33,355,819 
(71.13%) 
13,535,298 
(28.87%) 
26,917,728 
(80.1%) 
6,438,091 
10 
day:VEZF1 
47,534,861 35,144,419 
(73.93%) 
12,390,442 
(26.07%) 
29,419,272 
(83.7%) 
5,725,147 
Table 6.3 Performance of Bowtie ChIP-seq read alignment 
Peaks of VEZF1 ChIP-seq read enrichment were identified using MACS (see section 3.6 for 
a description). We did not have an input or non-immune IgG ChIP-seq reference dataset 
for 5 or 10 day erythrocytes at this stage, so we asked MACS to calculate peaks from the 
background signal in the VEZF1 ChIP-seq datasets. This approach can result in false 
positive and false negative peak calling, but it allows us to make a start in understanding 
VEZF1 binding events.  Initial MACS peak finding was performed on reads that were 
aligned to defined chromosomes only (~4.5% of reads removed) using default settings.  
Using these parameters 4,878 and 5,879 VEZF1 peaks were identified in the 5 and 10 day 
ChIP-seq samples respectively.  PeakSplitter was used to resolve clustered peaks to yield a 
total of 5,398 and 6,131 peaks for VEZF1 in 5 and 10 day erythrocytes, respectively. 
Further peak finding is planned once non-immune IgG ChIP-seq data are available for use 
in creating a more representative MACS background model. 
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6.4 Identification of specific DNA elements bound by VEZF1 at  
β-globin gene regulatory elements 
The enrichment of VEZF1 ChIP-seq reads across the β-globin gene cluster was compared 
between 5 and 10 day erythrocytes. Consistent with previous ChIP-QPCR analyses, VEZF1 
enrichments are observed at the HS4 insulator at both embryonic stages (Figure 6.8). 
Striking enrichments of VEZF1 are also observed at the both the ρ and ε embryonic globin 
gene promoters in 5 day embryonic erythrocytes. Little or no VEZF1 biding is observed at 
these elements in 10 day embryonic erythrocytes. This profile is consistent with VEZF1 
binding to the embryonic globin gene promoters specifically when they are 
transcriptionally active (Figure 6.2). The specific binding of VEZF1 to the ρ-globin 
promoter is consistent with previous ChIP-QPCR analyses (Figures 6.1 and 6.5), but the 
discovery of strong VEZF1 binding at the ε-globin promoter is novel. A minor enrichment 
of VEZF1 at the ε-globin promoter has been observed by ChIP-QPCR previously (Figure 
6.1), but close inspection using the UCSC genome browser shows that the QPCR primer 
set is located 270 bp away from the VEZF1 peak centre. 
VEZF1 enrichment is also observed at the βA globin promoter in 10 day embryonic 
erythrocytes, but not in 5 day embryonic erythrocytes (Figure 6.8). The specific binding of 
VEZF1 to the βA globin promoter is consistent with previous ChIP-QPCR analyses (Figures 
6.1 and 6.5). Again, this profile is consistent with VEZF1 binding to the βA gene promoter 
specifically when it is transcriptionally active (Figure 6.2). VEZF1 binding is also observed 
at βA/ε and HS2, the predominant enhancers of the β-globin locus (Figure 6.8).   
Comparison of the VEZF1 binding peaks, identified by MACS, with the ChIP-seq tracks on 
the UCSC genome browser shows that MACS has identified the majority of the observed 
peaks of VEZF1 ChIP-seq read enrichment (Figure 6.8). However, the width of the peaks 
has not been defined accurately and the binding of VEZF1 to HS2 in 5 day erythrocytes 
and to the βA/ε enhancer in 10 day erythrocytes has not been identified. These problems 
are likely to be due to the background model being created from the VEZF1 ChIP-seq 
tracks rather than a negative control. Once non-immune IgG ChIP-seq samples have been 
sequenced, the MACS analysis will be re-run. Further analyses of peak numbers, locations 
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and underlying sequence motifs will then be feasible. 
 
Figure 6.8 The interaction of VEZF1 with β-globin gene regulatory elements is 
developmentally regulated. 
UCSC genome browser view of VEZF1 ChIP-seq data from 5 and day 10 erythrocytes 
mapped to the β-globin gene cluster (gg4, chr1: 193,703,000-193,733,000). Peaks of ChIP-
seq read enrichment identified by MACS are shown below each track. ChIP-seq read 
numbers are normalised to total library size. A scale schematic of the chicken β-globin 
locus annotated to indicate the position of known gene regulatory elements.  A gg4 
assembly error that creates a 690 bp duplication at chr1:193711749-193712439 has been 
removed from this view. 
6.4.1 VEZF1 binding elements at the HS4 insulator element 
VEZF1 binding at the HS4 insulator has previously been mapped to three DNaseI 
footprinted sequences FI, FIII and FV by EMSA analyses (Dickson et al., 2010). We 
therefore compared the VEZF1 ChIP-seq profile in 5 and 10 day erythrocytes to these 
sequences to test the validity of using ChIP-seq to pinpoint VEZF1 binding elements in 
vivo. The maximal VEZF1 ChIP-seq read enrichment at HS4 aligns to footprints FI and FIII, 
with a lesser enrichment at FV (Figure 6.9). This profile is entirely consistent with the 
known affinity of VEZF1 to each of these sequence elements. I was therefore confident to 
use this approach to pinpoint the in vivo targets of VEZF1 binding to other gene 
regulatory elements at the β-globin gene cluster. 
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Figure 6.9 The interaction of VEZF1 with the HS4 insulator element. 
UCSC genome browser view of VEZF1 ChIP-seq data from 5 and day 10 erythrocytes 
mapped to the HS4 insulator element (gg4, chr1:193,704,573-193,705,164). ChIP-seq 
read numbers are normalised to total library size. A scale schematic of the 276 bp core 
HS4 insulator element with previously characterised footprint elements is shown.  
6.4.2 Putative VEZF1 binding elements at the embryonic ρ and ε-globin 
promoters 
ChIP-QPCR and ChIP-seq experiments have demonstrated that VEZF1 interacts with the 
promoters of the ρ and ε-globin genes specifically in 5 day embryonic erythrocytes 
(Figures 6.5 and 6.8). Previous characterisation of the ρ-globin promoter failed to identify 
discrete protein binding sites by DNaseI footprinting as the majority of the promoter was 
footprinted by erythrocyte nuclear extracts (Minie et al., 1992). Four putative VEZF1 
binding elements can be found within 300 bp of the ρ-globin transcription start site. Of 
these, it is apparent that a GGGGTGGGG motif centred 55 bp upstream of the TSS is the 
site of maximal VEZF1 ChIP-seq read enrichment in 5 day erythrocytes (Figure 6.10). It is 
notable that this VEZF1 site is 23 bp from a GATA motif. The asymmetry of the VEZF1 
peak suggests that VEZF1 may also occupy additional motifs further upstream of the TSS. 
 
Figure 6.10 The interaction of VEZF1 with the ρ-globin gene promoter. 
UCSC genome browser view of VEZF1 ChIP-seq data from 5 day erythrocytes mapped to 
the ρ-globin (annotated at HBG1) gene promoter (gg4, chr1:193,715,634-193,716,633). 
ChIP-seq read numbers are normalised to total library size. The coordinates of putative 
VEZF1 binding sites (blue) and GATA motifs (red) are shown beneath.    
The arrangement of VEZF1 and GATA motifs at the core ε-globin promoter is very similar 
to that of the ρ-globin promoter. Previous characterisation of the ε-globin promoter 
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found that a GGGGTGGGG motif centred 55 bp upstream of the TSS is footprinted by 
embryonic erythrocyte extracted proteins (Mason et al., 1996). It is apparent that this GT 
motif precisely located to the peak of maximal VEZF1 ChIP-seq read enrichment in 5 day 
erythrocytes (Figure 6.11). Again this GT motif is located 23 bp from a GATA motif, which 
is also footprinted by erythrocyte extracts (Mason et al., 1996). In contrast to the ρ-globin 
promoter, there are no other apparent VEZF1 motifs further upstream of the core GT 
motif. 
 
Figure 6.11 The interaction of VEZF1 with the ε-globin gene promoter. 
UCSC genome browser view of VEZF1 ChIP-seq data from 5 day erythrocytes mapped to 
the ε-globin (annotated at HBE) gene promoter (gg4, chr1:193,728,157-193,728,906). 
ChIP-seq read numbers are normalised to total library size. The coordinates of putative 
VEZF1 binding sites (blue) and GATA motifs (red) are shown beneath.    
6.4.3 Putative VEZF1 binding elements at the βA globin promoter 
A number of previous studies have carefully characterised the regulatory elements at the 
βA-globin promoter. One of the earliest studies identified a DNA-binding activity, termed 
Beta Globin Protein 1 (BGP1), that interacts with a long homopolymeric G string located 
186 bp upstream of the TSS (Lewis et al., 1988). Recently, BGP1 was identified to be 
VEZF1 (Dickson et al., 2010). Subsequent studies identified a number of additional 
elements that are footprinted by erythrocyte factor binding in vitro and make varying 
contributions to promoter activity in reporter assays (Emerson et al., 1985, Gallarda et al., 
1989). There are five putative VEZF1 binding elements within the sequences 200 bp 
upstream of the βA globin gene TSS. All of these elements fall within the peak of VEZF1 
ChIP-seq read enrichment in 10 day erythrocytes (Figure 6.12). The VEZF1 ChIP-seq peak 
at the βA-globin promoter is broad and likely incorporates multiple VEZF1 binding events. 
Close inspection indicates that the 17 base G-string at -186, the GGGGGAGGG motif at -
115 and the GAGGAGGGG motif at -46 lie at the three apparent sub-peaks. The GA site at 
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-46 is 18 bp from a GATA motif. Both lie within the Stage Selector Element (SSE), which is 
likely to determine stage-specific binding of VEZF1 (Choi and Engel, 1988).  
 
Figure 6.12 The interaction of VEZF1 with the βA globin gene promoter. 
UCSC genome browser view of VEZF1 ChIP-seq data from 10 day erythrocytes mapped to 
the adult β-globin (annotated at HBG2) gene promoter (gg4, chr1:193,723,622-
193,724,621). ChIP-seq read numbers are normalised to total library size. The coordinates 
of putative VEZF1 binding sites (blue), NFI (orange), CTF (green) and GATA motifs (red) are 
shown beneath. Promoter numbering is taken from (Emerson et al., 1985). Footprints F1 
to F4 are taken from (Gallarda et al., 1989). Sequences incorporating the stage selector 
element (SSE) defined by (Choi and Engel, 1988) are indicated with a horizontal red line. 
6.4.4 Putative VEZF1 binding elements at the β-globin HS2 and βA/ε 
 enhancers 
Previous studies have mapped the binding of at least five factors to the βA/ε enhancer in 
erythrocyte extracts (Emerson et al., 1987, Gallarda et al., 1989). The peak of maximal 
VEZF1 ChIP-seq read enrichment in 10 day erythrocytes maps to a GGGTGGGGG motif 
known as F3 in the βA/ε enhancer (Figure 6.13). The lack of additional sub-peaks or 
additional putative VEZF1 motifs indicates that F3 is the only VEZF1 site at this element. 
F3 is located 16 bp away from a palindromic GATA-TATC motif, which may be responsible 
for the erythroid-specific binding of VEZF1 to this element.  
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Figure 6.13 The interaction of VEZF1 with the βA/ε enhancer. 
UCSC genome browser view of VEZF1 ChIP-seq data from 10 day erythrocytes mapped to 
the βA/ε enhancer located downstream of the adult β-globin (annotated at HBG2) gene 
(gg4, chr1:193,725,790-193,726,340). ChIP-seq read numbers are normalised to total 
library size. The coordinates of putative VEZF1 binding sites (blue), NFI (orange) and GATA 
motifs (red) are shown beneath. The location of DNaseI footprints F1 to F5 are taken from 
(Emerson et al., 1987, Gallarda et al., 1989). Numbering is relative to adult β-globin TSS. 
A previous study mapped at least seven transcription factor binding events at the HS2 
enhancer in erythrocyte extracts (Abruzzo and Reitman, 1994). Two of these motifs, a 
GGTGCGGTGGG motif called F2 and a GGGCGTGGGG motif called F5, appear to overlap 
the peaks of maximal VEZF1 ChIP-seq read enrichment in 10 day erythrocytes (Figure 
6.14). However, VEZF1 appears to only interact with the F2 site in 5 day erythrocytes. 
Both the F2 and F5 GT motifs are located 24 bp from GATA binding sites. 
 
 
Figure 6.14 The interaction of VEZF1 with the HS2 β-globin enhancer. 
UCSC genome browser view of VEZF1 ChIP-seq data from 5 and 10 day erythrocytes 
mapped to the HS2 β-globin enhancer located upstream of the ρ-globin gene (gg4, 
chr1:193,710,790-193,711,550). ChIP-seq read numbers are normalised to total library 
size. The coordinates of putative VEZF1 binding sites (blue), SP1 (purple) and GATA motifs 
(red) are shown beneath. The location of DNaseI footprints F1 to F7 are taken 
from(Abruzzo and Reitman, 1994). Numbering is relative to ρ-globin TSS. 
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6.5 The affinity of VEZF1 for putative binding sequences found 
at β-globin gene promoters 
The binding of VEZF1 to the embryonic ρ- and ε-globin promoters specifically in primitive 
erythrocytes from 5 day stage embryos is novel and unexpected. In order to define the 
specificity and affinity of VEZF1 for putative sites in these promoters, sequences were 
selected for EMSA analyses of VEZF1 binding in vitro. The selection of putative VEZF1 
binding sites was performed prior to the completion of the VEZF1 ChIP-seq analysis 
described above. We had ChIP-QPCR data that revealed VEZF1 binding at the ρ-globin 
promoter in 5 day erythrocytes and we had the VEZF1 consensus motif GGGGnGGGG 
from an earlier VEZF1 ChIP-chip study (Strogantsev, 2009). Three 40 bp putative VEZF1 
binding sequences were selected for EMSA analysis. These incorporated the G8, G7 and 
GT motifs located 261, 106 and 55 bp upstream of the ρ-globin TSS (Figure 6.10) (Table 
6.4).
 
Table 6.4 Putative VEZF1 binding motifs within the ρ-globin gene promoter.   
Putative VEZF1 binding motifs are underlined, G residues associated with these motifs are 
shown in red. 
Each of the three sites were prepared as double stranded oligonucleotides that were 
radiolabelled for use in direct EMSA analyses as described previously (section 5.5). A 
series of six binding reactions were set up using each probe sequence, as before.  The first 
four reactions test whether endogenous proteins in chicken erythrocyte nuclear extract 
interact with the test sequence, whether any resulting complexes contain VEZF1 
(supershift with anti-VEZF1 antibodies) and whether they have the same DNA sequence 
specificity as reported for VEZF1 (competition with F1 and F1aaa1). The latter two 
reactions test whether recombinant VEZF1 interacts with the test sequence. The same 
concentration of DNA probes and proteins were used in each direct EMSA experiment 
below. In addition, the Rho_G7-106 site was methylated at the CpG dinucleotide 
associated with the putative VEZF1 binding motif, to examine whether methylation 
Probe Probe sequence
Rho_G8-261 GAATGCATCACGCAGAGGGGGGGGTTTGGTGCCTTCTGCA
Rho_G7-106 GGGTGGGGGTCCGTGCCGGGGGGGTCCGTCCATGGGGTGG
Rho_GT-55 TGACCCCACAGCATGGGGTGGGGAGGAGCTGTCAGCGGTG
VEZF1 consensus nnnnnnnnnnnnnnnnGGGGnGGGGnnnnnnnnnnnnnnnn
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overlapping this VEZF1 site might be responsible for regulating VEZF1 binding at the ρ-
globin promoter during development. 
Direct EMSA analysis shows that VEZF1 does interact with each of the ρ-globin elements 
in vitro, but that different relative affinities for each site can be observed (Figure 6.15). 
The Rho_G8-261 sequence is the highest affinity site for recombinant VEZF1, followed by 
Rho_G7-106 (Figure 6.15, compare lane 5 in panels B and D). Incubation with anti-VEZF1 
antibodies results in the inhibition of binding of full length VEZF1 or supershifted 
VEZF1:DNA complexes for each of these elements (Figure 6.15, compare lanes 5 and 6 in 
panels B and D). This is consistent with high affinity of VEZF1 for isolated G string 
sequences described earlier (section 5.5.4.1). Direct EMSA analysis of erythrocyte nuclear 
protein interactions with each of the G string sequences confirms the formation of 
complexes of the expected mobility for full length VEZF1, which are supershifted by anti-
VEZF1 antibodies (Figure 6.15, compare lanes 1 and 2 in panels B and D). However, the 
degree of VEZF1 binding to these elements is much lower than observed for longer G-
string elements studied in chapter 5, as shown by significant competition with the F1aaa1 
mutant VEZF1 site. CpG methylation of the Rho_G7-106 sequence has no effect of VEZF1 
binding (Figure 6.15, compare panels B and C).
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Figure 6.15 VEZF1 interactions with putative VEZF1 binding sites in the ρ-globin gene promoter.  Oligonucleotides corresponding in sequence to 
putative VEZF1 binding sites in the β-Rho promoter were radiolabelled and used as probe DNA in a series of EMSAs to determine whether a direct 
interaction between each DNA motif and VEZF1 protein can occur in vitro.  VEZF1-probe complexes are indicated by an arrow and confirmed by the 
supershift (SS) of specific bands by the addition of a VEZF1-specific antibody to binding reactions (A-D lanes 2 and 6).  Asterisks indicate non-specific 
bands.
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Direct EMSA analysis shows that VEZF1 binding to the Rho_GT-55 element in isolation is 
very weak in vitro. Complexes with recombinant VEZF1 are barely detectable (Figure 6.15, 
panel A, lanes 5 and 6). Some of the complexes formed between this site and erythrocyte 
nuclear proteins are supershifted by VEZF1 antibodies, but the contribution of VEZF1 to 
these complexes is minor (Figure 6.15, panel A, compare lanes 1 and 2). These findings 
are in agreement with my earlier results which show that VEZF1 does not efficiently 
recognise isolated GGGGTGGGG motifs in vitro (Section 5.5.4.3). 
The 40 bp ρ-globin core promoter sequence Rho_GT-55 studied by direct EMSA is 
identical to the GT-55 element found at the ε-globin promoter. Both elements are found 
at the peak of the VEZF1 ChIP-seq enrichments observed at these promoters in 5 day 
erythrocytes (Figures 6.10 and 6.11). The inability of VEZF1 to interact with these 
elements when isolated in vitro suggests that VEZF1 may require cooperative interactions 
with co-binding factors when interacting with these promoter elements in vivo. Such 
cooperativity is the likely mechanism that controls the stage-specific binding of VEZF1 to 
these elements. Both elements share identical spacing to a proximal GATA binding site. 
The two additional G7 and G8 motifs further upstream in the ρ-globin promoter are weak 
VEZF1 sites in isolation, but appear to be bound by VEZF1 in 5 day erythrocytes (Figure 
6.10). These additional weak VEZF1 sites may contribute to cooperative interactions that 
stabilise VEZF1 binding to the GT -55 element at the ρ-globin promoter. 
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6.6 The relationship between VEZF1 binding, promoter DNA 
 methylation and transcription of the ρ and βA genes 
6.6.1 Establishment of bisulphite DNA sequencing to study β-globin 
promoter methylation 
VEFZ1 binding sequences have been shown to function in the protection of CG-rich 
elements at promoters and insulators from de novo DNA methylation (Dickson et al., 
2010).  Early studies discovered that DNA methylation patterns at the β-globin genes 
change during chicken embryonic development (McGhee and Ginder, 1979). More recent 
studies show that the silencing of ρ-globin gene expression in definitive erythrocytes is 
dependent on methylation and conversely that activation of the βA globin gene at this 
same stage involves some form of DNA demethylation (Singal et al., 2002, Ramachandran 
et al., 2007). Given that we have shown that VEZF1 binding to the β-globin gene 
promoters is tightly regulated during erythrocyte development, it is of interest to study 
the relationship with DNA methylation. 
Given that circulating erythrocytes may contain a mixture of primitive and definitive 
erythrocytes expressing embryonic or adult β-globin genes, it is important to use an assay 
that allows the study of individual DNA molecules. We also wanted to use a technique 
that could study the methylation status of the bulk of CG dinucleotides in β-globin 
promoters to both reveal methylation patterns with respect to individual VEZF1 sites and 
to avoid the reliance on individual CGs as reporters for the whole promoter. We therefore 
opted to employ bisulphite DNA sequencing. Genomic DNA was prepared from 1x105 
circulating erythrocytes collected from embryos aged between 5 and 10 days post 
fertilisation. DNA was bisulphite modified and subjected to Taq polymerase PCR with 
primers that amplify a 510 bp CpG-rich portion of the ρ-globin promoter and a 257 bp 
CpG-rich portion of the adult β-globin promoter (Figure 6.16). 
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Figure 6.16 PCR amplification of β-globin promoter sequences from bisulphite modified 
erythrocyte DNA. 
Agarose gel electrophoresis of PCR products amplified from bisulphite modified 5 day 
embryonic erythrocyte DNA. 257 and 510 bp products were expected for the βA globin 
and ρ-globin promoter fragments, respectively.  No DNA template negative control 
reactions are also shown for each set of PCR primers. 
Bisulphite PCR products were gel purified and TA cloned into the pGEM-T easy vector. 
Transformed bacterial colonies were screen with blue/white selection and then subjected 
to colony PCR to check for the insertion of a PCR product of expected size (Figure 6.17). 
Plasmid DNA was prepared from colonies that passed this screening, with an aliquot 
checked for correct fragment insertion by restriction analysis (Figure 6.18). Plasmids 
containing bisulphite modified β-globin promoter fragments were subject to Sanger 
sequencing. The sequencing chromatograms were inspected to check the performance of 
sequencing over the cloned PCR products (Figure 6.19). At least 10 plasmid clones were 
sequenced for each bisulphite PCR in order to gain an average view of the DNA 
methylation status of 10 individual β-globin promoter molecules at each stage of 
development studied. 
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Figure 6.17 Colony PCR analysis of TA cloned bisulphite PCR products. 
Agarose gel electrophoresis of colony PCR products from white bacterial colonies 
transformed with TA cloning reactions. The ligation of the βA globin promoter bisulphite 
PCR product into pGEM-T easy would yield a 510 bp colony PCR product. Self ligation of 
pGEM-T easy would yield a 253 bp colony PCR product. 
 
Figure 6.18 Restriction analysis of TA cloned bisulphite PCR products. 
Agarose gel electrophoresis of Eco RI digested plasmid DNA prepared from white 
bacterial colonies transformed with TA cloning reactions. The ligation of the βA globin 
promoter bisulphite PCR product into pGEM-T easy would yield a 274 bp DNA fragment 
and a 3006 bp linear vector backbone after Eco RI digestion.  
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Figure 6.19 Sequence chromatogram of a 5 day βA promoter sequencing clone. 
Bisulphite modified DNA sequences were aligned with their corresponding genomic DNA 
sequence. Each sequence was firstly checked for the conversion of all non-CpG 
dinucleotide cytosine residues to thymine indicating complete bisulphite conversion. Fully 
converted molecules were then scored for the methylation status of CpG-associated 
cytosines, where TG reports non-methylation and CG reports methylation (Figure 6.20 A). 
The DNA methylation status of each CpG dinucleotide can then be summarised as a 
shaded box plot (Figure 6.20 B).  Box plots are ordered by the most heavily methylated 
molecules at the top to the least methylated molecules at the bottom.  Finally, an average 
percentage methylation score was calculated for each CpG based on the methylation 
status throughout all the molecules sequenced.  These scores can be presented as pie 
charts to allow quick comparisons between analyses (Figure 6.20 C).
Trace data
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Sample sequence
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A.              1 2           3                         4                 5        6                 7  8    9                     10  11        12           13                       14   15         16            17 18  
Un-Mod   GATGCCGCGTTCCCTCCCCCGGGGTGCCAAGGCTGGGGGCCCCTCCGGAGATGCAGCCAATTGCGGGGTGCCCGGGGAAGAGGAGGGGCCCGGCGGAGCGGATAAAAGTGGGGACACAGACGGCCGCTCACCAGCGTGCTATCCCCACGGGAGCAAGAGCCCAGACCTCCTCCGTACCGACAACCACACGCTACCCTCCAACCGCCGCCATG  
Clone 1  GATGTTGTGTTTTTTTTT-TGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGATGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTTGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG  
Clone 2  GATGTCGCGTTTTTTTTTTTGGGGTGTTAAGGTTGGGGGTTTTTTTGGGGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGATGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTTGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG  
Clone 3  GATGTTGTGTTTTTTTTTTTGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGATGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTTGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG  
Clone 4  GATGTTGTGTTTTTTTTT-TGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGATGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTTGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG  
Clone 5  GATGTTGTGTTTTTTTTTTTGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGATGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTTGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG  
Clone 6  GATGTTGTGTTTTTTTTTTTGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGATGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTTGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG  
Clone 7  GATGTCGCGTTTTTTTTTTTGGGGTGTTAAGGTTGGGGGTTTTT-TGGAGATGTAGTTAATTGCGGGGTGTTCGGGGAAGAGGAGGGGTTCGGCGGAGCGGATAAAAGTGGGGATATAGACGGTCGTTTATTAGCGTGTTATTTTTACGGGAGTAAGAGTTTAGATTTTTTTCGTATCGATAGTTATACGTTATTTTTTAATCGTCGTTATG  
Clone 8  GATGTTGTGTTTTTTTTTTTGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGATGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTTGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG  
Clone 9  GATGTTGTGTTTTTTTTTTTGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGATGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTTGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG  
Clone 10 GATGTCGCGTTTTTTCTTTTGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTCGGGGAAGAGGAGGGGTTTGGCGGAGCGGATAAAAGTGGGGATATAGATGGTCGTTTATTAGCGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTCGTATCGATAGTTATACGTTATTTTTTAATCGTCGTTATG  
Clone 11 GATGTTGTGTTTTTTTTTTTGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGATGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTTGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG  
Clone 12 GATGTTGTGTTTTTTTTTTTGGGGTGTTAAGGTTGGGGGCTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGATGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTTGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG  
Clone 13 GATGTCGCGTTTTTTTTTTCGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGCGGGGTGTTTGGGGAAGAGGAGGGGTTCGGTGGAGCGGATAAAAGTGGGGATATAGATGGTCGTTTATTAGCGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTCGTATCGATAGTTATACGTTATTTTTTAATCGTCGTTATG  
Clone 14 GATGTCGCGTTTTTTTTTTCGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGCGGGGCGTTCGGGGAAGAGGAGGGGTTCGGCGGAGCGGATAAAAGTGGGGATATAGACGGTCGTTTATTAGCGTGTTATTTTTACGGGAGTAAGAGTTTAGATTTTTTTCGTATCGATAGTTATACGTTATTTTTTAATCGTCGTTATG 
Clone 15 GATGTTGTGTTTTTTTTTTTGGGGTGTTAAGGTTGGGGGTTTTTTTGGAGATGTAGTTAATTGTGGGGTGTTTGGGGAAGAGGAGGGGTTTGGTGGAGTGGATAAAAGTGGGGATATAGACGGTTGTTTATTAGTGTGTTATTTTTATGGGAGTAAGAGTTTAGATTTTTTTCGTATTGATAGTTATATGTTATTTTTTAATTGTTGTTATG                             
 
Figure 6.20 Pipeline of analysis of bisulphite converted DNA sequencing samples.  
(A) Alignment of bisulphite modified βA promoter DNA sequences to their corresponding genomic sequence. Bisulphite conversion of C to T is shown in 
red text. Non-conversion of CpG-associated cytosine residues (methylated) are highlighted.  (B) Box plots summarising the non-methylation (open) or 
methylation (filled) of CpG-associated cytosines. Each row of boxes represents one sequenced clone.  (C) Pie chart presentation of percentage 
methylation scores for each CpG dinucleotide; black represents methylated cytosine, grey represents unmethylated cytosine.  The solid black horizontal 
line represents the region of the βA promoter amplified by PCR, the dashed line represents sequence outwith the PCR amplified region. PCR amplified 
CpG dinucleotides are numbered 1 – 18.  The coordinates of putative VEZF1 binding sites (blue boxes), NF1 (orange box), CTCF (green box) and GATA 
motifs (red box) are shown above.  Promoter numbering is taken from (Emerson et al., 1985).  Footprints F1 – F4 are taken from (Gallarda et al., 1989).  
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6.6.2 DNA methylation status of the ρ-globin promoter in erythrocytes 
during embryonic development 
The DNA methylation status of the ρ-globin promoter element was assessed in circulating 
erythrocytes collected from embryos 5, 5.5, 7, 8 and 10 days post fertilisation. 10 
promoter molecules were subjected to bisulphite sequencing for the 5 and 5.5 day 
samples and 15 molecules were sequenced from the 7, 8 and 10 day samples (Figure 
6.21). This analysis found that the ρ-globin promoter was entirely free from CpG 
methylation in 5 day erythrocytes. This is consistent with previous analyses that studied 
the methylation status of individual CpG dinucleotides across the ρ promoter at this time 
point (Singal et al., 1997).  At 5.5 days post-fertilisation three of the ten clones sequenced 
showed very low levels of DNA methylation however by the 7 day time point seven of the 
fifteen clones sequenced were heavily methylated.  In 8 day erythrocytes seven of the 
fifteen clones were still heavily methylated but showed higher methylation levels than 
those at embryonic day 7, i.e. there are fewer unmethylated cytosine residues within 
these clones.  By embryonic day 10, when the ρ globin gene is essentially silenced, 13 of 
the 15 sequenced clones are extensively methylated and the remaining 2 clones show 
light methylation of the ρ globin promoter, this finding is in line with previous analyses 
which studied the methylation status of CpG dinucleotides across the ρ promoter at this 
time point however these analyses found this regulatory element to be completely 
methylated 10 days after fertilisation (Singal et al., 1997) whereas our analysis found it to 
be 68 % methylated. 
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Figure 6.21 The DNA methylation status of the ρ-globin promoter is dynamic during 
chick embryogenesis.   
10 – 15 clones were sequenced for each time point.  Each box represents the cytosine 
residue of one CpG dinucleotide and each row represents one sequenced clone.  Black 
boxes denote methylated cytosine while white boxes denote unmethylated cytosine.  
CpG dinucleotides are numbered 1 – 23.  
Embryonic day 5 Embryonic day 5.5
Embryonic day 7 Embryonic day 8
Embryonic day 10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1718 19 20 21 22 23 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1718 19 20 21 22 23
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1718 19 20 21 22 23 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1718 19 20 21 22 23
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1718 19 20 21 22 23
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The average percentage methylation scores for each CpG site were calculated at each 
time point and are presented as individual pie charts in figure 6.22.  The average over all 
methylation score for each time point is also shown in this figure.  From the data 
presented in figure 6.22 it is evident that the ρ promoter is entirely unmethylated in 
circulating red blood cells at day 5 of chick embryogenesis and accumulates DNA 
methylation throughout the developmental time course studied, peaking at a level of 68 
% over all DNA methylation at the latest time point of embryonic day 10.                    
When these DNA methylation status results are considered alongside the gene expression 
and VEZF1 ChIP-seq results (figures 6.2 and 6.8 respectively) it is apparent that VEZF1 
binding at the ρ promoter correlates with active expression of this gene and a wholly 
unmethylated promoter element at embryonic day 5.  As embryogenesis progresses and 
the ρ gene is silenced, a steady increase in DNA methylation within the ρ promoter in 
erythrocytes is apparent.  This methylation reaches its peak at embryonic day 10 at which 
point VEZF1 protein is no longer associated with the ρ promoter element.  Thus the 
association of VEZF1 with the ρ promoter can be seen to correlate with active gene 
expression and an unmethylated or lightly methylated DNA state. 
It is indeterminable from this data whether the increase in DNA methylation levels seen 
across the ρ promoter results from an accumulation of CpG methylation in erythrocytes 
throughout the time course studied or whether the changes seen reflect the presence of 
two distinct cell populations, i.e. primitive and definitive.  In the case of the latter 
scenario, one population of cells which is unmethylated across the ρ promoter and is 
predominant early in embryogenesis may be outgrown over this developmental time 
course by a second population of cells which is heavily methylated across the ρ promoter.
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Figure 6.22 The DNA methylation status of the ρ-globin gene promoter is dynamic throughout chick embryogenesis.   
Solid horizontal line denotes the genomic region studied by bisulphite sequencing.  Vertical lines mark sites of CpG dinucleotides.  Pie charts represent 
individual CpG dinucleotides at indicated time points during chick embryogenesis.  Pie chart shading indicates the average DNA methylation status of 
each CpG dinucleotide; black represents methylated cytosine, grey represents unmethylated cytosine.  Average overall DNA methylation of all 
sequenced clones at each time point is shown on the right of the figure.  10 or 15 clones were sequenced per time point.  The coordinates of putative 
VEZF1 binding sites (blue boxes), GATA motifs (red boxes) and the ρ globin TSS are indicated.
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6.6.3 DNA methylation status of the βA promoter throughout chick 
embryogenesis 
The DNA methylation status of the βA-globin promoter element was assessed in 
circulating erythrocytes collected from embryos 5, 5.5, 7, 8, 9 and 10 days post 
fertilisation. 10 promoter molecules were subjected to bisulphite sequencing for the 5, 
5.5 and 9 day samples and 15 molecules were sequenced from the 7, 8 and 10 day 
samples (Figure 6.23).  This analysis found that the βA promoter was 83 % methylated in 5 
day erythrocytes.  At 5.5 day post-fertilisation all sequenced clones remained heavily 
methylated with 81 % overall methylation.  At embryonic day 7 the majority of clones 
remain heavily methylated however three of the fifteen clones sequenced showed very 
little DNA methylation.  By embryonic day 8, seven of the fifteen sequenced clones are 
lightly methylated or unmethylated.  At embryonic day 9 only two of the ten clones 
sequenced showed any DNA methylation and at embryonic day 10 only four out of fifteen 
sequenced clones were heavily methylated.  Thus the frequency of methylated clones is 
seen to decrease over this developmental time course, these findings are consistent with 
previous analyses which studied the methylation status of CpG dinucleotides across the 
βA promoter at 5, 8 and 10 days post-fertilisation by bisulphite sequencing 
(Ramachandran et al., 2007). 
213 
 
Figure 6.23 The DNA methylation status of the βA promoter is dynamic during chick 
embryogenesis.   
10 – 15 clones were sequenced for each time point.  Each box represents the cytosine 
residue of one CpG dinucleotide and each row represents one sequenced clone.  Black 
boxes denote methylated cytosine while white boxes denote unmethylated cytosine.  
CpG dinucleotides are numbered 1 – 18. 
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The average percentage methylation scores for each CpG site were calculated at each 
time point and are presented as individual pie charts in figure 6.24.  The average over all 
methylation score for each time point is also shown in this figure.  It is clear from the data 
collected that the βA promoter is heavily methylated in circulating erythrocytes at 
embryonic day 5 and that this genomic element becomes progressively less methylated 
as embryogenesis proceeds reaching just 9 % over all methylation at embryonic day 9.  At 
embryonic day 10, which was the latest time point analysed, the average level of overall 
DNA methylation across the βA promoter was 23 %. 
When these results are considered collectively with the βA gene expression data and 
VEZF1 ChIP-seq enrichment profiles at the βA promoter (figures 6.2 and 6.8 respectively) it 
is apparent that in 5 day red blood cells where the βA gene is not expressed its promoter 
is not bound by VEZF1 and is heavily methylated.  During the window of embryonic 
development investigated here the βA gene is seen to become actively expressed and 
reaches a plateau in mRNA expression at days 9 and 10 (figure 6.2).  This activation 
correlates with reduced DNA methylation across the βA promoter in circulating 
erythrocytes isolated from chick embryos (figures 6.23 and 6.24).  The observed 
activation of βA gene expression and reduction in DNA methylation levels of this gene 
promoter element can also be seen to correlate with the absence of association with 
VEZF1 protein in 5 day red blood cells and the enrichment of the βA promoter with VEZF1 
in 10 day red blood cells (figure 6.8).  
We cannot tell from this data whether the progressive reduction in DNA methylation of 
the βA gene promoter is the result of active DNA demethylation or is due to the expansion 
of a population of cells where the βA promoter is unmethylated.
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Figure 6.24 The DNA methylation status of the βA gene promoter is dynamic throughout chick embryogenesis.  Solid horizontal line denotes genomic 
region studied by bisulphite sequencing.  Dashed horizontal line represents sequence outwith the amplicon studied by bisulphite sequencing.  Vertical 
lines mark sites of CpG dinucleotides.  Pie charts represent individual CpG dinucleotides at indicated time points during chick embryogenesis.  Pie chart 
shading indicates the average DNA methylation status of each CpG dinucleotide; black represents methylated cytosine, grey represents unmethylated 
cytosine.  Average over all DNA methylation of all sequenced clones at each time point is shown on the right of the figure.  10 or 15 clones were 
sequenced per time point.  The coordinates of putative VEZF1 binding sites (blue boxes), NF1 (orange box), CTCF (green box) and GATA motifs (red box) 
are shown above.  Promoter numbering is taken from (Emerson et al., 1985).  Footprints F1 – F4 are taken from (Gallarda et al., 1989). 
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6.7 Discussion 
The aims of this chapter were to profile VEZF1 expression levels in circulating 
erythrocytes during chicken embryonic development, to identify VEZF1 binding sites at 
gene regulatory elements across the chicken β-globin locus, and to study the relationship 
between VEZF1 binding, promoter DNA methylation and transcription of the ρ and βA 
globin genes.   
VEZF1 mRNA levels were found to be relatively unchanged in circulating chick 
erythrocytes between 5 and 10 days post-fertilisation by RT-PCR (Figure 6.3).  It can 
therefore be concluded that any changes in VEZF1 enrichment at specific genomic 
elements across this timecourse do not arise due to changes in VEZF1 expression.   
ChIP-seq libraries were generated using VEZF1 ChIP DNA from chick erythrocytes 5 and 10 
days post-fertilisation, and used for NGS on the Illumina GAIIX platform.  During Bowtie 
alignment of ChIP-seq reads, it became apparent that the 5 and 10 day VEZF1 ChIP-seq 
libraries had high levels of sequence clonality, which resulted in 80 % and 84 % of reads 
respectively being discarded from each sequencing run.  This clonality is believed to have 
resulted from too little ChIP DNA being used in the library preparation.  Size selection 
during library preparation enriches for small ChIP DNA fragments in ChIP-seq libraries and 
I believe that the cross-linked chromatin isolated from erythrocytes was not sonicated to 
small enough average fragment sizes to retain a sufficient concentration of DNA 
fragments following size selection (Figure 6.4).  In light of this, chromatin samples will be 
sonicated to a lower average fragment size in the future, in order to reduce clonality and 
increase unique sequence reads and sequencing depth.  After the removal of clonal reads 
6,438,091 unique sequence reads from the 5 day VEZF1 ChIP-seq sample aligned to the 
chicken reference genome and 5,725,147 aligned from the 10 day ChIP-seq sample.  
These sequencing depths are below the guidelines of the ENCODE consortium, which aim 
for ≥10 million unique aligned reads per ChIP-seq dataset for a point-source DNA-binding 
transcription factor (Landt et al., 2012).  Therefore, weak VEZF1 enrichment signals may 
be lost amongst background signal, however enrichment peaks should still be apparent at 
more highly enriched genomic elements. 
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Peak finding, using the MACS programme followed by PeakSplitter, identified a total of 
5,398 and 6,131 peaks from 5 and 10 day VEZF1 ChIP-seq samples respectively.  The 
efficiency of VEZF1 peak finding was limited by the lack of input or IgG ChIP-seq reference 
samples, meaning that enrichment peaks were calculated using the background signal in 
the VEZF1 ChIP-seq datasets, which is less reliable.  It is intended that this peak calling will 
be repeated once IgG ChIP-seq reference samples are available.  
 
Plotting normalised VEZF1 ChIP-seq reads across the chicken reference genome revealed 
well defined VEZF1 enrichment peaks (Figure 6.8).  Enrichment across the chicken β-
globin locus in both 5 and 10 day erythrocytes revealed VEZF1 binding at the HS4 
insulator and the HS2 enhancer element at both stages.  The ρ and ε gene promoters 
were enriched by VEZF1 in 5 day erythrocytes, where these genes are expressed.  The βA 
promoter and βA/ε enhancer elements were enriched in 10 day erythrocytes, where the βA 
gene is expressed.  We identified putative VEZF1 binding motifs within each of the VEZF1-
enriched elements across the β-globin locus.   
 
At the ρ promoter, a GT motif (GT-55) was found to correlate with the site of maximal 
VEZF1 ChIP-seq read enrichment in 5 day erythrocytes.  This GT motif is located 23 bp 5’ 
of a GATA motif (GATA-32).  Minie et al found mutation of either the GT-55 or GATA-32 
motifs reduce ρ promoter activity by ≥10-fold, showing that these sequence motifs are 
essential for the regulation of ρ-globin expression (Minie et al., 1992).  At the ε promoter 
an identical GT motif (GT-55) was found to correlate with the peak of VEZF1 enrichment 
in 5 day erythrocytes.  This GT motif was also 23 bp 5’ of a GATA motif (GATA-32).  
Mutation of the GT-55 and GATA-32 motifs at the ε promoter results in reduced promoter 
activity (Mason et al., 1996), showing that these motifs are essential for regulation of ε-
globin expression. 
 
VEZF1 is known to bind a homopolymeric G17 motif in the βA promoter (Lewis et al., 
1988).  However, ChIP-seq revealed a broad VEZF1 enrichment peak across this promoter, 
within which three putative VEZF1 binding motifs (G17-186, GA-115 and GA-46) appeared 
to locate to three VEZF1 subpeaks (Figure 6.12). The G17-186 motif is the validated VEZF1 
binding site identified by Lewis et al (Lewis et al., 1988).  The homopolymeric G-string 
sequence of this motif correlates with those motifs characterised in chapter 5, by POSMO 
motif discovery and EMSA, with which VEZF1 consistently forms strong interactions.  The 
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other two putative VEZF1 binding sites are GA motifs, which locate to a Stage Selector 
Element (SSE) described by Choi and Engel.  The SSE mediates interaction between the βA 
promoter and the βA/ε enhancer, regulating βA gene expression in a developmental stage-
specific manner (Choi and Engel, 1988).  A GATA motif also lies within the SSE at 18 bp 3’ 
of the GA-46 putative VEZF1 binding motif.  The GA-46 motif is required for 
transcriptional activity of the βA promoter in definitive embryonic chick erythrocytes 
(Jackson et al., 1989).   Mutation of both the GA-46 and GATA motifs results in a ~10-fold 
reduction in βA promoter-mediated transcription of a transgene in HD3 cells.  Deletion of 
the upstream promoter beyond -112 bp (i.e. upstream of the SSE) reduces βA promoter-
mediated expression by only ~2-fold demonstrating that the SSE is the main element 
responsible for controlling βA promoter activity and that the G17-186 VEZF1-binding motif 
is not critical for βA promoter activity.  Barton et al demonstrated that both the GATA and 
GA-46 motifs are essential for transcriptional expression of the βA gene (Barton et al., 
1993).  Work published by Galladra et al (Gallarda et al., 1989) implicates a 65 kDa protein 
present in the cell extract of definitive erythrocytes as binding this GA-46 motif and 
referred to this protein as NF-E4.  The GA-46 motif is of the sequence GAGGAGGGG, 
which is very similar to the VEZF1 consensus binding motif (GGGGNGGGG), we therefore 
propose that this previously defined NF-E4 binding motif is actually a VEZF1 binding site 
within the βA promoter.  
A single putative VEZF1 binding motif was identified at the βA/ε enhancer.  This motif lies 
16 bp 5’ of a GATA motif and maps to the point of maximal VEZF1 enrichment in 10 day 
erythrocytes (Figure 6.13).  The binding of VEZF1 to the βA/ε enhancer appeared to be very 
low in the ChIP-seq analysis from 5 day erythrocytes (Figure 6.8). However, a strong peak 
of VEZF1 enrichment is seen at this element in the 5 day ChIP-seq data prior to the 
removal of identical reads (PCR clonality, not shown). Furthermore, VEZF1 ChIP-qPCR 
experiments found comparable levels of VEZF1 binding at the βA/ε enhancer in both 5 and 
10 day erythrocytes (Figure 6.1).   Repetition of VEZF1 ChIP-seq in 5 day and 10 day 
erythrocytes, to achieve lower read clonality and higher sequencing depth would reveal 
whether the βA/ε enhancer is enriched by VEZF1 at both timepoints.  As this enhancer is 
active at both 5 and 10 days to mediate expression of the ε and βA genes respectively, I 
expect this element to be enriched by VEZF1 at both timepoints. 
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Two putative VEZF1 motifs were identified within the HS2 enhancer (F2/GTC-4391 and 
F5/GTC-4311), which map to two VEZF1 enrichment summits in 10 day erythrocytes.  In 
the 5 day ChIP-seq dataset, VEZF1 appears to interact with the F2/GTC-4391 motif only.  
Both putative VEZF1 sites lie within 18 – 24 bp of a GATA motif. 
 
Most of the putative VEFZ1 binding sites which map to ChIP-seq enrichment peaks across 
the β-globin locus are GT or GA box motifs.  POSMO motif discovery and EMSA 
experiments have already shown VEZF1 to form relatively weak interactions with these 
types of motifs when isolated in vitro (chapter 5).  This was confirmed by a set of EMSA 
experiments, which used three putative VEZF1 binding motifs in the ρ-globin promoter as 
probe DNA and tested for complex formation with VEZF1 protein (6.15).  VEZF1 showed 
the highest relative DNA-binding affinity for the homopolymeric G8-261 motif 
(GGGGGGGG) followed by the homopolymeric G7-106 motif (GGGGGGG).  VEZF1 
interacted weakly with the GT-55 motif (GGGGTGGGG) in vitro.  As the GT-55 sequence is 
found at the VEZF1 ChIP-seq enrichment peaks at both the ρ and ε gene promoters, the 
inability of VEZF1 to interact with this sequence when isolated in vitro suggests that 
VEZF1 requires cooperativity with co-binding factors when interacting with this element 
in vivo.  It has been shown in the published literature that the putative VEZF1 binding site 
GA-46 and the GATA-28 sequence motifs are both required for βA promoter activity 
(Jackson et al., 1989).  As all of the VEZF1-enriched elements across the β-globin locus 
contain GATA motifs, most of which are within 16 – 24 bp from a putative VEZF1 binding 
motif, and as the GATA-1, -2 and -3 proteins are known to function in the regulation of 
hematopoiesis, we suggest a role for the binding of GATA factors to these motifs in 
facilitating VEZF1 binding to these erythroid-specific elements.  This hypothesis is 
supported by unpublished GATA-1 ChIP-qPCR data produced by Dr Ruslan Strogantsev, 
which shows the ρ, ε and βA gene promoters to be enriched by GATA-1 in embryonic chick 
erythrocytes at time points during when these genes are actively expressed, and the βA/ε 
enhancer to be constitutively enriched throughout this timecourse i.e. GATA-1 
enrichment of these genomic elements correlates with VEZF1 enrichment (data not 
shown). 
 
As VEZF1 binding sites have been shown to protect a transgene and a CGI from DNA 
methylation (Dickson et al., 2010) analysis of the methylation status of individual cytosine 
residues across the βA and ρ promoters by bisulphite sequencing was performed.  These 
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analyses showed that the DNA methylation status of the βA and ρ promoters change over 
the course of embryonic development (figures 6.22 and 6.24).  A correlation between 
DNA methylation status, gene expression and VEZF1-enrichment of promoter elements 
became apparent at this point, i.e. when genes are transcriptionally inactive their 
promoters are not enriched by VEZF1 and are heavily methylated.  Conversely, when 
genes are actively expressed their promoters are enriched with VEZF1 and are 
unmethylated or lightly methylated.  When these findings are considered alongside those 
of Dickson et al (Dickson et al., 2010), a model whereby VEZF1 association with DNA 
elements functions to protect those elements from de novo DNA methylation may be 
proposed.   
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Chapter 7 
Summary and Conclusions 
7.1 Summary of work presented in this thesis 
Identifying transcription factor binding sites is essential to the identification of regulatory 
elements and the understanding of diverse and complex regulatory networks which 
operate in eukaryotic organisms.  Work detailed in this thesis sought to reveal the 
regulatory elements with which the highly conserved transcription factor VEZF1 
associates.  A small number of VEZF1 binding sites have been reported in the published 
literature where they have been shown to function in the regulation of gene expression 
(Aitsebaomo et al., 2001) and in the protection of DNA from de novo methylation 
(Dickson et al., 2010).  VEZF1 is also known to have essential functions in vasculogenesis 
and lymphogenesis, with VEZF1 null mice exhibiting an embryonic lethal phenotype 
(Kuhnert et al., 2005, Zou et al., 2010).  A pilot project in my supervisor’s lab previously 
profiled VEZF1 binding sites across the ENCODE regions, which cover 1% of the human 
genome, in the K562 cell line by ChIP-chip.  This study found the majority of VEZF1 
binding sites to map to promoters and other putative gene regulatory elements 
(Strogantsev, 2009). 
 
The principal aims of this thesis were to identify and validate putative VEZF1 binding sites 
across the human genome and to determine the relative affinities with which VEZF1 binds 
to a range of G-rich motifs.  Sites of VEZF1 binding across the K562 genome were 
identified by ChIP-seq and used to generate VEZF1 consensus binding motifs.  Motif 
discovery was also performed within groups of VEZF1 peaks ranked by ChIP-seq read 
enrichment in order to determine whether VEZF1 binding motifs differ in correlation with 
levels of VEZF1 enrichment.  EMSA was employed to validate the relative affinity of VEZF1 
interactions with putative VEZF1 binding motifs in vitro.  Finally, ChIP-seq was used to 
identify VEZF1 binding sites across the chicken genome in an in vivo developmental 
system where the relationship between VEZF1 binding, gene expression and DNA 
methylation was investigated.   
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7.2  Identification and characterisation of VEZF1 binding sites 
 (Chapters 3 and 4)  
In chapter 3, ChIP-seq was performed using an anti-VEZF1 antibody in order to map 
VEZF1 binding sites across the human genome in K562 cells.  In total, 26,341 VEZF1 
binding sites were identified.  The VEZF1 ChIP-seq dataset contained 21,239,966 uniquely 
aligned reads, this is more than double the minimum read depth set by the ENCODE 
consortium for a point-source transcription factor, we are therefore confident that 
regions of both high and low levels of VEZF1 enrichment should be evident in this dataset.   
 
Analyses presented in chapter 4 show the majority of VEZF1 binding sites to be associated 
with regulatory elements, as 55 % of VEZF1 binding sites associate with gene promoter 
elements and 33 % associate with enhancers.  Within promoters and enhancers, VEZF1 
binding sites map to nucleosome depleted regions, which are essential for the correct 
regulation of gene expression (Bai et al., 2010).  The chromatin features surrounding 
these nucleosome depleted regions indicate that VEZF1-enriched promoter and enhancer 
elements are active in K562 cells. In support of this, VEZF1 enrichment levels were found 
to positively correlate with transcript levels from associated genes and with levels of RNA 
pol II and active chromatin marks.  These findings are consistent with a role for VEZF1 
binding in facilitating transcription activity.  Previous investigations into the effect of 
VEZF1 binding sites on transcription activity have generated varying results.  The G17 
VEZF1 binding motif within the βA promoter was found to be dispensable for promoter 
activity, while the stage selector element is essential for promoter activity (Jackson et al., 
1989, Barton et al., 1993).  However, we have identified a putative VEZF1 binding site 
within the stage selector element, which correlates with a VEZF1 ChIP-seq enrichment 
peak.  Therefore, this putative VEZF1 binding site may function in the regulation of βA 
promoter activity.  Mutation of a CT/GC-rich region of the human IL3 promoter, to which 
VEZF1 binds, reduces the basal transcription activity of the IL3 promoter, while deletion 
of a 53 bp region of the EDN1 promoter, to which VEZF1 binds, abolishes EDN1 
transcriptional activity (Aitsebaomo et al., 2001, Koyano-Nakagawa et al., 1994).  In order 
to determine the effects of VEZF1 binding on target gene expression, VEZF1 protein levels 
should be knocked down in the K562 cell line and the effect on target gene transcription 
measured by RT-QPCR.  This VEZF1 knock down may be achieved using lentiviral systems 
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or transcription activator-like effector nucleases or repressors (TALENs and TALE 
repressors respectively). 
 
VEZF1-enriched promoter and enhancer elements were found to be bound by numerous 
additional protein factors.  Most were general transcription factors that are known to 
associate with active promoter or enhancer elements.  The erythroid-specific 
transcription factors GATA1, TAL1, E2A, LMO2 and LDB1 are known to associate to form a 
TAL1-erythroid complex which functions to regulate expression of a subset of erythroid-
specific genes (Wadman et al., 1997, Lahlil et al., 2004, Xu et al., 2007, Dhami et al., 
2010).  A group of 1,586 VEZF1-associated enhancer elements were found to be bound by 
erythroid-specific transcription factors, possibly as a TAL1-erythroid complex.  Consistent 
with this finding, the erythroid-specific TAL1 +51 and HBB gene enhancers are found in 
this group. 
 
Only 249 VEZF1 ChIP-seq peaks mapped to insulator elements by comparison to the K562 
ChromHMM chromatin state map.  This was much lower than expected as it was 
predicted that profiling VEZF1 enrichment across the genome would identify novel 
insulator elements, due to VEZF1 binding sites being essential for barrier activity of the 
chicken HS4 insulator (Dickson et al., 2010).  When analysed by ChromHMM, the chicken 
HS4 insulator is assigned a promoter state.  As we know this element to have no 
transcriptional activity, I believe that the 14,619 VEZF1 ChIP-seq peaks reported to locate 
to promoter elements by comparison to the ChromHMM map contain a proportion of 
mis-identified insulator elements.  In order to investigate this further, VEZF1-enriched 
ChromHMM-defined promoters that are distal from annotated TSSs should be identified.  
The locations of these elements could be compared to the GENCODE human reference 
genome annotation (Harrow et al., 2012) to filter out un-annotated gene promoters and 
promoters of non-coding genes.  Following this filtering step, we would be left with a list 
of VEZF1-enriched potential insulator elements.  A proportion of the VEZF1-associated 
enhancer elements, which were identified by comparison to the ChromHMM map, 
appeared to be TSSs as judged by the high levels of RNA pol II extending from the VEZF1 
peak summits (Section 4.4.2, Figure 4.13).  It is therefore apparent that, while the 
ChromHMM chromatin state maps are an excellent tool for analyzing the distribution of 
ChIP-seq enrichment peaks amongst regulatory elements on a genome-wide scale, there 
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appears to be some accuracy issues in the definition of some insulator and enhancer 
elements. 
 
During the course of this project Gowher et al published results from VEZF1 ChIP-seq in 
the human cervical cancer HeLa cell line (Gowher et al 2012).  In this paper VEZF1 ChIP-
seq data was used to support a role for VEZF1 in regulating splicing events by mediating 
pausing of the elongating RNA pol II, however the function of VEZF1 binding DNA was not 
investigated beyond this.  When the publicly available files containing sequence reads 
from ChIP-seq in HeLa cells are viewed in the UCSC genome browser, the negative control 
input track shows substantial read enrichment at the same sites that appear enriched in 
the VEZF1 ChIP-seq track.  This indicates that VEZF1 ChIP did not specifically enrich for 
DNA elements that are bound by VEZF1 in HeLa cells.  If facilitating RNA pol II pausing was 
a major function of VEZF1 binding, we would expect a large proportion of the VEZF1 ChIP-
seq enrichment peaks in K562 to locate to regions of transcription elongation by 
comparison to the ChromHMM chromatin state map, however only 85 out of 26,341 
VEZF1 peaks do (section 4.3.2, figure 4.6).  When sites reported as VEZF1-mediated RNA 
pol II pause sites in HeLa by Gowher et al were investigated using publicly available ChIP-
seq tracks in the UCSC genome browser, I observed them to map to the 5’ ends of genes 
and to have the characteristics of promoters as they were enriched by RNA pol II, 
H3K4me3, H2A.Z and H3K27ac (data not shown).  No other RNA pol II peaks were present 
in the vicinity of these genes, indicating to us that regions observed to be simultaneously 
enriched by VEZF1 and RNA pol II by Gowher et al actually mark active promoter 
elements rather than RNA pol II pause sites. 
 
7.3  Definition of VEZF1 binding motifs and VEZF1 binding site 
 validation (Chapter 5) 
In chapter 5, a VEZF1 consensus binding motif of GGGGNGGGG was identified from VEZF1 
ChIP-seq binding sites.  This motif is consistent with validated chicken VEZF1 binding sites 
in the βA promoter (Lewis et al., 1988) and the HS4 insulator FI (Dickson et al., 2010), and 
with a motif generated using VEZF1 ChIP-chip binding sites from a previous study in our 
lab (Strogantsev, 2009).  Further analyses showed the most highly enriched VEZF1 sites to 
be homopolymeric 9(dG) motifs while decreasing VEZF1 enrichment levels were found to 
correlate with VEZF1 binding to degenerate motifs where G-strings were replaced by 
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GGGGNGGGG sequences.  Likewise, motif searching using promoter-associated VEZF1 
peaks identified a high specificity 9(dG) binding site, while at enhancers a divergent 
gGGGWGGGg site was discovered.   
 
EMSA assays confirmed these findings, as VEZF1 was found to have the highest relative 
DNA-binding affinity for homopolymeric G-strings in vitro.  Meanwhile, VEZF1 binding to 
GA and GT motifs was more variable, and VEZF1 was found to interact weakly with GC 
motifs in vitro.  VEZF1 was unable to interact with a number of putative binding sites 
when isolated in vitro.  These sites included GA and GT motifs found at the centre of 
VEZF1 ChIP-seq peaks at erythroid-specific gene associated elements including the      
TAL1 +51 and HBB enhancer elements.  These results indicate a potential role for co-
binding factors in mediating VEZF1 binding to low-affinity, non-homopolymeric dG motifs 
in vivo.  As these sites mostly locate to erythroid-specific regulatory elements, co-binding 
proteins such as the TAL1-erythroid complex factors identified in chapter 4 may be 
involved in the regulation of VEZF1 binding to divergent sites at erythroid-specific 
regulatory elements.  In support of this hypothesis, a GATA factor consensus binding 
motif was identified 38 bp 3’ of the putative VEZF1 binding motif at the TAL1 +51 
enhancer.  GATA binding motifs were also discovered 44 bp 3’ of the putative VEZF1 site 
at the HBB HS2 enhancer, and 17 bp 3’ and 19 bp 5’ of the putative VEZF1 site at the HBB 
HS3 enhancer element.  As each of these GATA motifs are situated in close proximity to 
putative VEZF1 binding sites, cooperative interactions between GATA factors and VEZF1 
at erythroid-specific regulatory elements are a feasible possibility.  In order to investigate 
this further, GATA1 protein expression could be knocked down in the K562 cell line and 
VEZF1 ChIP-seq performed to determine whether VEZF1 enrichment of erythroid-specific 
regulatory elements is lost in the absence of GATA1. 
 
7.4  The relationship between VEZF1, promoter DNA methylation 
 and transcription of the chicken β-globin genes (Chapter 6) 
In chapter 6, ChIP-seq was performed using an anti-VEZF1 antibody to profile VEZF1 
binding sites across the chicken genome in circulating erythrocytes isolated from chick 
embryos 5 and 10 days post-fertilisation.  In total 5,398 and 6,131 VEZF1 peaks were 
identified in the 5 and 10 day datasets respectively.  The 5 day sample contained 
6,438,091 unique aligned reads and the 10 day sample contained 5,725,147.  As these are 
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below the minimum read depth of 10,000,000 unique aligned reads set by the ENCODE 
consortium for a point-source transcription factor (Landt et al., 2012), weak VEZF1 
enrichment signals may be lost amongst background signal however enrichment peaks 
should still be apparent at more highly enriched elements.   
 
The developmentally regulated chicken β-globin locus shows stage-specific patterns of 
VEZF1 enrichment at 5 and 10 day timepoints.  The HS4 insulator and HS2 enhancer 
elements are enriched at both 5 and 10 days.  In the 5 day sample the promoters of the ρ- 
and ε-globin genes are enriched, correlating with active expression of these genes.  In the 
10 day sample the βA promoter is highly enriched correlating with the active expression of 
this gene, and the βA/ε enhancer is enriched to a lower extent.  Putative VEZF1 binding 
motifs were identified at VEZF1 enrichment peaks across the β-globin locus, the majority 
were GA or GT motif sites.  Despite these motifs being enriched by VEZF1 in vivo, as 
demonstrated by ChIP-seq, VEZF1 formed weak interactions with these elements in in 
vitro EMSA binding reactions.  As β-globin gene expression is erythroid cell-specific, these 
results provide support for VEZF1 having low affinity for cell type-specific VEZF1 sites in 
vitro and requiring co-binding factors to facilitate interaction with these sites in vivo.  
Consensus GATA motifs were identified within all VEZF1-enriched elements across the β-
globin locus, mostly at a distance of 16 – 24 bp from putative VEZF1 binding sites.  This 
spacing of GATA and VEZF1 binding motifs should allow cooperative interactions to occur.  
We know the ρ, ε and βA promoters are enriched by GATA1 in circulating erythrocytes at 
the developmental timepoints when these genes are actively expressed and associated 
with VEZF1 (Strogantsev et al unpublished).  These findings support a role for erythroid-
specific TFs in mediating VEZF1 binding to erythroid-specific genomic elements. 
 
Consistent with the proposed role for VEZF1 in mediating protection from de novo DNA 
methylation, VEZF1 binding at the ρ and βA gene promoters was found to correlate with 
an unmethylated promoter state and active gene expression.   At the ρ-globin promoter, 
loss of VEZF1 enrichment correlated with an accumulation of DNA methylation.  
Meanwhile, at the βA promoter, VEZF1 binding correlated with demethylation of the 
promoter element. Given the findings of Dickson et al, which showed VEZF1 binding sites 
to protect a transgene and a CGI from de novo DNA methylation and to direct active 
demethylation (Dickson et al., 2010), a model can be conceived whereby VEZF1 
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association with its cognate binding sites mediates both protection from DNA 
methylation and active demethylation. 
 
7.5 Conclusions 
Prior to this study, VEZF1 had been found to bind at a small number of cell type specific 
promoters and an insulator element but its role in gene regulation was unclear.  In this 
thesis I present evidence that VEZF1 is broadly associated with the activation of gene 
transcription.  Of the more than 26,000 identified in this thesis 88 % map to promoter and 
enhancer elements.  VEZF1 binding positively correlates with RNA pol II enrichment, gene 
transcription levels and with a non-methylated DNA state.  The discovery of VEZF1 
binding at enhancer elements is novel and has not been reported to date in the published 
literature.   
VEZF1 binds a range of G-rich motifs with varying relative affinities.  VEZF1 has high 
affinity for binding to homopolymeric stretches of ≥9 dG residues in vitro but shows 
variable or low affinity for binding to GA, GT or GC motifs.  This implicates co-binding 
factors in facilitating VEZF1 binding to these lower affinity sites in vivo.  Evidence to 
support this hypothesis comes from my finding that a number of VEZF1-enriched 
erythroid-specific enhancer elements are also bound by erythroid-specific transcription 
factors in the human genome, and from a previous finding in our lab that GATA1 is bound 
to the chicken ρ, ε and βA promoters at the same developmental timepoints as VEZF1.  I 
therefore propose a model whereby VEZF1 is recruited to low affinity binding sites in vivo 
via protein-protein interactions with co-binding cell type-specific transcription factors.  
Candidate co-binding transcription factors at erythroid enhancers bound by VEZF1 are 
GATA1, GATA2 and TAL1.  Given that VEZF1 is expressed at similar levels in most somatic 
cell types, we can hypothesise that other cell-type-specific transcription factors may 
mediate VEZF1 binding to low affinity sites at enhancer elements in other cell types.   
I present evidence that VEZF1 binding at gene regulatory elements occurs within 
nucleosome depleted regions flanked by positioned nucleosomes enriched in the variant 
histone H2A.Z.  This nucleosome profile is observed at both promoter and enhancer 
elements. We hypothesise that VEZF1 has general role in establishing the specialised 
chromatin structure at regulatory elements.  The underlying DNA sequence determines 
whether VEZF1 acts in a constitutive or cell type-specific manner at any given element.  
The exact nature of VEZF1 action remains to be determined but may relate to events such 
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as H2A.Z recruitment, nucleosome positioning, establishment of nucleosome depleted 
regions or recruitment of RNA pol II. 
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APPENDIX I: Primer Sequences 
A. ChIP-qPCR human primer sequences 
Abbreviations: P – promoter; dup – duplicated region; F – forward primer; R – reverse 
primer; T – TaqMan® probe. 
 
P-IL3_F: GGTTGTGGGCACCTTGCT 
P-IL3_R: TCTGTCTTGTTCTGGTCCTTCGT  
P-IL3_T: FAM–ACATATAAGGCGGGAGGTTGTTGCCAA–TAMRA  
P-EDN1_F: TGCCCCCGAATTGTCAGA 
P-EDN1_R: CAGGCCCGAAAGGAAATCA 
P-EDN1_T:  FAM–CGGGCGTCTGCCTCTGAAGTTAGCA–TAMRA  
FOXP4 intron 3_F: GAGATGTTTCCGGCGTGTGT 
FOXP4 intron 3_R: TCTGAGTGGTGCGTCTGCTAA 
FOXP4 intron 3_T: FAM–ACGGGTATTGAGATTTCCACGGG–TAMRA  
FLNA 3’ dup_F: CCTTGTGTTTTGGGTGTGG 
FLNA 3’ dup_R: CACGACCTCTGGACGTTTCT 
FLNA 3’ dup_T: FAM–TGCGCTTCTCTAAGCGTTCCATTCC–TAMRA  
FLNA intron 2_F: CCCAAAAGAGAGAGGGAAGG 
FLNA intron 2_R: ATGTTGGAAAGCAGCAGTGA 
FLNA intron 2_T: FAM–CCCAGGGCTGGGAGACTGTCTG–TAMRA  
P-STAG2_F: CGATCTCTCCATCCCTTCC 
P-STAG2_R: CCAGACCCCAGCCAATTTAG 
P-STAG2_T: FAM–TCAGTTTTCTTCGGGCAACAATTT–TAMRA  
P-POLR3K_F: GGGTGATGTTGTGCACGTAG 
P-POLR3K_R: ATCGTGGAGGAGGGACAAC 
P-POLR3K_T: FAM–TGTTGCAGGAGAAGCGGTGGC–TAMRA  
P-HISPPD2A_F: CCCTCCTCGGTACTCTCCTC 
P-HISPPD2A_R: GGGCCTTAGTGTCAGCGTAG 
P-HISPPD2A_T: FAM–CTCGCATCCCGACTCCACTAGCCTT–TAMRA  
TAL1+3_F: AGGAAAGGCTCCAAACACCT 
TAL1+3_R: ATGGCTGGGAATTACCTCCT 
TAL1+3_T: FAM–CGATTCCCTGGACTGGTTGGTCG–TAMRA  
TAL1+51_F: TTACAGCCCTTCACCCTCAC 
TAL1+51_R: TGGGAATGAGCGATAAGGAT 
TAL1+51_T: FAM–ATGTTCCTGCCCTGATCCAGAGGG–TAMRA  
P-RFX5_F: CTGGGCCCAAGTTCTCATTA 
P-RFX5_R: CCCTACGTCATCTCCCACAA 
P-RFX5_T: FAM–TTAATCTCGCCACGACTTCCCCC–TAMRA  
B. ChIP-qPCR chicken β-globin locus primer sequences 
15.9 (16 kb cond.)_F: CAGCAGACGCTGTGGTGAA 
15.9 (16 kb cond.)_R: CTTGCAGGATGCAGACTGGA 
15.9 (16 kb cond.)_T: FAM–ATCCCATCGGTGCCACCCTGAG–TAMRA  
21.7 (HS4)_F:  CGGGATCGCTTTCCTCTGA 
21.7 (HS4)_R:  CCGTATCCCCCCAGGTGTCT 
21.7 (HS4)_T: FAM–CGCTTCTCGCTGCTCTTTGAGCCTG–TAMRA  
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31.9 (P-β-Rho globin)_F: CAGAGGAGCCAACATTTGGG 
31.9 (P-β-Rho globin)_R: CCCCTCTGGGTGATGCATT 
31.9 (P-β-Rho globin)_T: FAM–CGCTGCAGGCGTGAAGCCATT–TAMRA  
39.8 (P-βA globin)_F: CTGTGGTCTCCTGCCTCACA 
39.8 (P-βA globin)_R: AGGCTGGGTGCCCCTC 
39.8 (P-βA globin)_T: FAM–CAATGCAGAGTGCTGTGGTTTGGAACTG–TAMRA  
C. RT-qPCR chicken gene expression primer sequences  
β-Actin_F: TGCTGCGCTCGTTGTTGA 
β-Actin_R: TCGCCGGGGACGATG 
β-Actin_T: TGGCTCCGGTATGTGCAAGGCC 
β-Rho_F: CAGCGTGGTGGCCCAT 
β-Rho_R: TGACTTTCACACTGTGTCCTGCT 
β-Rho_T: FAM – CCTGGCCTACAAGTACCACTGAGCTC – TAMRA  
β-Epsilon_F: GGCAGAAGCTGGTCAACGTT 
β-Epsilon_R: CCACGGCTGTGCTGCAG 
β-Epsilon_T: FAM – TGCTCTGGCCCGCAAGTACCACTG – TAMRA  
β-Adult_F: CGCGTGGTGGCCCAT 
β-Adult_R: AGGTGCTCCGTGATCTTTGGT 
β-Adult_T: FAM – CCCTGGCTCGCAAGTACCACTAAGCA – TAMRA  
β-Hatching_F: AGAAGATGGTGCGTGTGGTG 
β-Hatching_R: CAGGAGCATCTCCAAGTGGCT 
β-Hatching_T: FAM – CCCACGAGTACCACTGAGCCCCA – TAMRA  
VEZF1_F: AAAGGATCGCATGACCTACC 
VEZF1_R: AATGATCAGGCCTCGAGAAG 
D. Bisulfite Sequencing primer sequences 
P-β-Rho_F: GAATGTTGTAGAGGAGTTAATATTTGG 
P-β-Rho_R: TCAATACCCAAAATACAACTAAACC 
P-β-Adult_F: TTTGTTTTGAGTTTTATTTTGATGT 
P-β-Adult_R: ACTTCTCCTCAACAATCCAATACAC 
M13_F: GTTTTCCCAGTCACGAC 
M13_R: CAGGAAACAGCTATGAC 
231 
APPENDIX II: EMSA oligonucleotide sequences 
A. Chicken sequences 
Locus 
Beta Globin 
 HS4_FI_T GGAGCTCACGGGGACAGCCCCCCCCCAAAGCCCCCAGGGA 
 HS4_FI_B TCCCTGGGGGCTTTGGGGGGGGGCTGTCCCCGTGAGCTCC 
 HS4_FIaaa1_T GGAGCTCACGGGGACAGCAAACCCCCAAAGCCCCCAGGGA 
 HS4_FIaaa1_B TCCCTGGGGGCTTTGGGGGTTTGCTGTCCCCGTGAGCTCC 
 HS4_FIII_T  AGGCGCGCCCCGGTCCGGCGCTCCCCCCGCATCCCCGAGC 
  CGGGGCGCGCCT 
 HS4_FIII_B  AGGCGCGCCCCGGCTCGGGGATGCGGGGGGAGCGCCGGAC 
   CGGGGCGCGCCT 
B. Human sequences 
Locus  
Alpha Globin 
 HBA_HS40_T ATCCTGTGGGGGTGGAGGTGGGACAAGGGA 
 HBA_HS40_B TCCCTTGTCCCACCTCCACCCCCACAGGAT 
 HBA_HS14_T GCCGTGGGGCCGGGGCCGGGGGCGGAGGGGGCCAGA 
 HBA_HS14_B TCTGGCCCCCTCCGCCCCCGGCCCCGGCCCCACGGC 
 HBA_P-40_T CCGGGCGTGCCCCCGCGCCCCAAGCATAAA 
 HBA_P-40_B TTTATGCTTGGGGCGCGGGGGCACGCCCGG 
 HBA_P-177_T GACGTCCTGGCCCCCGCCCCGCGTGCACCC 
 HBA_P-177_B GGGTGCACGCGGGGCGGGGGCCAGGACGTC 
 HBA_P-380_T GTGCCAGGCCGGGGCGGGGGTGCGGGCTGA 
 HBA_P-380_B TCAGCCCGCACCCCCGCCCCGGCCTGGCAC 
 HBZ_Pro_T ACCCCTGCAGCCCCCTCCCCTCACCTGACC 
 HBZ_Pro_B GGTCAGGTGAGGGGAGGGGGCTGCAGGGGT 
Beta Globin 
 HBB_HS3GT_T CAGGGAGGGTGGGGTGGGGTCAGGGCTGGC 
 HBB_HS3GT_B GCCAGCCCTGACCCCACCCCACCCTCCCTG 
 HBB_HS2_T GGGGTCAGTGCCCCACCCCCGCCTTCTGGT 
 HBB_HS2_B ACCAGAAGGCGGGGGTGGGGCACTGACCCC 
 HBG_Pro_T CCTCTTGGGGGCCCCTTCCCCACACTATCT 
 HBG_Pro_B AGATAGTGTGGGGAAGGGGCCCCCAAGAGG 
 HBB_Pro_T TCCCAGGAGCAGGGAGGGCAGGAGCCAGGG 
 HBB_Pro_B CCCTGGCTCCTGCCCTCCCTGCTCCTGGGA 
TAL1 
 TAL1_P1bA_T TTCGATGGCCGGGGGGGGCGGTGGGGGGGCATTTTCCACG 
 TAL1_P1bA_B CGTGGAAAATGCCCCCCCACCGCCCCCCCCGGCCATCGAA 
 TAL1_P1bB_T TCCACGGACGCCCCCGCCCCGGCTGCCGCC 
 TAL1_P1bB_B GGCGGCAGCCGGGGCGGGGGCGTCCGTGGA 
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 TAL1_+3_T AAGGCGGGTGGGGGGAGGAGGGGGTAGAGG 
 TAL1_+3_B CCTCTACCCCCTCCTCCCCCCACCCGCCTT 
 TAL1_+20_T TCTCCACTCCTCCCCTCCCCTTTGGACCAG 
 TAL1_+20_B CTGGTCCAAAGGGGAGGGGAGGAGTGGAGA 
 TAL1_+51_T TCCCAGGGCCTGGGGAGGGGGAGCCTCTGG 
 TAL1_+51_B CCAGAGGCTCCCCCTCCCCAGGCCCTGGGA 
FLNA 
 FLNA_IRA_T TCCCTCCACGCCCCGCCCCCGCCTCGGCAC 
 FLNA_IRA_B  GTGCCGAGGCGGGGGCGGGGCGTGGAGGGA 
 FLNA_IRB_T GCGCGTCTGGGGGGTCGTGGGGAAGCAGGG 
 FLNA_IRB_B CCCTGCTTCCCCACGACCCCCCAGACGCGC 
 FLNA_IRC_T CAGCGCCACCACCCACCCCCCCGGGAGCCG 
 FLNA_IRC_B CGGCTCCCGGGGGGGTGGGTGGTGGCGCTG 
 FLNA_int_T GCTGGATGGCCCCGCCCCATCCCACCCCCC 
 FLNA_int_T GGGGGGTGGGATGGGGCGGGGCCATCCAGC 
EHD1 
 EHD1_bound16A_T TGGGGTAATGGGGGGCGGGGCGGGGGGCCAGGCAGG 
 EHD1_bound16A_B CCTGCCTGGCCCCCCGCCCCGCCCCCCATTACCCCA 
 EHD1_bound17A_T GGATATCATCCCCTCCTCCCCCCAGACACA 
 EHD1_bound17A_B TGTGTCTGGGGGGAGGAGGGGATGATATCC 
 EHD1_bound17B_T GGCCCAGGTCGGGGGAGGGGCAGTGTCCTT 
 EHD1_bound17B_B AAGGACACTGCCCCTCCCCCGACCTGGGCC 
CKMT 
 CKMT_boundA_T CTGGACTCCAGCCCCACCCCTCCTGGCGCA 
 CKMT_boundA_B TGCGCCAGGAGGGGTGGGGCTGGAGTCCAG 
 CKMT_boundB_T CCGATACCGCCCCCAGCCCCAGCCACTCCC 
 CKMT_boundB_B GGGAGTGGCTGGGGCTGGGGGCGGTATCGG 
 CKMT_boundC_T AGCCACTCCCCCACCGCCCCCGGCCTTCAC 
 CKMT_boundC_B GTGAAGGCCGGGGGCGGTGGGGGAGTGGCT 
IL3-GMCSF 
 IL3_proP_T GCCTGCCCCACACCACCACCTCCCCCCGCCTTGCCCGGGG 
 IL3_proP_B CCCCGGGCAAGGCGGGGGGAGGTGGTGGTGTGGGGCAGGC 
 IL3_proD_T AACCTCCCAGGCCAGCCCCTCCCCCAGCTCCCAGTGACAG 
 IL3_proD_B CTGTCACTGGGAGCTGGGGGAGGGGCTGGCCTGGGAGGTT 
 IL3_-37_T AGGTCTTTCTCAAACAACCTCCCCCACAAAATCATATTGA 
 IL3_-37_B TCAATATGATTTTGTGGGGGAGGTTGTTTGAGAAAGACCT 
 GMCSF+30A_T CCCTGCCTGCCTCTAGGGGTGGGGTAGGTGAGGTAGGAGT 
 GMCSF+30A_B ACTCCTACCTCACCTACCCCACCCCTAGAGGCAGGCAGGG 
 GMCSF+30B_T AGGAACCCCTTTCCCCACCCCCCCCACCCACTGCAGAAAC 
 GMCSF+30B_B CTTTCTGACAGTGGGTGGGGGGGGTGGGGAAAGGGGTCCT 
 GMCSF_pro_T TAAGTGTCTCCCACGCCCCACCCCAGCCATTCCAGGCCAG 
 GMCSF_pro_B CTGGCCTGGAATGGCTGGGGTGGGGCGTGGGAGACACTTA 
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DNMT3B 
 DNMT3B_proA_T TCGGCACCGCCCCCTCCCCACCCACTCCCG 
 DNMT3B_proA_B CGGGAGTGGGTGGGGAGGGGGCGGTGCCGA 
 DNMT3B_proB_T TCCCTCGTCCCCGCCCCCCCGTTCCCCCCGCGCCCGG 
 DNMT3B_proB_B CCGGGCGCGGGGGGAACGGGGGGGCGGGGACGAGGGA 
MECP2 
 MECP2_proA_T CTGAGACCTCCCCCCTCCCCCGTCCTCCCC 
 MECP2_proA_B GGGGAGGACGGGGGAGGGGGGAGGTCTCAG 
 MECP2_proB_T ACCCTTGCCGGGGGGCGGGGGTCAGGGGCG 
 MECP2_proB_B CGCCCCTGACCCCCGCCCCCCGGCAAGGGT 
NRXN2 
 NRXN_boundA_T GCCTTGAGTGTGGGGAGGGGTGCAGGCAGG 
 NRXN_boundA_B CCTGCCTGCACCCCTCCCCACACTCAAGGC 
 NRXN_boundB_T CTGCCCGCCCCATGGCCCCCCCAGACTGCC 
 NRXN_boundB_B GGCAGTCTGGGGGGGCCATGGGGCGGGCAG 
IGF2 
 IGF_5HSA_T TGGAGCCGGGTGGGGCTGGGGAAGCGAGTT 
 IGF_5HSA_B AACTCGCTTCCCCAGCCCCACCCGGCTCCA 
 IGF_5HSB_T GGGTTAGCCCCCAGGCCCCTCCTGCCCATC 
 IGF_5HSB_B GATGGGCAGGAGGGGCCTGGGGGCTAACCC 
LYL1 
 LYL1_proA_T CTCACTTTCCCTGGGGGGGACCTACGCGGA 
 LYL1_proA_B TCCGCGTAGGTCCCCCCCAGGGAAAGTGAG 
 LYL1_proB_T CCGGGCCGCCGGGGGCGGGGAGAAGGCGGG 
 LYL1_proB_B CCCGCCTTCTCCCCGCCCCCGGCGGCCCGG 
GMPPA-ACCN4 
 GMPPA_boundA_T CATGGGGTGTGGGGGGCGGGGGCTCTGTCA 
 GMPPA_boundA_B TGACAGAGCCCCCGCCCCCCACACCCCATG 
POLR3K 
 POLR3K_pro_T CTGCAGCCGCCCCACCCCCCCCGGCGCGCC 
 POLR3K_pro_B GGCGCGCCGGGGGGGGTGGGGCGGCTGCAG 
SPA1 
 SPA1_boundA_T GACCAGGTTGGGGGAGGGGGTGAATGTCAC 
 SPA1_boundA_B GTGACATTCACCCCCTCCCCCAACCTGGTC 
HMGN1 
 HMGN_proA_T GGCGCCCGGGGGGGGGGGGGGGGCCCCCGG 
 HMGN_proA_B CCGGGGGCCCCCCCCCCCCCCCCGGGCGCC 
RFX5 
 RFX5_proA_T CCGCTACCCCGCCCCACCCCCGCTCCACTT 
 RFX5_proA_B AAGTGGAGCGGGGGTGGGGCGGGGTAGCGG 
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STAG2 
 STAG2_proA_T CTACGGAGACCCCCCCCCCCCATGGGTGGC 
 STAG2_proA_B GCCACCCATGGGGGGGGGGGGTCTCCGTAG 
BRWD1 
 BRWD1_proA_T CGCCCGCCCCCGGCCCCCCGCCCCCCGCCCCCCCCGCGCCGGAG 
 BRWD1_proA_B CTCCGGCGCGGGGGGGGCGGGGGGCGGGGGGCCGGGGGCGGGCG 
EDN1 
 EDN1_proA_T CGGAGCTGTTTACCCCCACTCTAATAGGGG 
 EDN1_proA_B CCCCTATTAGAGTGGGGGTAAACAGCTCCG 
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